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Abstract 
 
ACAT (acyl coenzyme A: cholesterol acyltransferase, syn: sterol O-acyltransferase) catalyzes the 
esterification of free cholesterol (FC) by reaction with long-chain acyl CoA derivatives to form 
cholesterol esters (CE). In humans, ACAT enzymes are expressed from two genes (ACAT-1 and 
ACAT-2) and play important roles in cholesterol trafficking and regulating FC/CE ratios within 
cells.  Various cholesterol-associated diseases such as gallstone formation appear to be associated 
with “abnormal” expression levels of these genes. This project developed quantitative methods to 
estimate the relative expression of ACAT-1 and ACAT-2 genes in various human tissues.  Real time 
quantitative PCR after reverse transcription of total RNA (RT-qPCR) was used to quantify ACAT 
mRNAs, and Western Blots after SDS-PAGE was used to quantify ACAT proteins. β-actin was 
chosen as an endogenous reference (“housekeeping gene”) to compare expression levels of both 
mRNA and protein in different samples. 
 
Chapters 2 and 3 address a number of technical issues, including the development of RT-qPCR 
assays that provide a realistic estimate of the molar ratio of ACAT-2/ACAT-1 mRNA in any sample.  
Assays for each ACAT isoform used TaqMan® oligonucleotide probes to quantify PCR products, 
and were multiplexed with an assay for β-actin for the analysis of ACAT-1 and ACAT-2 mRNA 
abundance in human samples. Chapter 3 describes the adoption of a higher-throughput PCR 
machine and improved TaqMan® probe, and the development of strategies for comparing the 
results obtained by improved assay systems with assays using the original methods described in 
Chapter 2.   
 
Chapter 4 describes the assessment of six antisera for ability to detect ACAT proteins after SDS-
PAGE and Western blot analysis of human liver preparations.  Five ACAT-2 antisera gave complex 
and variable banding patterns and none were considered sufficiently well characterised for use in 
quantitative analysis.  However, the ACAT-1 antiserum was highly specific and reproducibly 
detected a single protein of ~48 kDa, and was used for a survey ACAT-1 protein levels in 16 of the 
17 human liver samples assayed for the survey of ACAT mRNA described in Chapter 2.   Novel 
procedures are described for minimising errors when calculating mean ACAT-1/β-actin protein 
ratios from scans of band intensity in replicate Western blots.  No correlation was found between 
ACAT-1 protein and ACAT-1 mRNA abundance. It was concluded that in human liver, ACAT-1 
protein levels tend to fluctuate around a mean value that shows little relationship to ACAT-1 mRNA 
levels.   
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As a fraction of total ACAT mRNA, ACAT-2 was on average about 10 times more abundant than 
ACAT-1 in duodenum (69% of total ACAT mRNA, n=10) than in liver (7% of total ACAT mRNA, 
n=17). These results demonstrated quantitatively that ACAT-1 was the predominant mRNA isoform 
in all human liver samples assayed, and that ACAT-2 was more abundant in 9 of the 10 human 
duodenal samples.  ACAT-2 represented 11% of total ACAT mRNA in kidney (n=3), an organ not 
usually associated with ACAT-2 expression.  In spleen (n=1) and peripheral blood mononuclear 
cells (PBMC, n=7), ACAT-2 mRNA represented 1.8% and 1% respectively of total ACAT mRNA, 
consistent with expectations given the reported ubiquity of ACAT-1 in most tissues. 
 
Three of the liver samples were from gallstone patients, whose ACAT-2 mRNA levels tended to be 
higher as a fraction of total ACAT mRNA (i.e. ACAT-1 levels tended to be lower) compared to the 
non-gallstone patients.  This agrees with trends towards higher ACAT-2 expression (as mRNA 
abundance and enzyme activity) in gallstone patients reported by other workers.  When our mRNA 
and protein data for ACAT-1 were combined as mRNA/protein ratios, the gallstone patients gave 
relatively high values, i.e. ACAT-1 protein levels were low compared to ACAT-1 mRNA levels in 
the gallstone patients compared to non-gallstone controls. Although our sample size was small, the 
trends summarized above suggest that ACAT-2 mRNA expression generally tends to be higher and 
ACAT-1 mRNA and protein expression lower, in the gallstone patients.  Based on these and other 
lines of evidence, it is proposed (as a working hypothesis) that ACAT-1 and not ACAT-2 may be 
responsible for regulating the pool of FC that is secreted into bile, and that lower ACAT-1 levels 
could increase the amount of FC available for secretion and hence potentiate gallstone formation. 
 
Perhaps the most definitive finding of this study was the hypervariable expression of ACAT-2 
mRNA in human liver, which showed a 320-fold range relative to β-actin among 17 liver samples, 
and a 97-fold range relative to ACAT-1.  This phenomenon does not appear to be an artefact of 
sample preparation.  The expression levels reported in this and other studies are discussed in 
relation to factors regulating the expression and relative functions of ACAT-1 and ACAT-2.  
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CHAPTER 1  
 
INTRODUCTION AND LITERATURE REVIEW 
 
The aim of the work described in this thesis was to investigate the expression of two key genes, 
named ACAT-1 and ACAT-2, involved in the synthesis, partitioning and distribution of cholesterol 
esters in health and disease. This involved the use of PCR-based techniques to quantify and 
compare transcripts in various human tissues and organs (“real time” quantitative PCR), followed 
by analysis of the protein products of these genes using immunological techniques. 
 
1.1 Overview of cholesterol in human health and disease 
 
1.1.1 Cholesterol in human biology  
 
Cholesterol (Fig. 1.1) was first isolated from gallstones in 1784 and since then has attracted 
attention from many different areas of science and medicine (Brown and Goldstein, 1986). As 
described in more detail below, cholesterol not only modulates membrane fluidity to maintain the 
barrier between cell and environment, but also acts as a raw material for the synthesis of bile acids 
and steroid hormones and related bioactive molecules. Cholesterol is of interest to physicians due to 
the observation that elevated levels of blood cholesterol correlate with accelerated formation of 
atherosclerotic plaques, leading to heart attacks and strokes. Cholesterol is of interest to organic 
chemists and biochemists due to its complex ring structure, and mechanisms that regulate the levels 
of free and esterified cholesterol in various body compartments and tissues. Such studies, for 
example, can be directed towards the identification of targets for drug development that control 
pathologically deleterious levels in the body. The study of the enzymes that convert free cholesterol 
to cholesterol esters is therefore a subject of considerable interest to medical research. 
 
1.1.2 Overview of cholesterol location, transport and delivery  
 
Cholesterol is amphipathic due to its single hydroxyl (sterol) group and its large polycyclic 
hydrocarbon steroid nucleus (Brown and Goldstein, 1986). The hydrocarbon moieties of cholesterol 
molecules tend to aggregate in an aqueous milieu to form micelles, or together with phospholipids 
and proteins to form biological membranes as observed in mammals. The major role of unesterified 
“free” cholesterol (FC) in mammals is to confer fluidity to membranes, where its concentration is 
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generally highest in the plasma membrane (~20-25% of bilayer leaflet components). In most tissues 
only a small portion of the pool of FC is located in intracellular structures such as the endoplasmic 
reticulum (ER), Golgi apparatus or nucleus (Dietschy & Turley, 2004). However, cholesterol and its 
esters (together with triglycerides) can be stored in lipid droplets suspended in the cytosol (Walther 
& Farese, 2012). Another important role is as a precursor of steroid hormones, and cholesterol 
production and storage is a major function of the adrenal glands which make and secrete such 
hormones. 
 
Although the hydrophobic bias of cholesterol tends to contain it within cells and membranes, it 
must be transported from tissues of synthesis or absorption to tissues of storage or consumption via 
the blood stream which is aqueous. Multicellular organisms solve the problem of cholesterol 
transport by esterifying the sterol group with a long chain fatty acid to form cholesteryl esters (CE) 
(Fig. 1.1), and packaging these esters (which are more hydrophobic than cholesterol itself) within 
the hydrophobic core of plasma lipoproteins such as VLDL or chylomicrons. Plasma lipoproteins 
are complex particles that include CE, FC, triglycerides (TG), phospholipids (PL), and 
apolipoprotein (Brown and Goldstein, 1986). 
 
The large size and hydrophobic nature of CE attract them to the hydrophobic core of cell 
membranes and hence impede their ability to pass through membranes. This problem of delivery of 
CE from blood particles is solved by lipoprotein receptors that carry CE molecules into cells by 
receptor mediated endocytosis (Brown and Goldstein, 1986). Further details of cholesterol synthesis 
and uptake, packaging for export and trafficking in the plasma, are considered in Sec. 1.3.4. 
 
1.1.3 ACAT enzymes and their role in cholesterol transport  
 
 
 
Figure 1.1: Reaction showing cholesteryl ester formation catalysed by ACAT (reproduced from 
Lehninger, 1993) 
HO 
+ CH3-(CH)n-CO-S-CoA ACAT 
CH3-(CH)n-COO 
 
Cholesterol Cholesteryl ester Fatty acyl CoA 
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The formation of CE is catalysed by an integral membrane protein located in the endoplasmic 
reticulum (ER) named acyl coenzyme A:cholesterol acyltransferase (ACAT) (Suckling and Stange 
1985). ACAT enzymes catalyse the esterification of FC by reaction with long chain fatty acyl-
coenzyme A derivatives as shown in Fig. 1.1.  By regulating the balance of cholesterol and 
cholesterol esters in various cell types, ACAT-1 and ACAT-1 play an important role in regulating 
the import and export of cholesterol between various tissues around the body – this will be reviewed 
in more detail in Sec 1.3.4. 
 
Sterol O-acyl transferase (SOAT, E.C. 2.3.1.26) is the official name of acyl coenzyme A: 
cholesterol acyltransferase (ACAT), and ACAT is the official name given to another enzyme, 
acetyl-coenzyme A acetyltransferase 1 (= acetoacetyl coenzyme A thiolase, cf. 
http://www.gene.ucl.ac.uk/cgi-bin/nomenclature/searchgenes.pl). However, ACAT is an accepted 
alias of SOAT (http://www.gene.ucl.ac.uk/cgi-bin/nomenclature/searchgenes.pl) that is commonly 
used in the literature in place of SOAT, and this alias will be used throughout this thesis. Related 
enzymes are DGAT-1 (acyl CoA: diacyl glycerol acyltransferase 1) (Hofmann., 2000), and LCAT 
(lecithin: cholesterol acyltransferase, cf. Lin et al., 2010) also named PCAT 
(http://www.books.google.com.au/books?isbn=160831412X). 
 
1.2 Human ACAT genes and their expression 
 
Two ACAT genes are known in humans and other organisms including yeasts.  The first ACAT gene 
to be discovered (ACAT-1) was cloned by T-Y Chang and coworkers in 1993 (Chang et al., 1993).  
The second, ACAT-2, was cloned in 1998 (Cases et al., 1998; Anderson et al., 1998; Oelkers et al., 
1998).  The two genes have 47% overall nucleotide identity (Chang et al., 1993; Oelkers et al., 1998) 
and encode specific ACAT proteins which have 43% amino acid sequence identity and 63% 
similarity.  These and other studies have provided evidence that ACAT-2 is expressed primarily in 
liver and intestine, whereas ACAT-1 is expressed in a wide variety of tissue types.  Further details of 
the discovery, structure and expression of ACAT-1 and ACAT-2 genes are discussed below. 
 
1.2.1 Cloning the first human ACAT gene, ACAT-1     
 
In preliminary work, Chang et al. (1993) demonstrated that a human DNA fragment restored ACAT 
activity when transfected into ACAT-deficient Chinese hamster ovary (CHO) cell lines. The DNA 
fragment was used to screen a macrophage cDNA library, enabling the isolation of a full length 
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human cDNA clone of 4kb (named clone K1) that contained an open reading frame (ORF) of about 
1.65 kb that encodes a protein of 550 amino acids. This clone expressed ACAT activity when 
transfected into the ACAT-deficient mutant Chinese hamster ovary cells (Chang et al., 1993).  
 
1.2.2 A second human ACAT gene: ACAT-2, and a homolog DGAT-1  
 
Interrogation of the yeast genome sequence by the human ACAT cDNA clone K1 identified two 
ACAT-related genes, named ARE1 and ARE2 (Yang et al., 1996). Screening yeast and human 
cDNA libraries with K1 and other probes enabled the isolation of two yeast cDNAs and two full 
length cDNA clones named ARGP1 and ARGP2 (ARGP = ACAT Related Gene Products). 
Expression of these clones in mutant yeast strains deficient in sterol esterification showed that 
ARGP2 catalysed the esterification reaction between oleoyl CoA and cholesterol and so this gene 
was renamed as ACAT-2. ARGP1 did not express cholesterol esterifying activity, but was 
subsequently shown to esterify diacyl glycerol with long chain fatty acids, and was named DGAT-1 
(acyl CoA: diacyl glycerol acyl transferase 1) (Hofmann, 2000).  
 
Both ACAT-1 and ACAT-2 along with DGAT-1 belong to the membrane-bound O-acyltransferase 
(MBOAT) family (Hofmann., 2000; Chang et al., 2011). The enzymes of this superfamily catalyse 
the transfer of coenzyme A-linked organic acids such as long-chain fatty acids onto hydroxyl 
groups present in membrane-embedded targets. This superfamily does not include LCAT, which 
catalyzes transacylation of the fatty acid present in the sn-2 position of lecithin to the 3-hydroxyl 
group of cholesterol, and hence LCAT can act in extracellular environments (such as plasma) in the 
absence of coenzyme A (Sorci-Thomas et al., 1990). 
 
1.2.3 Genomic organisation and transcription of the human ACAT-1 gene   
 
Northern analysis of various human tissues and cell types has identified four ACAT-1 mRNAs of 
size 7.0, 4.3, 3.6 and 2.8 kb (Chang et al., 1993, Wang  et al., 1996). All four transcripts include 16 
exons encoded by 64,891 bases at the 1q25 locus of chromosome 1 (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=SOAT1).  The 3.6 and 2.8 kb transcripts are encoded entirely on chromosome 
1 and constitute 70-80% of total ACAT-1 mRNAs in various tissues, and are presumed to differ in 
the size of their 3’-UTR (Li et al., 1999, Yang et al., 2004a). The 4.3 kb and 7.0 kb mRNA are 
unique by including additional exons at their 5’ end that are encoded on chromosome 7, as 
summarized in Fig. 1.2. In humans, the 4.3 kb species is a relatively minor component and 
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constitutes less than 20% of total ACAT-1 mRNAs in various human tissues (Chang et al., 1993). 
The 7 kb mRNA constitutes 5-15% of total ACAT-1 mRNAs, and may represent an intermediate 
during formation of the chimeric 4.3 kb mRNA (Li et al., 1999).   
 
The structure and origin of all four mRNAs is summarized in Fig. 1.2. The 16 exons shared by all 
four mRNAs include a long open reading frame (ORF) of 1,650 nt that begins 8 nt downstream 
from the exon 1/exon 2 junction (total length of exon 2 = 126 nt), and terminates 47 nt downstream 
from the exon 15/exon 16 junction (total length of exon 16 > 1018 nt, Li et al., 1999). Hence the 
common ORF includes all of exons 3-15 and extends into the subtending exons 2 and 16, with exon 
1 located entirely in the 5’-UTR. The common ORF is translated as such by the 2.8 and 3.6 kb 
mRNAs, and encodes the same deduced 550-amino-acid protein sequence in each of these two 
mRNAs.  
 
The 4.3 kb mRNA appears to be produced by a splicing or fusion event from primary transcripts 
encoded on both chromosomes 1 and 7 that involves the 7.0 kb transcript as a putative intermediate 
(Fig. 1.2).  The chimeric 4.3 kb mRNA has a unique, extended 5’ region that includes an “optional” 
(i.e. additional) exon of 1279 nt, named Xa, encoded entirely on chromosome 7, which is fused to a 
second additional, palindromic exon of 10 nt named Xb, that is not encoded on any chromosome 
and appears to be a product of the fusion event (Li et al., 1999). Exon Xb is fused to the 5’ end of 
exon 1 derived from chromosome 1 (Fig. 1.2). This results in the 4.3 kb mRNA possessing a 
lengthened ORF beginning with an alternative (and unusual) GGC start codon located 6 nt upstream 
from the junction between Xa and Xb (Yang et al., 2004a), and includes all of Xb, exon 1 (99 nt) and 
the first 8 nt of exon 2 prior to the “normal” start codon for the common ORF. The new start is in-
frame with the common ORF, resulting in the common ORF being lengthened by 123 nt (41 amino 
acids), giving a total ORF of 1773 nt that encodes a 591 amino acid protein (extension size deduced 
using the information provided in Fig. 5A of Yang et al. (2004a). 
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Figure 1.2: Scheme showing transcription of elements of the ACAT-1 gene located on chromosomes 
1 and 7 of the human genome. Chromosome 1 is transcribed to produce two mRNA isoforms (2.8 
and 3.6 kb) that share a common ORF but differ in the length of their 3’-UTR. The 7.0 kb mRNA is 
a transcriptional fusion product derived from both chromosome 1 and 7, and appears to be a 
precursor of the mature 4.3 kb mRNA. The 4.3 kb mRNA has a lengthened ORF (fused to the 
common ORF present in the 2.8 and 3.6 kb mRNAs) that includes a new start codon located in exon 
Xa (from chromosome 7) followed by exon Xb (generated by the fusion event), exon 1, and part of 
exon 2. Blue triangles represent introns; red stars represent transcriptional initiation or termination 
sites; P1, P7 represent the promoters of chromosomes 1 and 7 respectively (drawing not to scale). 
Adapted from Li et al. (1999). 
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Interestingly, 5’-RACE experiments produced no evidence that a trans-spliced homologue of the 
human 4.3 kb ACAT-1 mRNA exists in mouse, rat or rabbit, and this chimeric ACAT-1 species may 
occur only in primates or humans (Chang et al., 1993). ACAT-1 appears to be ubiquitously present 
in all (or most) human tissues, with the 16 exons from chromosome 1 expressed under the control 
of the “P1” promoter, and the optional Xa exon expressed under the control of the “P7” promoter 
(Fig. 1.2). The P1 promoter region is the 648 bp genomic sequence immediately upstream from 
exon 1, and the P7 promoter region is the 612 bp genomic sequence immediately upstream from 
exon Xa. (Li et al., 1999).  A number of regulatory elements have been identified in these promoter 
regions, none of which were known to bind sterol regulatory element binding proteins (SREBPs) 
(Li et al., 1999; Chang et al., 2009).  
 
1.2.4 Translation (protein) products of the human ACAT-1 gene 
 
Based on mRNA, immunohistochemical and protein immunoblot analysis, ACAT-1 appears to be 
ubiquitously expressed in all or most human tissues e.g. Sakashita et al. (2000). In the small 
intestine, Chang et al. (2000) showed that ACAT-1 was present in the villus-crypt axis, and was 
abundantly expressed in both foetal and adult human liver, with more intense signals in periportal 
zones and epithelial cells lining the hepatic ducts and less intense signals in the pericentral zones. 
Contrary results were reported by (Parini et al., 2004) from immunohistological studies of adult 
human liver, who failed to detect a strong reaction for ACAT-1 in hepatocytes but detected strong 
ACAT-1 signals in Kupffer (macrophage) cells.  
 
SDS-PAGE and Western (immunoblot) analysis in various laboratories has identified a single 48-50 
kDa protein in a variety of human tissues and cell lines using various antibodies raised against 
ACAT-1 (Chang  et al., 1995; Chang et al., 2000; Chang et al., 1995;  Parini et al., 2004). This 
presents a puzzle, because the 550 amino acid protein deduced from the ORF common to all ACAT-
1 mRNAs was calculated by Chang’s group to have a size of 63.8 kDa (other sources cite a 
calculated protein size of 64.7 kDa, cf. http://www.genecards.org/cgi-
bin/carddisp.pl?gene=SOAT1).  
 
The cause of the disparity between the predicted size of ACAT-1, and the size identified using 
SDS-PAGE of cell-free preparations from human tissues, was attributed to its high basic isoelectric 
point (9.78) and hydrophobic nature, causing it to “bind more SDS” and hence “migrate faster on 
SDS-PAGE than a typical protein” (Yang et al., 2004a). Other explanations are possible, e.g. the 
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hydrophobic residues could aggregate and compact to some extent despite the presence of SDS, 
causing less retardation by the gel matrix than more hydrophilic proteins which are more loosely-
aggregated.   
 
The common 1.65 kDa ORF for ACAT-1 (which represents the only expressed ORF in the 2.8 and 
3.6 kb mRNA isoforms) possesses a second AUG start codon, six codons downstream from (and in-
frame with) the presumptive “normal” start codon for the 550 amino acid protein described above. 
Codon mutation and other analyses indicated that the second start codon initiated <5% of total 
ACAT-1 proteins in test expression systems. Because the active site of ACAT-1 is located near its 
C-terminus, it was concluded that the 49 kDa protein had no functional significance other than 
possibly guaranteeing the expression of ACAT-1 during evolution (Yang et al., 2004b). 
 
The chimeric 4.3 kb (and 7.0 kb) mRNA of ACAT-1 possesses a longer ORF derived from both 
chromosomes 1 and 7 that encode a 41-amino acid extension at the N-terminus of the common 
ORF.  Yang et al. (2004a) transfected a human cDNA clone derived from this mRNA into a mutant 
Chinese hamster ovary cell line AC29 that lacks ACAT-1, and observed copious expression of a 56 
kDa ACAT-1 protein in addition to the “normal” 50 kDa protein previously reported in various 
human tissues and cell lines. The 56 kDa protein presumably represents the extended 691 amino 
acid protein encoded by both chromosome 1 and chromosome 7. However the 56 kDa protein could 
not be detected (or was barely detectable) in a variety of human tissues and various cell lines 
including hepatocytes, fibroblasts, A293 cells, hepG2 cells, HeLa cells and Caco2 cells, but was 
induced during treatment of THP-1 macrophages with phorbol esters, and during differentiation of 
cultured monocytic cells into mature macrophages. The 56 kDa protein was shown to be 
enzymatically active using ACAT assays, and it was concluded that its function was to “increase 
ACAT-1 diversity” (Yang et al., 2004a).  
 
On the question of whether ACAT-1 is subject to post-translational processing (e.g. trimming to 
produce smaller proteins), no signal sequence has been predicted for this protein (cf. 
http://www.proteinatlas.org/ENSG00000057252/gene). As far as we are aware there are no reports 
of glycosylation, so it is presumed that this trans-membrane protein is inserted into the ER without 
prior transit through the ER lumen. Furthermore, in vitro transcription and translation systems for 
ACAT-1 (from African green monkey) gave proteins of the expected ~50 kDa size, suggesting that 
post-translational processing does not occur in vivo (cf. Sec. 1.2.6).  
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Databases record ACAT-1 species or splice variants of mRNA encoding proteins other than those 
described above (cf. http://www.genecards.org/cgi-bin/carddisp.pl?gene=SOAT1; 
http://www.proteinatlas.org/ENSG00000057252/gene), and although these require further 
examination, the ACAT-1 proteins actually observed in human tissues appear to be adequately 
explained by the work described above. 
 
1.2.5 Genomic organization and transcription of the human ACAT-2 gene 
 
It was first reported by Song et al. (2001) that the human ACAT-2 gene contains 15 exons and spans 
over 18kb of genomic sequence on human chromosome 12 (12q.13.13) 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/av.cgi?db=human&c=Gene&l=SOAT2), confirming 
a concurrent database analysis of intron/exon splice junctions in our laboratory (presented in 
Chapter 2, Sec. 2.2.4 and reported by Smith, Rangaraj et al. (2004). The first exon of ACAT-1 
appears to have no equivalent in ACAT-2, and the ACAT-2 gene structure was confirmed by 
Katsuren et al. (2001) who identified the protein coding region, which starts in exon 1 (homologous 
to exon 2 of ACAT-1) and terminates in exon 15 (homologous to exon 16 of ACAT-1). We are not 
aware of any reports of ACAT-2 components being located at other chromosomal loci as seen with 
ACAT-1.  The complete ACAT-2 polypeptide deduced from its full length cDNA sequence consists 
of 522 amino acids with a calculated size of 59.9 kDa (http://www.genecards.org/cgi-
bin/carddisp.pl?gene=SOAT2) or 60.7 kDa (Rudel et al., 2001). The promoter region of the human 
ACAT-2 gene is 1.3 kb in length and contains many potential cis-acting elements for multiple 
transcriptional regulatory factors.  
 
Soon after its discovery, ACAT-2 expression was detected by RT-PCR in human adult liver and 
intestine and in cell cultures of hepatocytes and intestinal enterocytes, but was not found in THP1 
monocytes, and macrophages (Oelkers et al., 1998). However as noted below and in Sec. 1.2.6, 
many studies have experienced difficulty in detecting ACAT-2 expression in adult human liver.  
 
Northern analysis initially identified a sole 2.2 kb ACAT-2 transcript in human foetal liver samples 
(Oelkers et al., 1998).  However when Yao and colleagues (2005) subjected total RNA from 
intestinal Caco-2 cells to RT-PCR, different-sized fragments of human ACAT-2 cDNA were 
amplified. This resulted in the cloning of two novel cDNA isoforms named ACAT-2b and ACAT-2c 
produced by alternative splicing, additional to the original full-length isoform now named ACAT-
2a. Whereas the full length ACAT-2a mRNA encodes a deduced ~60 kDa protein consisting of 522 
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amino acids, the ACAT-2b and ACAT-2c variants encode proteins of 502 amino acids and 379 
amino acids, respectively. ACAT-2b mRNA differs from ACAT-2a mRNA by lacking exon 4, while 
ACAT-2c mRNA differs from ACAT-2a mRNA by lacking exons 4, 5, and 8, 9 and 10 (Yao et 
al.,2005).  
 
Using cycle-limited RT-PCR and Western blots, all three of the above mRNAs and their cognate 
proteins were detected in various (but not all) cultured cell lines, human foetal tissues and cancerous 
liver.  However no ACAT-2 mRNA was detected in adult liver (Yao et al.,2005), in agreement with 
previous reports of low levels of ACAT-2 expression in adult human liver compared to foetal liver 
(cf. also Chang et al., 2000). ACAT-2c mRNA was a minor component compared to (ACAT-2a + 
ACAT-2b) mRNA in some cultured cell lines (human Caco-2 and HepG2), but was of similar 
abundance in human foetal lung and liver and cancerous adult liver. The above work was published 
after completion of the RT-qPCR assays reported in Chapter 2 (cf. Sec. 2.4.1 and 2.4.2). The 
presence or absence of ACAT-2 expression in adult liver is a matter of contention and will be 
discussed further in the next section and in Chapter 2 (e.g. Sec. 2.4.5.1) and Chapter 5 (Sec. 5.8.2).  
 
Protein and other databases (http://www.proteinatlas.org/ENSG00000167780/gene; 
http://www.genecards.org/cgi-bin/carddisp.pl?gene=SOAT2) record other ACAT-2 mRNA species 
or splice variants including two encoding smaller protein isoforms of size 34.9 kDa (310 amino acid 
residues) and 19.3 kDa (170 residues) deduced from transcripts identified in cDNA databases. 
These reports require further examination. It appears that our knowledge of ACAT-2 protein 
diversity in different tissues and cell types is far from complete. 
 
1.2.6 Translation (protein) products of the human ACAT-2 gene 
 
In contrast to ACAT-1, which appears to be ubiquitously expressed (based on mRNA and protein 
immunoblot analysis) in all or most human tissues, ACAT-2 expression has been detected in fewer 
human tissues. ACAT-2 expression products are particularly abundant in the villi apices of the 
small intestine (enterocytes) and also in fetal hepatocytes (Chang et al., 2000) and various cultured 
human cell lines such as HepG2 and Caco-2 (Yao et al., 2005). However ACAT-2 expression levels 
diminished in hepatocytes as children aged and was virtually undetectable in adults (Chang et al., 
2000).  
Chang et al. (2000) reported that human foetal liver (as well as cultured HepG2 and Caco-2 cells) 
expressed ACAT-2 as a single ~46 kDa protein. Yao et al. (2005) failed to detect ACAT-2 
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expression in adult liver under RT-PCR conditions that detected copious expression of the three 
splice variants (ACAT-2a, b and c) in fetal and cancerous adult liver. However, Yao et al. (2005) did 
not include protein size markers when examining the expression of the splice variants from clones 
transfected into ACAT-deficient cell lines, so the apparent size of the ACAT-2b and ACAT-2c 
proteins after SDS-PAGE has not been defined (also see Chapter 4, Sec. 4.4.1).  Rudel and 
coworkers have reported that antibodies raised against synthetic epitopes of the deduced ACAT-2 
protein detected a single ~48 kDa protein in adult human liver (e.g. Parini et al., 2004), slightly 
larger than the ~46 kDa protein reported by Chang and coworkers.  
 
Similarly to ACAT-1, the single ~48 or ~46 kDa ACAT-2 band detected by Western analysis noted 
above does not correlate with the calculated (~60 kDa) size of the deduced full-length (522 amino 
acid) ACAT-2a protein.  This disparity is presumably caused by anomalous electrophoretic 
migration of a basic, hydrophobic protein, as postulated for ACAT-1.  Despite Oelkers et al. (1998) 
noting that ACAT-2 has two putative N-linked glycosylation sites, we are not aware of any reports 
of actual ACAT-2 glycosylation. It is noted that the commercial supplier of an anti-ACAT-2 
antibody reported that their preparation could detect a 60 kDa protein in human fibroblasts, a 49 
kDa protein in human Jurkat cell lysates, and 60 kDa proteins in mouse and rat liver, intestines and 
fibroblasts (https://www.caymanchem.com/app/template/Product.vm/catalog/100027). As with 
ACAT-1 (cf. last paragraph of Sec. 1.2.4), reports of ACAT-2 proteins much larger than ~50 kDa 
should be treated with caution.  
 
In a key experiment, Anderson et al. (1998) used an in vitro transcription and translation system to 
express ACAT-1 and ACAT-2 proteins from African green monkey (whose ACATs are highly 
homologous to human ACATs). The expressed proteins migrated as single bands with apparent 
sizes of ~50 kDa for ACAT-1 and ~47 kDa for ACAT-2 after SDS-PAGE, sizes very similar to 
those reported for their human homologues by the Rudel group. Because post-translational 
processing (e.g. trimming, resulting in a shorter protein) would be expected to be minimal using this 
in vitro expression system, this result would appear to confirm the view that the hydrophobic 
character of ACAT proteins causes them to migrate faster during SDS-PAGE than would be 
expected from their calculated molecular mass in kDa. 
 
Parini et al. (2004) presented evidence, based on immunoblotting of cell-free preparations, 
immunostaining of tissue slices, and activity assays, that in human liver ACAT-1 is found mostly in 
Kupffer cells and ACAT-2 mostly in hepatocytes. Immunohistochemistry has the advantage over 
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enzyme activity assays and SDS-PAGE/Western analysis, of identifying target proteins in different 
cell types within the same tissue. Using whole liver homogenate preparations, ACAT-2 enzyme 
activity was slightly greater (on average) than ACAT-1 enzyme activity in human liver (Parini et 
al., 2004, cf. Ch 5, Sec 5.8.1). ACAT-2 was much more highly expressed in whole liver and 
hepatocyte preparations of monkey, mice and rabbits than in humans (e.g. Parini et al., 2004). 
Chang et al. (2009) concluded that the difficulty in detecting ACAT-2 expression in human 
liver could be related to its greater regulation (e.g. between and within tissue types), resulting in 
highly variable expression in the liver of different individuals. Hence the problem is one of access 
to human liver samples, and the livers from some individuals appear to express ACAT-2 at 
very low levels that are nonetheless presumed to be sufficient for their needs. These issues will 
be discussed further in Chapter 5, Sec. 5.8. 
 
1.3 Structure and function of ACAT proteins 
 
1.3.1 Human ACAT-1 (hACAT-1) protein structure    
 
The three-dimensional structure of ACAT-1 has not yet been determined (cf. Ohshiro & Tomoda, 
2011). Highly purified (7,000 fold) preparations of a recombinant hACAT-1 protein bearing an 
additional N-terminal sequence have been obtained by heterologous expression (Chang et al 1998., 
2010). The 7,000 fold purified protein migrated with an apparent size of 54 kDa after SDS-PAGE 
(cf. ~50 kDa for the native protein), and retained enzymatic activity when reconstituted in micelles 
(Chang et al., 1998). Such expression systems have been used to produce ACAT-enriched 
membranes for the study of ACAT structure and function, as summarized below. 
 
Current models view human and monkey ACAT-1 as an intrinsic protein with multiple trans-
membrane domains (TMDs) embedded in the ER.  Guo et al. (2005) proposed a model with 9 
TMDs for human ACAT-1 expressed in Chinese hamster ovary AC29 cells (Fig. 1.3). However, 
Joyce et al (2000) using a series of monkey ACAT-1 truncations (at the C-terminus) proposed a 
model with five TMDs. Chang et al. (2009) suggested that this discrepancy between the models of 
Guo et al. (2005) and Joyce et al. (2000) could have been caused by the truncations resulting in 
changes of overall ACAT-1 structure, resulting in the loss of some of the TMDs present in the 
native protein. 
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Various studies using site-specific mutations (cf. Joyce et al., 2000, Das et al., 2008b) have 
demonstrated that Ser-456, His-460 (within a HEY motif) and Asp-400 are essential for hACAT-1 
activity, and the tyrosine (Y) residue of the highly conserved FYXDWWN motif (residues 403-410) 
together with Y518 were also important for ACAT activity (cf. Das et al.,  2008b). Guo et al. (2005) 
have proposed that His-460, located within the 7th TMD, may serve as a general base in catalysis, 
while Asn-421, located within the 3rd large cytosolic loop, may be involved in binding the long-
chain fatty acyl-coenzyme A (Chang et al., 2010, 2011).). A catalytic site located within TMD7 
would enable CE to be generated and accumulate within the lipid bilayer of the ER, where it could 
“leave the cytoplasmic leaflet of the membrane to form lipid droplets, or be recruited to the lumen 
of the membrane for the VLDL assembly process” (Chang et al., 2009). 
 
 
 
 
Figure 1.3:  Revised model proposed by (Guo et al., 2005) showing membrane topography of 
hACAT-1 protein with 9 TMDs expressed in the ER of CHO cells. His 460 is represented as a 
larger green circle within the 7th TMD. 
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1.3.2. Human ACAT-2 (hACAT-2) protein structure and comparison with ACAT-1 
 
Joyce et al. (2000) have proposed an ACAT-2 model with five TMDs, while Lin et al. (2003) have 
proposed a model with two TMDs followed by multiple cytoplasmic loops separated by domains 
that are only partially embedded in the ER. Each group of workers propose that both ACAT-1 and 
ACAT-2 have their N-termini located in the cytosol. However while Joyce et al. (2000) propose 
that the C-terminus of each enzyme is located in the ER lumen, Chang and coworkers (Chang 
et al., 2009) place the C-terminus of ACAT-1 in the lumen and ACAT-2 in the cytosol.   
 
Similarly to His-460 in ACAT-1, its homolog His-434 in ACAT-2 appears to be essential for 
enzymatic activity (Das et al., 2008a; Chang et al., 2009). By analogy with the thioesterase domain 
of fatty acid synthase, which appears to require a catalytic triad of Ser-His-Asp residues, Das et al. 
(2008a) proposed that Ser-456, H-460 and Asp-400 in hACAT-1 were their catalytically equivalent 
residues. However, hACAT-2 appears to differ from hACAT-1 in that only His-434 (and possibly 
Asp-378) of its homologous residues were shown to be essential for ACAT-2 activity, and Das et 
al. (2008b (FASEB abstract)) proposed that esterification is catalysed in a substrate-assisted manner 
where the 3’-hydroxyl group of cholesterol acts as a nucleophile. 
 
The models described above are largely useful for their predictive values when designing 
experiments intended to probe ACAT function. ACAT-2 is also expressed as splice variants that 
include ACAT-2b which lack exon 4, and ACAT-2c which lacks exons 4, 5, 8, 9 and 10 (cf. Sec. 
1.2.5). We are not aware of any analysis of the putatively functional domains and amino acids noted 
above that would be removed by excision of the above exons. 
 
1.3.3 Regulation and inhibition of ACAT expression and activity 
 
1.3.3.1 ACAT-1 activation and induction 
 
ACAT-1 is subject to substrate activation, and the 48-50 kDa ACAT-1 protein expressed 
exclusively from chromosome 1 assembles as a more active homotetramer (Yu et al., 1999) that is 
under allosteric control that is activated most strongly by its biological substrate, free cholesterol 
(FC) (Chang et al 1998; Chang et al., 1997; Liu et al., 2005; Zhang et al., 2003). There is little 
evidence that ACAT-1 (or ACAT-2) activity is regulated by phosphorylation, based on analyses of 
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rat liver microsomes before it was known that liver ACAT activity included both ACAT-1 and 
ACAT-2 (Corton & Hardie, 1992). 
 
Despite its apparently ubiquitous presence in various human cell types and tissues (cf. Sec. 1.2.4), 
cellular ACAT-1 activity can be further enhanced by increased gene expression in addition to 
substrate activation. For example Seo et al. (2001) demonstrated that incubation with free fatty 
acids resulted in the induction of ACAT-1 (but not ACAT-2) mRNA by up to 2-fold in cultured 
HepG2 hepatocyte cells, but not in THP1 macrophage cells. In work published prior to the 
discovery of ACAT-2, Wang et al. (1996) identified two ACAT-1 (as now known) transcripts that 
were induced either six-fold (3.7 kb mRNA) or three-fold (4.2 kb mRNA) during the transition of 
monocytes to macrophages (that are destined to form foam cells).   
 
Leon et al. (2005) and Chang et al. (2009 review) summarise further examples of ACAT-1 up-
regulation that is induced by treatment of human monocytic cell lines by various agonists (such as 
all-trans-retinoic acid and interferon gamma) that target some cis-elements in the ACAT-1 promoter 
in chromosome 1. However as noted in Sec. 1.2.5, ACAT-1 is not regulated by other effectors (e.g. 
sterols) that target sterol regulatory elements in the promoter. It therefore appears that although 
ACAT-1 is ubiquitous and expressed at a relatively high basal level (cf. Sec. 1.2.3, 1.3.4), it can 
also be further up-regulated (and the balance of the isoforms derived from chromosome 1 or 
chromosomes 1+7 possibly altered) during development e.g. during the differentiation of 
monocytes. 
 
1.3.3.2 ACAT-2 activation and induction 
 
In a study that compared the specificity of ACAT-1 and ACAT-2 for various sterols, Temel et al. 
(2003) suggested that ACAT-2 may also be subject to allosteric activation. Using a partially 
purified preparation of hACAT-2 expressed in CHO cells, Liu et al. (2005) observed sigmoidal 
kinetics suggestive of allosteric activation by cholesterol. ACAT-2 shows specificity for a wider 
range of fatty acids, compared to ACAT-1 which strongly favours oleolyl CoA (Song et al., 2001; 
Seo et al., 2001), a property which is useful when probing ACAT-2 function in vivo (e.g. Alger et 
al. 2010). Zhang et al. (2010) demonstrated that saturated (palmitate) but not unsaturated (oleate) 
fatty acids induced ACAT-2 mRNA levels ~2-6 fold when incubated with human cell lines (HepG2, 
Hu7) and primary mouse hepatocytes (P<0.05), but had little effect on ACAT-1 mRNA levels 
(Zhang et al., 2010). Mice fed a diet rich in saturated fatty acids (largely hydrogenated coconut oil) 
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showed a transient doubling of liver ACAT-2 mRNA levels after 2 days (P<0.05), followed by a 
decline to control levels over the following week or so (Zhang et al., 2010). 
 
ACAT-2 appears to be subject to much greater transcriptional regulation than ACAT-1, as evidenced 
by low levels of mRNA/protein expression in most tissues and cell types other than intestines and 
foetal liver, and variable expression in adult human liver (cf. Sec. 1.2.5 and 1.2.6). In another study 
using immunoblots and RT-PCR, Sakashita et al. (2003) reported the expression of only ACAT-1 in 
immature human macrophages (derived from blood-borne monocytes), but detected expression of 
both ACAT-1 and ACAT-2 in fully differentiated macrophages and in advanced atherosclerotic 
plaque (in both cases ACAT-2 transcript and protein levels were lower than ACAT-1). 
 
Although the hACAT-2 promoter lacks sterol-responsive elements (Sec. 1.2.5), ACAT-2 mRNA 
expression can be induced by free cholesterol in some human-derived cell lines but not others 
(Pramfalk et al., 2007). Promoter-luciferase reporter assays indicate that promoter activity of the 
human ACAT-2 gene varies with different cell lines (Song et al., 2001), a result that correlates with 
tissue-specific pattern of expression of endogenous ACAT-2 (Chang et al., 2000). This suggests that 
differential ACAT-2 expression patterns could be attributed to diverse promoter activity within the 
1.3 kb promoter region in different cell types (Song et al., 2001), despite the lack of sterol-
responsive elements that bind sterol responsive element binding proteins (SREBP). Presumably, 
ACAT-2 expression is regulated by elements that respond to developmental and tissue-specific 
stimuli other than sterol availability. 
 
1.3.3.3 ACAT inhibitors 
 
A number of synthetic ACAT inhibitors have been developed to probe the biological role of ACAT 
in health and disease, with the potential to develop drugs against cholesterol-related disease 
(reviewed by Farese, 2006; Chang et al., 2006). The initial set of ACAT inhibitors were non-
specific and decreased the activity of both ACAT-1 and ACAT-2 (reviewed by Leon et al., 2005). 
Lada et al. (2004) devised an assay for isoform specificity and identified a number of compounds 
that inhibit ACAT-1 more efficiently than ACAT-2. One compound pyripyropene A (PPPA, 
derived from the fungus Aspergillus fumigatus), was found that specifically inhibited ACAT-2 
without affecting ACAT-1. The site of interaction between ACAT-2 and PPPA has been identified 
by Das et al. (2008c). In a more recent review covering the prospects of ACAT inhibitors as 
potential drugs, Ohshiro & Tomoda (2011) noted that PPPA (and its more potent derivatives) 
17 
 
remained the only known specific ACAT-2 inhibitors. A competitive inhibitor, K-604, with much 
higher specificity for ACAT-1 than ACAT-2, was identified and characterized by Ikenoya et al., 
2007.  Oshiro et al., (2011) list the IC50 values of PPPA, K-604 (and further ACAT-1 specific 
inhibitors), together with various non-specific ACAT inhibitors that have been widely used in 
previous studies. 
 
1.3.4 Biological role(s) of mammalian ACAT-1 and ACAT-2 
 
As noted in Sec. 1.1.2, free cholesterol (FC) is a polar lipid that is attracted to lipid-aqueous 
interfaces and is present as a major component of the lipid bilayer of plasma membranes in 
mammalian cells including humans. However in aqueous milieu such as cytosol (e.g. as micelles), 
FC is toxic, and is converted to the non-polar (and non-toxic) cholesteryl esters (CE) for storage and 
movement between membranes and other lipoidal structures within and between cells (cf. Leon et 
al, 2005). Because CE are highly non-polar, they tend to aggregate with other non-polar molecules 
in aqueous environments, and are packaged with triglycerides in structures associated with the ER 
to form particles for storage within cells e.g. as lipid droplets (Walther & Farese, 2012), and 
particles for export e.g. as chylomicrons and VLDL that transport CE and FC between cells 
(Ikonen, 2009). Hence together with cholesterol ester hydrolase (CEH), ACAT participates in the 
movement of cholesterol between sites within cells, the influx and efflux of cholesterol across 
plasma membranes, and the movement of cholesterol from “source” to “sink” cells throughout the 
body.  
 
An overview of our current understanding of the uptake, synthesis and movement of cholesterol 
throughout the body, to be discussed in more detail in later sections, is summarised in Fig. 1.4 (cf. 
Leon et al. (2005) (cf. Sec 1.4.3 for brain).  ACAT-2 is most abundant in enterocytes and 
hepatocytes, cell types that are unique in that they package CE-containing lipoprotein particles for 
export, and ACAT-2 expression is very low in most other cell types.  In comparison, ACAT-1 is 
relatively abundant and ubiquitous in all or most cell types. Dietary cholesterol and its esters after 
digestion of food, together with cholesterol secreted in the bile (for recycling), reaches the small 
intestine as FC, which is taken up by enterocytes and esterified by ACAT-2 to CE. The CE 
(together with triglycerides, TG) are packaged into chylomicron particles (QM) that enter the 
lymphatic system and blood, and move to the liver (or peripheral cells), where the CE are taken up 
and hydrolysed by CEH, and the FC is presumed to be re-esterified by ACAT-2 in hepatocytes.  
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Hepatocytes also use ACAT-2 for the production of CE destined for export to the blood as VLDL 
particles. 
 
When VLDL and chylomicrons transfer FC and CE to peripheral cells that lack ACAT-2 such as 
macrophages, the cells presumably hydrolyse the CE to FC during uptake (cf. Sec. 1.4.1.5). For 
example, macrophages (which lack ACAT-2 until very late in maturation) take up the FC, where 
ACAT-1 converts it to CE and modulates the FC/CE ratio, and hence the composition of 
atherosclerotic plaque formed by macrophage accumulation and foam cell degeneration in the wall 
of blood vessels. Excess FC in peripheral cells such as macrophages can be exported to HDL 
particles in the blood (Fig. 1.4), where LCAT can convert the FC to CE for delivery to hepatocytes 
(cf. Sec 1.4.1.3, 1.4.1.5 for more details). In hepatocytes, the CE received from HDL can be 
hydrolysed back to FC, and the FC exported to the bile either as itself or after conversion to bile 
salts.  
 
Figure 1.4:  Dietary cholesterol uptake, intracellular cholesterol metabolism, and the proposed role of 
ACAT-1 and ACAT-2 in these processes. Cellular cholesterol content is the net result of local de 
novo synthesis (Endogenous, En cf. Sec. 1.4.1.3), influx, and efflux. This figure illustrates some of the 
cholesterol metabolic pathways involved in the liver, macrophage, and small intestine of primates and other 
mammals such as mice.  Adapted from Leon et al. (2005).  Cf. Sec. 1.4.1.5 for details of reverse cholesteryl 
transport via HDL. FC, free cholesterol; CE, cholesterol esters; QM, chylomicrons; QMr, chylomicron 
remnants; VLDL, very low-density lipoproteins;  LDL, low-density lipoproteins; HDL, high density 
lipoproteins; TG, triglycerides; CEH, cholesterol ester hydrolase; LCAT, lecithin: cholesterol 
acyltransferase. Note that ACAT-1 and ACAT-2 are located on the endoplasmic reticulum within each cell 
type. 
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Most cells in the body are a site of endogenous (de novo) cholesterol synthesis (En in Fig. 1.4). FC 
synthesis begins in the cytosol and is completed in the ER 
(http://themedicalbiochemistrypage.org/cholesterol.php). Because cells lacking or extremely 
deficient in ACAT-2 (such as macrophages) can carry out de novo FC synthesis, it is presumed that 
ACAT-1 is primarily responsible for converting newly-synthesized FC to CE and regulating the 
FC/CE ratio. Cells that appear to possess both ACAT-2 and ACAT-1 (such as enterocytes and 
hepatocytes) may also use ACAT-1 for dealing with cholesterol synthesized de novo (cf. Ch. 5, Sec. 
5.8.2). Further details of the relative roles of ACAT-1 and ACAT-2 are reviewed in Sec. 1.4.  
 
1.4 Role of ACAT in health and disease, and rationale for this project  
 
1.4.1 Atherosclerosis and related phenomena 
 
Atherosclerosis is a disease process in which there is a build-up of fatty substances, cellular waste 
products, calcium and cholesterol in the inner lining of the arteries (http://www.americanheart.org/). 
In one of the layers of the arterial wall, the intima, monocytes develop into macrophages and finally 
foam cells, which contribute to both the initiation and progression of atherosclerosis and coronary 
heart disease (CHD) (Linton et al., 2003). The macrophages take up FC and convert it to CE by the 
action of ACAT-1; the CE interconverts dynamically with FC, resulting in the formation of the 
abundant lipid droplets containing both FC and CE contained within the foam cells (Chang et al., 
1997).  
 
It has been proposed (e.g. Shah, 2003) that inhibition of ACAT-1 has the potential to decrease CE 
formation leading to an anti-atherogenic effect in macrophages in humans (Shah, 2003), but see Sec 
1.4.1.2 for contrary scenarios in mutant mice). In addition, if ACAT-2 were inhibited it could lead 
to decreased cholesterol absorption in the intestine, resulting in reduced levels of circulating 
cholesterol (Shah, 2003). Interest in CHD aetiology and treatment is perhaps the greatest driver of 
ACAT research, but this research may also have application to gallstones. 
 
1.4.1.1 Towards the development of anti-atherosclerotic drugs 
 
Animal models and analysis of human populations have demonstrated that diets rich in cholesterol 
and triglycerides lead to hypercholesterolemia (i.e. elevated plasma cholesterol) accompanied by an 
increased incidence of atherosclerosis in predisposed individuals. Reduction of dietary fats, or 
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treatment with drugs known as statins, can result in reduced levels of plasma cholesterol (especially 
in LDL) accompanied by a reduced incidence of atherosclerosis (cf. Bhatnagar et al., 2008; 
Charlton-Menys & Durrington, 2007).  Statins act by inhibiting the rate-limiting step of cholesterol 
biosynthesis, catalysed by HMG-CoA reductase. Statins have been reported to suppress the 
expression of ACAT-2 in human gallstone patients (Parini et al., 2008; discussed further in Chapter 
2, Sec 2.4.4.2). Chang et al. (2006) comment that the use of statins has significantly reduced the 
mortality of CHD patients by 20-35%, but note that CHD mortality still remains high and a need 
exists for other drugs to complement the action of statins. Inhibition of ACAT activity in vivo, e.g. 
with ACAT inhibitors, represents a means to exploring the potential for developing such drugs (cf. 
Leon et al., 2005). 
 
Another approach to investigating the effect of ACAT inhibition on hypercholesterolemia and 
atherosclerosis has been via gene knockouts in mice. Both ACAT-1-/- and ACAT-2-/- mice have 
been produced; both types are viable and apparently healthy (ACAT-1: Meiner et al., 1996; ACAT-
2: Buhman et al., 2000). However as detailed below, studies on single knockout mice have been of 
limited use, and double knockouts (e.g. ACAT-1-/- mice also carrying apo E-/- or LDLR-/-), or 
simultaneous treatment of apo/LDLR knockouts with ACAT inhibitors, has been needed to identify 
links with atherosclerosis. Apo E (together with apo B100) is a constituent lipoprotein on the outer 
surface of blood particles carrying CE and TGs (chylomicrons, VLDL, LDL, HDL etc.), and docks 
with the LDL receptor (LDLR) in liver and peripheral cells, enabling the uptake of CE and TGs by 
these cells, and hence the clearance of CE and TGs from the blood (Charlton-Menys & Durrington, 
2007). Hence inhibition or loss of the Apo E or LDLR proteins leads to increased levels of CE 
(hypercholesterolemia) and TGs (hypertriglyceridemia) in the blood and potentiates atherosclerotic 
progression (Chiwata et al., 2001). 
 
1.4.1.2 Effects of ACAT-1 inhibition 
 
ACAT-1-/- single knockout mice were healthy, fertile, grew normally, and cholesterol absorption 
from the diet was similar to ACAT-1+/+ control mice, consistent with ACAT-2 handling the uptake 
of cholesterol from the GI tract (Meiner et al., 1996). Liver CE levels were similar when the 
knockouts and controls were fed a high-fat diet, consistent with ACAT-2 in enterocytes enabling 
the uptake of dietary FC and its export as CE via chylomicrons, and ACAT-2 in hepatocytes 
assisting the uptake of FC from the blood. However plasma total cholesterol was much higher in the 
ACAT-1-/- knockouts on both low- and high-fat diets, consistent with ACAT-1-dominant peripheral 
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cells such as macrophages not taking up CE from lipoprotein particles. The CE content of 
macrophages and adrenal glands in ACAT-1-/- mice was only ~10% or less of that  in ACAT-1+/+ 
controls (Meiner et al., 1996). All these observations are consistent with the cellular location 
and roles for ACAT-1 and ACAT-2 outlined in Fig. 1.4. 
 
Despite the above findings, ACAT-1-/- single knockout mice did not appear to show any significant 
differences in atherogenesis compared to the wild type. Cultured peritoneal macrophages of the 
ACAT-1-/- mice were deficient in CE and had higher levels of FC, as could be predicted given that 
ACAT-1 is predominant in macrophages (Meiner et al., 1996). However, high cholesterol diets 
did not translate into increased atherosclerosis in ACAT-1-/- single knockout mice. 
Furthermore, (Su et al., 2005) used bone marrow transplantation to produce mice with ACAT-1-/- 
macrophages, and such mice had normalised plasma cholesterol levels and apparently normal levels 
of aortic CE and apoptosis. 
 
To examine any physiological effect of ACAT-1 knockouts on CHD, it was first necessary to create 
mouse lines pre-disposed to atherosclerosis. For example, knockout of either Apo E-/- or LDLR-/- 
results in mice with elevated serum cholesterol levels due to a reduction in FC/CE clearance from 
the plasma to peripheral cells (cf. Sec. 1.4.1.1 & 1.4.1.3). Hence when either Apo E-/- or LDLR-/- is 
combined with ACAT-1-/- in double knockout mice, FC synthesized de novo in macrophages cannot 
be either exported back to the liver (e.g. in HDL), or converted to CE within the macrophage. This 
results in the accumulation of FC within macrophages. Because FC is cytotoxic, the double 
knockout mice also exhibited increased lesion size of atherosclerotic plaques and other defects 
including cholesterol deposition in skin and brain (Accad et al., 2000; Fazio et al., 2001; Su et al., 
2005). In summary, such studies suggest that inhibition of ACAT-1 (in an appropriate genetic 
background) can lead to excessive accumulation of intracellular FC in aortic macrophages, 
leading to ER stress and apoptosis, which can lead to the accumulation of necrotic foam cells, 
resulting in an increased incidence and severity of atherosclerosis (Feng et al., 2003; Warner et 
al., 1995; Rong et al., 2013). Note that this phenomenon would not be diet-induced atherogenesis. 
 
Conversely to the mouse knockout experiments described above, partial inhibition of ACAT 
activity has provided some evidence for suppression of atherosclerosis. Administration of the 
selective anti-ACAT-1 inhibitor K-604 to fat-fed hamsters reduced the CE content within 
atherosclerotic lesions and caused plaque regression without altering overall serum cholesterol 
levels (Ikenoya et al., 2007). A recent study with apoE-/- mice (Rong et al., 2013) showed that the 
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non-specific inhibitor F1394 at levels that provided partial inhibition of ACAT activity, resulted in 
retarded plaque progression accompanied by lowered plaque cholesterol content (both FC and CE)  
however this effect was not ACAT-1 specific. In humans co-treated with statins however, low doses 
of the non-specific ACAT inhibitor CI 1011 failed to potentiate any decrease in coronary 
atherosclerosis (clinical trial NCT00268515 cited by Nissen et al., 2006).  
 
Taken together, the above studies have cast doubt on the potential of ACAT-1 inhibitors for 
development as anti-atherogenic drugs (cf. Leon et al., 2005; Ohshiro et al., 2011), although the 
positive effects of partial inhibition using mouse models provide some hope (Rong et al., 2013). 
However studies on the inhibition of ACAT-2 show more promise for countering atherosclerosis 
(cf. Ohshiro et al., 2011), as outlined in the next section. 
 
1.4.1.3 Effects of ACAT-2 inhibition: knockout mice 
 
Single knockout ACAT-2-/- mice were healthy and produced viable offspring in Mendelian ratios 
when crossed with ACAT-2+/+ mice (Buhman et al., 2000). Total ACAT activity was reduced by 
92% in the small intestine and by 99% in the liver when fed a lean diet (the reduction was slightly 
less when fed a fatty diet), indicating that ACAT-2 is the major functional isoform in intestine and 
liver, consistent with Fig. 1.4. Compared to a balanced diet, wild type ACAT-2+/+ mice fed a high 
fat/cholesterol diet showed a greatly elevated level of total plasma cholesterol (the increase was 
mostly CE) (Buhman et al., 2000). In comparison, the ACAT-2-/- single knockout mice showed 
similar levels of total plasma cholesterol (which was almost completely FC) when fed either a 
balanced or high fat/cholesterol diet, indicating that the ACAT-2-/- mice were resistant to diet-
induced hypercholesterolemia. 
 
The single knockout ACAT-2-/- mice also showed elevated levels of plasma TG compared to the 
wild type when fed a high fat/cholesterol diet, presumably because TG replaced CE in the core of 
plasma lipoproteins (Buhman et al., 2000). These mice also showed a reduced capacity for gallstone 
formation when fed a high fat/cholesterol diet. It was proposed that the lack of plasma CE 
accompanied by resistance to gallstone formation in the ACAT-2-/- mice was a consequence of 
reduced cholesterol absorption and esterification in the small intestine, i.e. the mice were 
“shielded” from dietary cholesterol, especially when fed a high cholesterol diet (Buhman et 
al., 2000).  
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Conversely to the ACAT-1 double knockout mice that show an increased propensity for diet-
induced atherosclerosis, ACAT-2 double knockout mice showed a reduced propensity for 
atherogenesis (Willner et al., 2003). However similarly to ACAT-1, single ACAT-2-/- knockouts 
did not show any effect, and double knockouts were required to demonstrate any effect on 
atherosclerosis. Such studies used ACAT-2-/- knockout mice bearing either ApoE-/- or LDLR-/-, 
which predisposes the animal to atherosclerosis by reducing the exchange (and clearance) of 
cholesterol between ApoB containing lipoprotein particles and pools of (FC+CE) within cells (note 
that ApoE docks with receptors in many cell types, and its loss reduces the removal of lipids from 
plasma liopoproteins). For example when fed a high-fat/cholesterol diet, the double knockout 
ACAT-2-/- / ApoE -/- mice were unable either to export CE from enterocytes/hepatocytes to 
chylomicrons/VLDL (consequence of ACAT-2-/-), or transfer lipids to peripheral cells (consequence 
of ApoE -/-), and exhibited diet-induced elevated levels of lipoprotein particles and total lipids, 
consisting primarily of TG rather than CE in plasma. Hence the double knockouts with ACAT-2-/- 
had depressed levels of plasma cholesterol (mostly FC), compared to the ACAT-1-/- double 
knockouts which showed elevated levels of plasma cholesterol (mostly CE). 
 
The ACAT-2-/- / ApoE-/- mice double knockouts showed reduced levels of atherosclerosis when fed 
a high fat/cholesterol diet compared to ACAT-2+/+ / ApoE -/-  mice, i.e. the additional knockout of 
ACAT-2 protected the animals from atherogenesis (Willner et al., 2003). Presumably both dietary 
and endogenous (de novo) cholesterol can contribute to the accumulation of cholesterol in 
macrophages during atherogenesis, and suppression of the dietary source (via ACAT-2 knockout) 
reduces the amount of cholesterol accumulated, and hence suppresses diet-induced atherosclerosis. 
The ACAT-2 knockout macrophages still contain active ACAT-1, which sequesters endogenously-
synthesized FC to CE, and hence toxic levels of FC do not accumulate as they do in the ACAT-1 
double knockouts. In addition, plasma HDL in the double ACAT-2 knockouts contained somewhat 
higher levels of CE, suggesting that increased mobilisation of FC from macrophages to HDL may 
also have contributed to the anti-atherogenic effect (Willner et al., 2003). 
 
In another study, when fed a high cholesterol diet, double knockout ACAT-2-/- / LDLR-/-  mice 
exhibited total plasma cholesterol concentrations 19% lower and atherosclerosis 88% lower than 
wild type mice (Lee et al., 2004). Using another approach, Bell et al. (2006) used LDLR-/- mice in 
an apoB100-only background (apoB100-only mice lack ApoB-48, which predisposes the mice to 
greater severity of dietary-induced atherosclerosis, cf. Veniant et al., 1998). Treatment of these mice 
with antisense oligonucleotides (ASO) that specifically targeted hepatic ACAT-2 expression 
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resulted in an 80% reduction of hepatic ACAT-2 mRNA levels without affecting intestinal ACAT-2 
expression. Compared to controls, the ASO-treated mice showed highly reduced levels of aortic CE, 
indicating that a reduction of hepatic ACAT-2 expression had a suppressive effect on 
atherosclerosis.  
 
Another enzyme that can convert FC to CE is LCAT (lecithin: cholesterol acyl transferase, cf. Sec. 
1.1.2), a plasma enzyme that converts FC to CE in circulating lipoprotein aggregates (e.g. LDL and 
HDL) in the blood. Conversely to the ACAT-2-/- / LDLR-/- double knockout mice that show reduced 
levels of atherosclerosis, double knockout LCAT-/- / LDLR-/- mice exhibited higher total plasma 
cholesterol concentrations with higher levels of atherosclerosis (Lee et al., 2004). Hence 
suppression of LCAT activity, or ACAT-1 activity as noted previously, has not been viewed as 
an attractive approach to developing management strategies for atherosclerosis. On the basis 
of gene knockout experiments and other studies using specific ACAT-2 inhibitors (see below), 
it has been suggested by various reviewers that ACAT-2 could be used as a target for 
developing therapeutic agents that reduce plasma cholesterol levels and atherosclerosis (e.g. 
Chang et al., 2009; Leon et al., 2005; Chang et al., 2006; Farese, 2006; Charlton-Menys and 
Durrington, 2007).  
 
1.4.1.4 Effects of ACAT-2 inhibition via chemical inhibitors and targeted knockouts  
 
Ohshiro et al. (2011) investigated the effect of the ACAT-2-specific inhibitor PPPA on wild type 
and ApoE-/- mice and found that intestinal absorption of dietary cholesterol was inhibited in a dose-
dependent manner, without affecting the expression of intestinal or hepatic ACAT-2 (enzyme 
activity, mRNA levels). Using ApoE-/- mice, PPPA treatment lowered total plasma cholesterol in 
VLDL and LDL, but not chylomicrons or HDL, suggesting a specific shift in hepatic but not 
intestinal or macrophage cholesterol metabolism. The PPPA treatment significantly reduced the size 
and cholesterol content of atherosclerotic lesions compared to untreated controls, and had no 
apparent side effects (toxicity, diarrhoea etc.) compared to ACAT-1 inhibition reported previously 
(Sec. 1.4.1.2).  It was concluded that ACAT-2 should still be considered as a potential target for the 
treatment of atherosclerosis (Ohshiro et al., 2011). 
 
Because appreciable levels of ACAT-2 are predominantly expressed in the intestine (enterocytes) 
and liver (hepatocytes), the question arises: what is the relative contribution of each of these cell 
types to systemic cholesterol homeostasis? To address this question, Zhang et al. (2012) generated 
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two sets of conditional ACAT-2 knockout mice, one set targeted to the intestines, the other set to 
the liver. Predictably, only the intestine-targeted knockouts showed reduced dietary cholesterol 
absorption. However the intestine-targeted knockouts also exhibited reduced levels of plasma 
VLDL and hepatic CE, traits that are controlled by the liver, and which were mimicked by the liver-
targeted knockout mice whose livers receive dietary cholesterol. It was concluded that in research 
directed towards control of atherogenic hyperlipidemia, ACAT-2 inhibitors targeting either the 
intestine or liver could be beneficial.  
  
1.4.1.5 Emerging aspects of ACAT-2 function 
 
ACAT-2 has been shown to be associated with the control of other cholesterol-related functions 
additional to the production of ApoB-containing lipoproteins such as VLDL and chylomicrons 
(Alger et al., 2010).  
 
Fatty liver disease In humans, high-fat diets appear to be associated with non-alcoholic fatty liver 
disease (NAFLD), characterized by the accumulation of neutral lipids (TG and CE) in lipid droplets 
within hepatocytes, a condition known as hepatic steatosis. As noted above, in mouse models 
suppression or loss of ACAT-2 causes TG accumulation in plasma lipoprotein particles despite 
lower levels of total plasma cholesterol (Willner et al., 2003; Bell et al., 2006). Alger et al. (2010) 
used a mouse model to show that under conditions where high cholesterol diets induce hepatic 
steatosis, hypertriglyceridemia was accompanied by reduced steatosis when ACAT-2 was 
suppressed using ACAT-2-/- or treatment with ACAT-2 specific ASO. It was suggested that ACAT-
2-specific inhibitors may have therapeutic potential to treat fatty liver disease in addition to 
treatment of atherosclerosis. 
 
Reverse cholesterol transport (RCT) is the process of removal of extra hepatic cholesterol to the 
liver for recycling or secretion into the bile and hence faeces. This process is also termed 
“macrophage reverse cholesterol transport” when used to describe the removal of excess cholesterol 
from macrophages to prevent the progression of atherosclerosis (Cuchel & Rader al., 2006). 
Potentially, insufficient or impaired RCT can lead to cholesterol accumulation in macrophages to 
produce foam cells and atherosclerosis, while excessive RCT can lead to gallstone formation. The 
classic RCT process is via the hepatobiliary route:  cholesterol in peripheral cells such as 
macrophages > HDL > liver > FC + bile acids > bile > faeces > excretion, cf. Fig 1.4. However 
there are many examples of inhibition or blockage of biliary processes whereby there is no change 
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in total sterols excreted via the faeces. Hence a process that bypasses the hepatobiliary route, 
termed “trans-intestinal cholesterol efflux, or TICE” or “non-biliary route”, has been 
proposed: liver cholesterol > plasma lipoproteins > small intestine > faeces (Temel et al., 2010; 
Marshall et al., 2014). It is not yet known which lipoproteins mediate this process or how the 
cholesterol in lipoproteins is secreted from plasma into the intestinal lumen (Marshall et al., 2014).  
 
Suppression of ACAT-2 activity has been shown to stimulate the TICE pathway. Marshall et al. 
(2014) used liver-targeted ASO knockdowns of ACAT-2 in mice, which would be predicted to 
increase the hepatic FC/CE ratio without affecting total cholesterol levels. However when fed a 
high cholesterol diet, the concentration of CE in the liver of ASO-knockdown mice was reduced by 
70% without a reciprocal increase in FC. The reduction in CE was accompanied by a ~2-fold 
increase in faecal sterol loss with no change in biliary cholesterol. This suggests that the reduction 
in ACAT-2 activity caused hepatic FC, that otherwise would have been converted to CE, to be 
diverted into the TICE pathway for excretion. The TICE pathway opens up new therapeutic 
opportunities that target the intestine as an inducible sterol-excretory organ (Marshall et al., 2014). 
 
1.4.2 Cholesterol gallstones 
 
1.4.2.1 Gallstones and their formation 
 
Gallstones are hard solid matter found in the gall bladder. They are formed by the precipitation and 
crystallization of FC and bilirubin from bile, resulting in the two major forms of gallstones: pigment 
(mostly bilirubin) gallstones, and cholesterol gallstones (http://www.gastro.org). Free cholesterol 
(FC) and bilirubin are important components of bile, together with bile acids that emulsify the FC to 
form mixed micelles with other polar lipids such as phosphadityl choline (Wang et al., 2009;  
Farina et al., 2009, Pauli-Magnus et al., 2010). Bile acids are formed via the cytochrome P450-
mediated oxidation of FC and other reactions in hepatocytes, followed by conjugation of the bile 
acids (with glycine or taurine) and export to the biliary canaliculi. The most important source of 
biliary FC appears to be from CE via HDL/LDL uptake from blood by hepatocytes as shown in Fig. 
1.4 (together with some de novo synthesized FC), followed by the secretion of FC into biliary 
canaliculi from the canalicular membrane of hepatocytes via ABC transporters (Dikkers and Tietge, 
2010). 
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1.4.2.2 Pathogenesis of cholesterol gallstones  
 
It has been reported that ~10-15% of the adult population of the USA have gallstones (Everhart et 
al., 1999), and in other populations such as women in Latin American countries the frequency of 
gallstones can reach 50% (Diehl, 1991).  The following three types of abnormalities have been 
proposed for cholesterol gallstone formation, termed “cholesterol lithogenesis” (Acalovschi, 2001; 
Amigo et al., 2000): 
a) Bile super-saturation with cholesterol: As bile is concentrated in the gallbladder, a “sludge” 
of FC-containing micelles can be produced. This can result in the crystallization of FC and 
accompanying polar lipids to form gallstones. It has been proposed (Acalovschi, 2001) that 
such cholesterol super-saturation may occur via:  
(i)  excessive cholesterol biosynthesis or secretion of FC into the bile; or 
(ii)   decreased ACAT activity, which results in decreased cholesterol esterification and 
increased levels of hepatic FC, leading to excessive excretion of FC into bile as 
described in Sec. 1.4.2.3; or  
(iii)  reduced activity of the rate limiting enzyme for bile acid biosynthesis (cholesterol 7-
hydroxylase), which decreases the conversion of cholesterol into bile acids in non-obese 
individuals, resulting in the diversion of FC into the bile.  
b) Other factors can potentiate gallstone formation, including 
 (i)  enhanced nucleation of cholesterol crystals by mucins etc.  
 (ii)  low emptying of the gall bladder, further increasing the FC concentration in the bile; 
and  
 (iii)  Intestinal hypomotility leading to delayed digestion, which enhances microbial action in 
the gut that converts bile salts into compounds that down-regulate hepatic bile acid 
biosynthesis, and the excess hepatic FC is diverted into the bile.  
All of the above mechanisms can potentially contribute in varying degrees to the formation 
of gallstones. Diet-induced gallstone formation, e.g. high fat/cholesterol diets that promote 
excessive accumulation of hepatic cholesterol, falls within category (a) (i) (as can genetic or 
age/lifestyle factors). 
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1.4.2.3 Role of ACAT in gallstone formation 
 
Decreased ACAT activity (type (a) (ii) in previous section) has been proposed as one of the factors 
contributing to cholesterol gallstones (Acalovschi, 2001). Evidence comes from assays conducted 
on human microsomal fractions (Smith et al., 1986; Smith et al., 1990), and mouse models 
(Buhman et al., 2000, cf. Sec. 1.4.1.3).  Human cholesterol gallstone patients showed decreased 
levels of total hepatic ACAT activity compared to non-gallstone controls. This was proposed to 
result in the accumulation of the unesterified FC in parts of the ER, causing the excess FC to be 
diverted into the bile, which in turn results in elevated biliary FC to produce “lithogenic bile” that 
results in gallstone formation (Smith et al., 1986; Smith et al., 1990).  
 
A high-fat/cholesterol “lithogenic” diet fed to wild type mice causes hypercholesterolemia and 
gallstone formation. However the same diet fed to ACAT-2-/- knockout mice is accompanied by 
complete resistance to diet induced hypercholesterolemia and cholesterol gallstone formation due to 
decreased cholesterol absorption from the gut (Buhman et al., 2000; cf. Sec. 1.4.1.3). Similar 
studies on ACAT-1 knockout mice (cf. Sec. 1.4.1.2) have not shown any relief from gallstone 
formation. Other studies using knockout mice have shown that suppression of ApoE (Amigo et al., 
2000) and ApoB48 but not ApoB100 (Wang & Wang, 2005) also led to a significant reduction in 
biliary cholesterol secretion and gallstone formation when the mice were fed high cholesterol or 
high-fat lithogenic diets. In both cases, the knockouts were presumed to impair cholesterol uptake 
and its movement to the liver, resulting in lower hepatic cholesterol levels and hence lower 
cholesterol secretion into the bile (Di Ciaula et al., 2013).  
 
Parini et al. (2008, 2009) have reported differences in ACAT-2 expression in human gallstone 
patients, and lower hepatic ACAT-2 mRNA levels in gallstone patients treated with statins; these 
papers will be discussed in Chapter 2, Sec. 2.4.4.2. Because suppression or inhibition of ACAT-2 
has the potential to mitigate or prevent atherogenesis, ACAT-2 is being investigated as a target for 
the development of anti-atherosclerotic drugs (Sec. 1.4.1.3 & 1.4.1.4); such drugs may also be 
useful for treatment of cholelithiasis. 
 
1.4.3 Brain cholesterol, Alzheimer’s Disease (AD), and ACAT-1 
 
The central nervous system including brain has a high requirement for FC in the lipid bilayer of 
neuronal cells such as myelin, and has the highest total cholesterol content of any tissue (15-20 mg 
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chl/g fw compared to ~2.2 mg/g fw in the whole body). Because virtually no cholesterol enters the 
brain from plasma lipoproteins as a consequence of the blood-brain barrier, the brain must rely on 
cholesterol synthesized de novo (Dietschy & Turley, 2004).  ACAT-1 is the major ACAT isoform 
in mammalian brain, while ACAT-2 protein and mRNA are nearly undetectable (reviewed by Chang 
et al., 2010). However, most of the brain cholesterol is present as FC in myelin and levels of CE are 
very low (<1% of total brain cholesterol), so the roles of ACAT-1 and CE in brain are not clear.  
 
AD is associated with various forms of memory defects and the accumulation of abnormal amounts 
of a 39-43-residue amyloid–-peptide (A) in the brain. Cholesterol turnover and biology has been 
linked to AD based on circumstantial evidence (summarized from Chang et al., 2010; Bryleva et al. 
2010; Murphy et al., 2013), including observations that inhibition or knockdown of ACAT-1 in 
mice can result in reduced accumulation of amyloid peptides accompanied by ameliorated cognitive 
defects. However the mechanism and role of ACAT-1 in this process is a matter for speculation and 
ongoing research.  
 
1.4.4 Rationale for the project 
 
Summarising the literature surveyed above, since its initial discovery in rat liver (Mukherjee et al., 
1958, Goodman et al., 1964), ACAT activity has been detected in a diverse range of tissues and cell 
types (Suckling and Stange, 1985), and has been shown to play an important role in cell biology and 
in the pathogenesis of important lipid related diseases such as atherosclerosis (Suckling and Stange, 
1985) and cholesterol gallstones (Smith et al., 1990).  An excess of plasma cholesterol (as FC + CE) 
can lead to atherosclerosis, and an increased secretion of cholesterol (as FC) in bile can predispose 
individuals to cholesterol gallstones.  Not surprisingly, ACAT has been the focus of considerable 
research over the past decade because of its obvious pharmacological relevance.  
 
When this project began, current evidence suggested that ACAT-2 is expressed primarily in liver 
(albeit at very low levels in some studies) and intestine, whereas ACAT-1 is expressed in a wide 
variety of tissue types.  Working with cells isolated from monkey liver, Rudel and colleagues 
(Anderson et al., 1998) estimated by Northern blot analysis that the ACAT-1 mRNA level in 
hepatocytes was approximately half that in Kupffer cells, whereas the ACAT-2 mRNA level in 
hepatocytes was about six times that found in Kupffer cells.  They concluded that both ACAT-1 and 
ACAT-2 are present in hepatocytes, while Kupffer cells contain predominantly, if not solely, ACAT-1.  
While important tissue expression information was provided by these initial studies (Chang et al., 
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1993; Cases et al., 1998; Anderson et al., 1998; Oelkers et al., 1998), the precise relative intra- and 
inter-tissue/cellular expression levels and roles of the two ACAT isoforms, especially in human 
tissues, were uncertain because of limitations in the methodologies used.   
 
As a working hypothesis it had been proposed that ACAT-1 is constitutively expressed and likely 
functions to maintain the intracellular balance of free and esterified cholesterol, while ACAT-2 is 
associated with intestinal cholesterol absorption and hepatocyte-specific functions such as lipoprotein 
particle assembly and production of bile (Cases et al ., 1998; Anderson et al., 1998; Oelkers et al., 
1998; Lee et al., 1998; Chang et al., 2000; Lee et al., 2000; Meiner et al., 1996; Joyce et al., 2000).  
However, the lack of human hepatic ACAT-2 expression in some studies cast some doubts on this 
hypothesis. Knowledge of precise differences in the relative expression of ACAT-1 and ACAT-2 in 
the tissues of human individuals of each sex representing various states of health and disease was 
deemed likely to assist our ability to assign defined functions to each ACAT isoform in health and 
disease. Such a study of individual variation was lacking. 
 
Therefore the initial aims of the present study, briefly stated, were two-fold: (a) to develop improved 
procedures to quantify the abundance of ACAT-1 and ACAT-2 transcripts in human tissues; and (b) 
to apply these procedures to the analysis of various human tissues, particularly liver and duodenum, 
from a variety of individuals in health and disease.  It was envisaged this would be followed up by 
analysis of ACAT protein levels and enzymatic activities in the same tissue samples, as elaborated 
in Sec. 1.6. 
 
 
1.5 Use of “real time PCR” (RT-qPCR) for quantifying mRNA  
 
When planning for this project began (in 2000), mRNA levels in tissue samples were mostly 
determined by estimating the intensity of Northern blots, or by gel electrophoresis after reverse 
transcription (RT) of total RNA followed by cycle-limited (i.e. end-point) PCR, which may not 
detect lower levels of mRNA targets. Real time, quantitative PCR (qPCR, as defined below) had 
been developed for diagnostic analysis of DNA samples, and its application to mRNA analysis after 
reverse transcription of total RNA samples (RT-qPCR) was in its infancy.  
 
Real time, quantitative PCR after reverse transcription of total RNA (RT-qPCR) was selected as the 
simplest and most flexible high-throughput approach for quantifying the relative abundance of 
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ACAT-1 and ACAT-2 mRNAs. In real time PCR, DNA amplification products are quantified in 
“real time” after each polymerase cycle of the chain reaction, starting from the cDNA template 
generated by reverse transcription. If the PCR is run for a sufficient number of cycles, detection 
limits as low as a single cDNA target can be achieved. The chemistries available for qPCR at the 
start of this project used either dye-labelled probes that hybridize to specific sequences within the 
DNA amplification products (e.g. TaqMan®, Molecular Beacons), or fluorescent dyes that bind 
non-specifically to any sequence of double–stranded DNA (e.g. SYBR® Green) (Bustin, 2000).  
 
The RT-qPCR method chosen for most of the work described in this thesis was the TaqMan® 
assay, which employs a dye-tagged DNA probe that binds specifically to a site within the amplified 
DNA sequence, and hence is unable to bind to any non-specific amplification products. The dye 
contains a reporter dye at its 5’-end and a quencher dye at its 3’-end that suppresses fluorescence 
from the reporter dye via FRET, Fluorescence Resonant Energy Transfer. Once bound to the 
amplified DNA, the probe is degraded by the 5' exo-nuclease activity of Taq polymerase, causing 
release of the reporter dye and resulting in increased fluorescence by loss of FRET (Bustin, 2002). 
The reporter dye is detected and quantified by fluorescence monitored after each cycle of the PCR 
(http://www.appliedbiosystems.com/support/tutorials/pdf/rtpcr_vs_tradpcr.pdf). Bustin (2002) has 
listed the advantages of TaqMan® over alternative methods for quantifying transcripts in total RNA 
derived from tissue samples (Bustin, 2002).  
 
 
1.6 Specific project aims and experimental strategy 
 
When the planning for this project was started in the year 2000, previous work in our laboratory had 
examined the activity of ACAT enzymes in liver samples at various times after collection (e.g. 
Smith et al., 1989). That work was done with a view to developing methods for routine screening of 
ACAT enzyme activity (as a marker for ACAT gene expression) in samples from patients showing 
cholesterol-related disease symptoms such as gallstone formation. Quantitative RT-qPCR offered a 
simpler high-throughput approach for measuring ACAT gene expression, and transcript analysis 
had the added advantage of much greater ease and specificity than protein analysis for 
distinguishing ACAT-1 from ACAT-2 expression products. Hence the detailed project aims as 
initially envisaged were to: 
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1. Develop and validate TaqMan® based RT-qPCR methods specific for mRNAs expressed 
from each ACAT gene (hACAT-1 and hACAT-2). 
2. Test the methods on an initial (pilot study) set of human tissue samples representing diverse 
collection and pathological conditions, and hence determine the relative abundance of 
ACAT-1 and ACAT-2 mRNAs in each sample. 
3. Develop immunologically-based and/or enzyme-activity-based methods for quantifying each 
ACAT protein isoform, and compare them with the transcript abundance assays done 
previously. 
4. Identify ACAT expression trends and patterns showing correlations with patient pathology 
or sample collection conditions, and hence assist the development of hypotheses and sample 
collection strategies for further research. 
5. Refine and improve the methods for ACAT transcript and protein analysis as appropriate. 
6. If time permitted, apply the improved methods to screen a new and larger collection of 
human tissue samples designed to test the most amenable hypotheses developed during the 
project. 
 
This work was started with the scope of a PhD project but, for reasons set out in the 
Acknowledgements (recurring sickness), had to be curtailed. Thus it was not possible to commit to 
the sourcing and analysis of matched human samples representing specified pathological and 
control samples, to test any hypotheses formulated on the basis of the pilot study. Furthermore, the 
pilot study was restricted to the analysis of transcript and protein levels of ACAT-1 and ACAT-2 
(activity-based analyses were not explored). Hence the thesis was submitted for a MPhil. 
 
Chapter 2 describes the development of TaqMan® assays for both ACAT-1 and ACAT-2 (each 
multiplexed with the human β-actin gene as an endogenous reference “housekeeping gene”). The 
assays were applied to survey a cryogenically-stored collection of human tissue samples. When the 
survey was well advanced the ACAT-1 assay was found to be less robust than expected from initial 
validation experiments, requiring additional replication (re-assay) to obtain statistically acceptable 
results. The results of this survey have been published (Smith, Rangaraj et al., 2004). 
 
Chapter 3 describes improvements to the ACAT-1 assay. However adoption of a new, higher-
throughput qPCR machine resulted in unexpected disparities between the multiplexed ACAT and β-
actin assays that were not evident with the original PCR machine. Strategies for avoiding (or 
accommodating) these issues in future are proposed. 
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Chapter 4 describes the assessment of one antibody preparation for detecting ACAT-1 protein in 
human liver samples, and five antibody preparations for detecting ACAT-2 (one of which was 
produced as part of this project). Using SDS-PAGE and Western Blot (WB) analysis, the ACAT-2 
antibody preparations gave complex and variable banding patterns, and none were yet deemed 
suitable for screening human tissue samples. However the ACAT-1 antibody gave a clear and 
reproducible banding pattern, and was used to develop a quantitative ACAT-1 protein assay 
(referenced to β-actin) that was applied to 16 liver samples previously assayed for ACAT-1 
transcripts by RT-qPCR. 
 
Chapter 5 summarises the key findings, integrates the mRNA and protein analyses, and proposes 
hypotheses to account for variation in ACAT gene expression in individuals representing different 
sampling backgrounds and pathotypes. 
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CHAPTER 2 
 
QUANTITATIVE REAL TIME PCR ASSAYS OF ACAT-1 AND ACAT-2 
TRANSCRIPTS IN HUMAN TISSUES  
 
2.1 Introduction 
 
The aim of this project was first to measure the transcript levels, and then the protein levels, of 
ACAT-1 and ACAT-2 in human tissue samples. This chapter deals with transcript levels. When this 
work commenced, methods available for comparing and quantifying transcripts included: Northern 
blotting, in situ hybridisation, RNAse protection assays, and reverse transcription followed by the 
polymerase chain reaction. As noted in Chapter 1 (Sec. 1.4), quantitative real time PCR (qPCR) 
after reverse transcription (RT) of an RNA template (RT-qPCR) was chosen since it is a much more 
sensitive method for quantifying transcript levels compared to the other three methods, and is better 
suited for routine analysis of multiple samples.   
 
The TaqMan® assay can allow two or more different target sequences to be assayed simultaneously 
using reporter dyes with different fluorescence emission wavelengths, hence enabling an internal 
reference gene (β-actin) to be assayed (“multiplexed”) in the same reaction tube.  This chapter 
includes a description of the development and validation of the primers, probes and assay 
conditions used for the analysis of relative transcript levels of ACAT-1, ACAT-2 and β-actin in 
human tissues. 
 
As summarised in Sec. 1.3.4 and elaborated in Sec. 1.4, the liver and intestines are major sites of 
cholesterol ester synthesis, and contain cells that act as source or sink for cholesterol transport that 
are thought to be involved in the development of cholesterol-related disease. Multiple human 
samples from these tissues are in principle available from surgical treatment of patients with 
diseased tissues (e.g. prior to transplants), and non-diseased organ donors and persons deceased 
from other causes.  Kidney and spleen are other tissues potentially available after surgical 
procedures, and various cell types from blood are more readily obtained from donors of any desired 
disease status.   
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Because limited numbers of human tissue samples representing various tissues and disease states 
etc. were available, this part of the investigation was intended as a pilot study, first to establish and 
trial the technology, and secondly to identify possible differences in ACAT expression as a basis for 
future larger-scale studies directed towards identifying relationships linking ACAT gene expression 
with disease syndromes (cf. Sec. 1.5). It was of particular interest to compare the relative expression 
of ACAT-1 and ACAT-2 (as ACAT-2/ACAT-1 ratio), to define tissue-specific differences 
characteristic of each tissue type, and explore evidence forc coordinated regulation of these two 
genes in individuals of differing physiological and disease status. 
 
Some of the literature reviewed in Chapter 1 was published after this project began and after we 
published the work on ACAT-2/ACAT-1 mRNA ratios (Smith, Rangaraj et al., 2004) to be described 
below. In particular, the landmark publication of Parini et al. (2004) who demonstrated 
convincingly that in liver ACAT-2 is predominantly located in hepatocytes while ACAT-1 is 
located in Kupffer cells (cf. Sec. 1.2.6), and the demonstration of three splice variants of ACAT-2 
(Yao et al., 2005, cf. Sec.1.2.5, 1.2.6), were unknown to our laboratory at the time of submitting 
Smith, Rangaraj et al (2004) for publication. These and other more recent publications affect the 
interpretation of the data as published in Smith, Rangaraj et al. (2004), and will be addressed Sec 
2.4. 
 
2.2 Materials and Methods 
 
2.2.1 Clinical samples 
 
Clinical material was accessed from a variety of sources (Table 2.1) with appropriate consent. The 
Royal Brisbane, Mater Misericordiae, Greenslopes Private, and Princess Alexandra Hospital ethics 
committees approved all procedures and protocols used. Most liver samples were obtained from 
organ donors after obtaining consent for the use of tissue for scientific purposes from the next of 
kin. A sample of spleen was also obtained from one of the organ donors. Some liver samples were 
also obtained from patients undergoing cholecystectomy for gallstones and liver biopsy. Extensive 
studies by my collaborators (Smith et al., 1990; Smith et al., 1986; Smith et al., 1989) have 
demonstrated that total ACAT enzyme activity is clinically relevant and comparable in liver 
samples from these sources. Furthermore, useful data on the abundance of transcripts unrelated to 
ACAT have been obtained from some of these same samples (Bridle et al., 2003). Duodenal 
biopsies were obtained from patients having gastroscopy for clinically indicated reasons, such as 
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investigation for abdominal pain, iron deficiency, weight loss, anemia, and reflux. Biopsies were 
performed by a single gastroenterologist and were taken from the second part of the duodenum and 
contained predominantly intestinal mucosal cells (mostly enterocytes with some goblet, Paneth, and 
endocrine cells). Each biopsy is also likely to have contained small numbers (<5%) of fibroblasts, 
lymphoblasts, macrophages, and connective tissue and muscle cells. The duodenal samples were 
supplied as total RNA preparations by K.Stuart (a co-author in Smith, Rangaraj et al., 2004).  
 
Apparently normal kidney samples adjacent to cancerous tissue were collected at the time of 
nephrectomy from patients with renal cell carcinoma. As soon as tissue samples were available, 
they were plunged into liquid nitrogen and stored at -80 ºC until processed. Peripheral blood 
mononuclear cells (PBMC) were isolated immediately from freshly collected whole blood taken 
from healthy volunteers and patients with confirmed cholesterol gallstones (after cholecystectomy) 
using Ficoll gradient centrifugation (Ficoll Hypaque; Pharmacia). The clinical characteristics of the 
subjects and patients from whom samples were collected are shown in Table 2.1. 
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Sample 
label 
Tissue 
Type 
Age(yr) Sex Subject/Patient group or 
investigation for 
Warm Ischemia 
Time* (min) 
1 Liver 24 Male Liver donor 0 
2 Liver 37 Male Liver donor 0 
3 Liver 48 Male Liver donor 0 
4 Liver 48 Female Liver donor 0 
5 Liver 41 Male Liver donor 0 
6 Liver 43 Female Liver donor 0 
7 Liver 38 Male Liver donor 0 
8 Liver 14 Female Liver donor 0 
9 Liver 50 Female Liver donor(>60% fat) 0 
10 Liver 22 Male Liver donor (visual gallstones) 0 
11 Liver 72 Female Gallstone patient+ simvastatin** 0 
12 Liver 65 Male Gallstone patient+ simvastatin** 0 
13 Liver 9 Female Kidney donor 21 
14 Liver 61 Female Kidney donor 24 
15 Liver 71 Male Liver resection 75 
16 Liver 55 Female Liver resection 90 
17 Liver 58 Female Liver resection 120 
A Duodenum 57 Female Iron deficiency  0 
B Duodenum 63 Female Iron deficiency 0 
C Duodenum 61 Female Iron deficiency: insulin dependent , type 
2 diabetic with chronic renal failure 
0 
D Duodenum 25 Male Abdominal pain 0 
E Duodenum 39 Male Abdominal pain 0 
F Duodenum 41 Male Abdominal pain 0 
G Duodenum 54 Male Abdominal pain 0 
H Duodenum 48 Male Weight loss 0 
I Duodenum 32 Male Reflux 0 
J Duodenum 72 Female Anaemia 0 
a Kidney N/A N/A Renal-cell carcinoma 0 
b Kidney N/A N/A Renal-cell carcinoma 0 
c Kidney N/A N/A Renal-cell carcinoma 0 
 Spleen   Organ donor 0 
a PBMC 39 Male Healthy control 0 
b PBMC 34 Female Healthy control 0 
c PBMC 31 Female Healthy control 0 
d PBMC 29 Female Healthy control 0 
e PBMC 49 Female Cholesterol gallstones 0 
f PBMC 25 Female Cholesterol gallstones 0 
g PBMC 24 Female Cholesterol gallstones 0 
Table 2.1: Clinical characteristics of subjects and patients; N/A= not available. 
* Warm ischemia time = lack of blood flow to the tissue at 37 ºC before sample collection. 
** Patients were administered Simvastatin 20 mg/day for 3 weeks prior to taking biopsy. 
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2.2.2 Extraction of total RNA  
 
RNA was isolated from clinical samples using TRI Reagent (Molecular Research Centre Inc., 
Cincinnati, Ohio, USA) or Trizol (Life Technologies from Invitrogen, Mt. Waverley, Victoria, 
Australia) using protocols recommended by the manufacturer.  The amount of tissue used for the 
RNA extraction was 50-100 mg for liver, spleen and duodenal biopsies and 10 ml whole blood for 
PBMC.  
 
Diethyl pyrocarbonate (DEPC) treated water was prepared by adding 1 ml of DEPC to 1000 ml of 
MilliQ water in a bottle, bottle shaken intermittently and allowed to stand overnight. This DEPC 
treated water was used for all RNA work and also for washing apparatus and instruments coming in 
direct contact with liver tissue. Forceps, spatula etc were baked at 160-180 ºC overnight in an oven 
to inactivate any RNase. The following total RNA extraction protocol was followed: 
1. 50-100mg of tissue (human liver, spleen and kidney) or cells pelleted from 10 mL whole 
blood (PBMC) was homogenised with 1ml of TRI Reagent or Trizol using a homogeniser at 
half speed, five upward and five downward strokes. 
2. Samples were incubated at room temperature for 5 min; 200 µL choloroform added, 
vortexed for 15 s, then incubated for 10 min at room temperature. Tubes were centrifuged 
for 15 min at 13,000 x g at 4 ºC. 
3. The aqueous phase was transferred to a fresh tube, 500 µL of isopropanol was added and 
mixed and allowed to stand for 5 min at room temperature, then centrifuged at 4 ºC at 
13,000 x g for 10 min to obtain the RNA pellet. 
4. The supernatant was discarded and the pellet washed with 1 mL 70% ethanol, vortexed, and 
centrifuged at 4 ºC for 5 min to consolidate the pellet; the ethanol wash was discarded. 
5. The pellet was air dried for about 5-10 min and resuspended in 200 µl RNase free water. 
6. The RNA concentration was measured spectrophotometrically at 260nm. 
 
2.2.3 cDNA synthesis 
 
After the development of primers and probes for the assay of ACAT-1 and ACAT-2 (cf. Sec 2.2.4), 
three commercially-available reverse transcriptase preparations were compared for preparing cDNA 
samples for routine assays: Superscript II™ (from Invitrogen (Mt. Waverley, Victoria, Australia) 
and Multiscribe™ (from Invitrogen (Mt. Waverley, Victoria, Australia), both derived from 
recombinant Moloney murine leukemia virus (rMoMuLV), and AMV derived from recombinant 
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Avian Myeloblastosis Virus reverse transcriptase (rAMV, Promega Corporation (Madison, USA). 
AMV-generated cDNAs consistently gave Ct values two or more cycles later than cDNAs prepared 
using Superscript IITM or MultiscribeTM (data not shown), and no amplification signal was detected 
after 45 cycles for ACAT-2 from AMV preparations, hence AMV was not explored further. Other 
experiments (data not shown) indicated that reverse transcription was more efficient at 42 ºC (i.e. 
smaller Ct values after qPCR) compared to 48 ºC, and that Superscript was more efficient and 
consistent than MultiscribeTM. Amounts of RNA in the range 0.5-2 µg as recommended by the 
manufacturer and widely cited in the literature (e.g. Wong et al., 1998) appeared to give similarly 
efficient yields of cDNA using Superscript IITM (data not shown), and were used without extensive 
validation.  
 
Procedure: cDNA was generated from 0.5-2 µg samples of total RNA at 42 ºC for 50 min (reaction 
volume 10 µL) using random hexamer primers and reverse transcriptase (Superscript IITM kit, Life 
Technologies) using protocols recommended by the manufacturer, as described below.  
1. To an Eppendorf tube containing 2 µL of RNase free water and 0.5 µL of random hexamer 
solution (supplied with kit), 0.5-2 µg of total RNA was added and incubated at 70 ºC for 10 
min, then placed on ice for 5 min. 
2. A mixture containing 2 µL of 5X buffer, 1 µL of 0.1M DTT (dithiothreitol) and 0.5 µL of 
10 µM dNTP (deoxynucleotide triphosphate solution) was added to the RNA solution (1 
above) and incubated at 42 ºC for 5 min. 
3. Then 0.5 µL of Superscript IITM reverse transcriptase solution was added and incubated at 
42 ºC for 50 min. 
4. The reaction was terminated by denaturation at 70 ºC for 15 minutes. 
 5.  The reaction mixture was diluted with 40 µL RNase-free water, or a specified volume of 
water depending on the concentration of cDNA required. 
 
2.2.4 ACAT primer and probe design 
 
To avoid possible signal production from potential contaminating genomic DNA, specific primers 
for each ACAT gene were designed across a common exon-exon splice junction, selected as 
described below from the published full-length cDNA sequences (Oelkers et al., 1998, Li et al., 
1999).  At the time this work was undertaken, the exon-intron boundary junctions were known only 
for ACAT-1 (Li et al., 1999).  Using the published cDNA sequence of ACAT-2 (Oelkers et al., 
1998), its cognate genomic sequence was found in the human sequence database, and an alignment 
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identified 15 exons for human ACAT-2, subsequently verified by Song et al. (2001) and Katsuren et 
al. (2001).  In comparison, ACAT-1 has 16 exons that subtend 15 introns (Li et al., 1999).  Although 
a homolog of the first intron of ACAT-1 is absent from ACAT-2, most of the other intron splice sites 
for ACAT-1 and ACAT-2 are highly conserved (see Results, Section 2.3.1).  Exons and introns for 
ACAT-1 and their ACAT-2 homologs are numbered elsewhere in this thesis as described in Sec. 
1.2.3 and Sec. 1.2.5 respectively, according to the ACAT-1 designations of Li et al. (1999). From an 
alignment of the ACAT-1 and ACAT-2 cDNAs, the splice site joining exons 5 and 6 for ACAT-1 (i.e. 
the exon 5/6 junction), and the exon 4/5 junction for ACAT-2, were found to be homologous to each 
other, and exhibited suitable sequence divergence and GC content for the design of cDNA-specific 
PCR primer pairs including one that spans the splice junction.  
 
Forward and reverse primers and TaqMan® probes specific for ACAT-1 and ACAT-2, respectively, 
were designed for the real time PCR assays using Primer Express software version 5 (Applied 
Biosystems) as indicated in Figure 2.1. To prevent amplification from any contaminating genomic 
DNA, one of the primers for each assay (forward primer) was designed over exon-exon splice 
junction 5/6 for ACAT-1 (4/5 for ACAT-2), and the reverse primer was located within exon 6 for 
ACAT-1 (exon 5 for ACAT-2). The location of splice junctions are indicated below by arrows ( ). 
 
ACAT-1 assay (amplicon size 89 nucleotides):  
Forward primer ACAT1FWD1 (= 1F1): 
 5'-CAAGGCGCTCTCTCTTAGA TGAAC-3' 
 Reverse primer ACAT1REV1 (= 1R1): 
5'-GATAAAGAGAATGAGGAGGGCAATAA-3' 
TaqMan® Probe (synonymous with forward strand): 
5'-(FAM)-CTTGAAGTGGACCACATCAGAACAATATATCACATG (TAMRA)-3'.  
 
ACAT-2 assay (amplicon size 70 nucleotides): 
 Forward primer ACAT2FWD1 (= 2F1): 
 5'-GCAAGTCCCTGCTTGA TGAGC-3' 
Reverse primer ACAT2REV1 (= 2R1): 
 5'-CCAGCGATGAACATGTGGTAGAT-3';  
Probe (synonymous with reverse strand): 
 5'-(FAM)-TGCGGAAATGCTGCACCTCCAT-(TAMRA)-3'.  
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Figure 2.1:  Design of human ACAT-1 and ACAT-2 primers and probes 
 
The TaqMan® probes were synthesized with the fluorescent reporter dye FAMTM (6-carboxy-
fluorescein) attached to the 5'-end, and the quencher dye TAMRATM (6-carboxy-tetramethyl-
rhodamine) attached to the 3'-end. Primers were ordered from Sigma Genosys (Sigma-Aldrich, 
Castle Hill, NSW, Australia).  TaqMan® probes for the ACAT assays, and 2x Master mix cat. # 
4304437 containing Taq Gold DNA polymerase were obtained from Applied Biosystems (Foster 
city, USA). Human β-actin was used as an internal reference to compare expression levels, using a 
pre-developed assay primer/probe reagent kit (PDAR, Applied Biosystems, cat. # 431088IE) 
containing the primer-pair and a TaqMan®  probe labelled at the 5'-end with the reporter dye VICTM 
and the quencher dye TAMRATM at the 3’-end.  
 
2.2.5 Multiplex RT-qPCR assays with β-actin as internal reference 
 
Multiplex assays were developed for total cDNA samples, using a single reaction mixture that 
included the PDAR reagents for β-actin (as an endogenous “internal” reference representing a 
“housekeeping” gene), together with the primers and TaqMan® probe for either ACAT-1 or ACAT-
2. Target sequences were quantified by PCR using an ABI Model 7700 Sequence Detector (Applied 
Biosystems).  Reagent concentrations and PCR conditions were optimised by limiting the 
concentration of the β-actin primers (experimental data not shown) to enable amplification signals 
from ACAT-1 or ACAT-2 (FAMTM labelled probes) to be detected in a single reaction tube without 
interference from β-actin amplification (VIC® labelled probe) (cf. Section 2.3.3.3).   
 
43 
 
qPCR reactions (25 L final volume), each containing human cDNA equivalent to 20 ng of total 
RNA (unless otherwise specified) prior to reverse transcription, were set up as follows: 
 
Reaction mixture: reaction tubes (25 µL final volume) contained 0.3 M of each ACAT primer 
as specified, 0.2 M of its cognate TaqMan® probe, and 1.25 L of the human -actin 
primer/probe PDAR reagent.  
 
PCR program: Reaction mixtures were pre-incubated for 2 min at 50C (for hydrolysis of 
possible contaminating dUTP-containing template produced by previous PCRs in the laboratory 
(assays used dUTP in place of dTTP, and the master mix for Taq Gold used uracil-N-
glycosylase (UNG) to degrade products of previous PCRs).  The PCR program was 10 min of 
Taq Gold activation at 95C, followed by 45 cycles of 15 sec at 95C and 1 min at 60C 
(maximum ramping speed between temperatures).   
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Figure 2.2: Typical RT-qPCR amplification plots for ACAT-1, ACAT-2, and β-actin showing how 
their relative expression levels can be assayed by quantitative real-time PCR using a cDNA 
template derived from RT treatment of 20 ng of RNA from a single human liver sample #6. A: 
Amplification plots for β-actin in the two multiplex tubes used to assay ACAT-1 (tube 1) and 
ACAT-2 (tube 2) are closely superimposed within experimental error. B: Amplification plots for 
ACAT-1 and ACAT-2 in tubes 1 and 2, respectively. When the amplification plots for β-actin are 
identical, the difference between the Ct values for ACAT-1 and ACAT-2 (arrow) indicates the Ct 
value as defined in the text. Rn is the relative fluorescence of the reporter dye in arbitrary units.  
 
 
The PCR cycle number at which the fluorescence signal from each assay target reached the 
threshold detection line was determined (Ct value, cf. Figure 2.2).  Generally, cDNA samples were 
assayed on at least two and up to six occasions to check for assay reliability using duplicate assay 
reactions on each occasion. The Ct for the ACAT isoform assayed in each tube was calculated as 
Ct = [Ct (ACAT isoform) - Ct (-actin)].   Ct values from all assay reactions were pooled to 
determine the mean Ct value and standard error for each sample.  Assuming transcripts of ACAT-1 
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and ACAT-2 generate equal TaqMan® fluorescence signals from each transcript, the relative 
abundance of ACAT-2 to ACAT-1 can be calculated by the following equations:  
Ct = Ct(ACAT-2) – Ct(ACAT-1)  
Ratio (ACAT-2)/(ACAT-1)  = 2-Ct 
For each sample, standard errors (SE) for Ct for the difference between the two means were 
calculated according to Arkin and Colton (1966) using the following equation: 
SE = [(21 /n1) + (22 /n2 )]1/2        
where 1   = standard deviation for Ct (ACAT-1/(-actin), 2  = standard deviation for Ct (ACAT-
2/(-actin), n1 = number of assays for Ct (ACAT-1/(-actin), n2 = number of assays for Ct 
(ACAT-2/(-actin). Standard errors for ratios of each sample were determined from (Ct + SE) and 
(Ct - SE) or (Ct + SE) and (Ct - SE) as detailed in the ABI PRISM 7700 user manual 
(Bulletin #2).  To compare sets of different samples, mean values of ACAT-isoform/-actin or 
ACAT-2/ACAT-1 for each tissue type (cf. Fig. 2.7) were calculated directly from the ratio values 
calculated (via 2-Ct or 2-Ct) for each individual sample, and are presented  SE unless otherwise 
indicated. Calculations and statistical analysis of data were achieved using appropriate functions 
embedded within software for Microsoft Excel spreadsheets. 
  
Figure 2.2 shows typical amplification plots for ACAT-1, ACAT-2 and β-actin for liver #6 (Table 
2.1), and illustrates how the relative difference in abundance of ACAT-1 and ACAT-2 transcripts in 
a single cDNA sample (Ct) was calculated.  The amplification plots for -actin (tubes one and 
two, Fig. 2.2 A) and ACAT-1 and ACAT-2 (tubes one and two, Fig. 2.2 B) have been superimposed 
to illustrate typical assay data from a single sample. Two independent portions of tissue were taken 
from liver #6, and RNA extracts prepared and assayed independently by RT-qPCR gave very 
similar results (data not shown), indicating the general reliability of the  procedures used for this 
work.  In the comparison of ACAT data for all samples examined in this study, Figure 2.2 presents 
the pooled data from the two samples of liver #6. Most other accessions used RNA derived from a 
single portion taken from each frozen tissue sample. 
 
2.2.6 Validation of the multiplex assays for ACAT-1 and ACAT-2 
 
Cloned cDNAs for human ACAT-1 (pcDNA3, a gift from T-Y Chang via Sandra Erickson) and 
human ACAT-2 (pRS426-GalPro, a gift from Steven Sturley) were quantified by spectrophotometry 
at 260 nm. A260 values were converted to plasmid copies/mL using the deduced molecular weights 
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for each plasmid, calculated from their size (3743 bp for ACAT-1, pcDNA3; 8402 bp for ACAT-2, 
pRS426-GalPro), assuming an average MW of 616 Daltons for a base pair and Avogadro’s number, 
and assuming a 1 mg/mL solution of dsDNA has an A260 of 20. A dilution series was prepared for 
each of the clones as follows: 5× 106 molecules/µl, 5× 105 molecules/ µL, 5× 104 molecules/µL, 5× 
103 molecules/µL, 5 x 102 molecules/ µL, 50 molecules/ µL, 5 molecules/ µL, and 0.5 molecule/µL;  
2 µL of each dilution was used per reaction for duplicate assays.   
 
2.3  Results 
 
2.3.1 Development of highly specific assays for ACAT-1 and ACAT-2  
 
As noted in Section 2.2.4, to avoid spurious PCR amplification from human genomic DNA, the 
forward primer for each ACAT isoform was designed to span an exon-exon splice junction common 
to both ACAT-1 and ACAT-2. As part of the design process, the cDNA sequences of ACAT-1 and 
ACAT-2 were aligned, and 11 of the 15 splice junctions in ACAT-1 were found to be identical to the 
cognate splice junctions in ACAT-2. The exceptions were the splice sites joining: 
i) exons 1/2 for ACAT-1 (intron 1 for ACAT-1 was missing from ACAT-2);  
ii) exons 2/3 for ACAT-1 (cognate exon 1/2 splice site was 3 bp downstream in ACAT-2);  
iii) exons 4/5 for ACAT-1 (15 nucleotides flanking the ACAT-1 splice site were deleted from the 
cognate exon 3/4 splice site for ACAT-2, and the splice site for ACAT-2 was 15 bp upstream 
from the splice site for ACAT-1 in the aligned sequence); and 
iv) exons 8/9 for ACAT-1 (splice site was 10 bp upstream of the cognate exon 7/8 splice site in 
ACAT-2).  
 
Sequences flanking splice junction 5/6 for ACAT-1, and junction 4/5 for ACAT-2, were used to 
design forward primers for both ACAT-1 and ACAT-2 that should be highly specific for transcripts 
of each gene (cf. Sec. 2.3.2). Additionally, each assay should be able to amplify cDNA without 
amplifying any contaminating genomic DNA (gDNA) (cf. Sec. 2.3.3.1).  
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2.3.2  Validation of the TaqMan® real-time qPCR assays using cDNA clones of ACAT-1 and 
ACAT-2 as template  
 
2.3.2.1 Sensitivity and amplification efficiency of the ACAT assay protocols 
 
Short PCR amplicons were designed to minimise inaccuracy related to possible differential 
degradation of RNA samples during extraction and reverse transcription, and to enhance the 
sensitivity and efficiency of the PCR.  To check PCR sensitivity and efficiency, a ten-fold dilution 
series of full-length cDNA clones of both ACAT-1 and ACAT-2 was tested in the absence of assay 
reagents for β-actin. 
 
The ACAT-1 assay detected the cloned ACAT-1 cDNA template at high sensitivity (Figure 2.3), for 
example 107 and 104 template copies were detected with Ct values of 16.5 and 27.2 cycles, 
respectively. Similarly, the ACAT-2 assay detected 107 and 104 template copies of the cloned ACAT-
2 cDNA template with Ct values of 16.3 and 25.8 cycles, respectively (Figure 2.4).  Ct values (data 
not shown) were highly variable for reactions expected to contain only one template, presumably 
because the actual number of templates per reaction tube varied. However consistent data were 
obtained from replicates or reactions expected to contain 10 (Ct values of about 38 cycles) or more 
templates.  
 
Theoretically, there should be a doubling of PCR product after each amplification cycle, i.e. Xn = 
Xo x 2
n where Xo = initial number of target molecules, Xn = number of target molecules after n PCR 
cycles. However in practice, amplification products may not double with each cycle for reasons 
such as inefficient priming on template or the presence of Taq inhibitors, and the amplification 
efficiency E can be calculated from the equation:  
Xn = Xo(1 + E)
n, where  Xn  represents the number of amplified DNA copies after n PCR cycles, 
starting from X0 copies of cDNA template (www3.appliedbiosystems.com/cms.groups/mcb_marketing 
documents/generaldocuments/cms_040377.pdf). Amplification efficiency E was calculated from plots of Ct 
vs. log (amount cDNA), using the relationship (1+E) = 10–(1/slope). 
 
The Ct vs. log (amount cDNA) plots shown in Figures 2.3 and 2.4 gave slopes which demonstrated 
that the increase in Ct after each 10-fold dilution approximated to the theoretical value of +3.32 
cycles expected for maximum (2n) PCR efficiency (Table 2.2). Although the ACAT-1 assay 
appeared to be slightly less efficient (~95%) than the ACAT-2 assay (~100%), this difference was 
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small and thought to represent experimental error, and the primer/probe combinations used for the 
assays of transcripts of each ACAT isoform appeared to be sufficiently sensitive and efficient for 
large scale screening of samples. 
 
 
Figure 2.3: Standard curve for a dilution series of cloned human ACAT-1 cDNA (pcDNA3) assayed 
by qPCR. Data points represent the mean of duplicate reaction tubes set up as described in the 
Methods but omitting the primers/probe for β-actin.  
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Figure 2.4: Standard curve for a dilution series of cloned human ACAT-2 (pRS426-GalPro) assayed 
by qPCR. Data points represent the mean of duplicate reaction tubes set up as described in the 
Methods but omitting the primers/probe for β-actin. 
 
 
Assay Correlation co-efficient 
(R2) 
Slope 
 
Amplification 
efficiency: (1+E), % E 
ACAT-1 0.9912 -3.44 (1.947),   95.0% 
ACAT-2 0.9997 -3.31 (2.0037),    100.4% 
 
Table 2.2: Data derived from qPCR assays of dilution series of cloned human cDNAs of human 
ACAT-1 and ACAT-2 as shown in Figures 2.3 and 2.4. Slope indicates the change in Ct value (i.e. 
number of PCR cycles) per 10-fold increase in number of template copies. Amplification efficiency 
(E) is calculated by first determining the value 10-(1/slope) which corresponds to (1 + E) as defined in 
the Results section 2.3.2.1. 
 
 
2.3.2.2 Specificity of each ACAT assay for its target cDNA clone  
 
Using 107 cloned cDNA copies of ACAT-1 or ACAT-1 as template, each TaqMan® assay was 
highly specific for its intended target (Table 2.3), and cross-reactivity (observed as much later Ct 
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values for the other ACAT isoform) was very small or negligible. Hence the ACAT-1 assay detected 
107 cloned copies of ACAT-1 DNA after ~16.7 cycles, i.e. about 19-20 cycles earlier than 107 
cloned copies of ACAT-2 DNA (~36 cycles). Similarly the ACAT-2 assay detected 107 cloned 
copies of ACAT-1 DNA after ~16.4 cycles, i.e. 28 or more cycles earlier than 107 cloned copies of 
ACAT-1 DNA (>45 cycles).  
 
 
 Ct values for 107 copies 
 ACAT-1 clone ACAT-2 clone 
ACAT-1 assay 16.5, 16.8 (mean: 16.7) 36.5, 35.5 (mean: 36.0) 
ACAT-2 assay >45 16.4, 16.4 (mean: 16.4) 
 
Table 2.3: Samples (107 copies) of each cDNA clone (pcDNA3 for ACAT-1, pRS426-GalPro for 
ACAT-2) were assayed in turn by the TaqMan® qPCR assays for ACAT-1 and ACAT-2 (in the 
absence of primers/probe for β-actin). Data represent values of duplicate assays. 
 
 
Specificity ratios for each ACAT assay were calculated by comparing the apparent abundance of 
each cloned ACAT target in the sample of 107 copies being assayed (Table 2.3). For the ACAT-1 
assay, the apparent ACAT-2/ACAT-1 abundance ratio was: 
 = 2-ΔCt  = 2-(36.0-16.7)     =  2-(19.3)   =   1.55 x  10-6    
i.e.  ~2 x10-6  
 
Thus the ACAT-1 assay appeared to detect ~1/(2 x10-6 = 0.5 x 106) times more copies of the ACAT-
1 clone than the ACAT-2 clone, when used to assay 107 copies of each clone. Therefore, if a 
sample contained ~0.5 x106 times more copies of ACAT-2 than ACAT-1 as template, each 
ACAT isoform would contribute equally to the apparent ACAT-1 abundance, i.e. the actual 
abundance of ACAT-1 would be half (0.5) its apparent abundance. If a cDNA sample contained 
104 times (say) more copies of ACAT-2 than ACAT-1, the contribution from ACAT-2 to apparent 
ACAT-1 abundance would be about:  0.5 x [104 /(0.5 x106)]  =  1 x 10-2   =  0.01   =  1 % , and hence 
negligible. 
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Similarly, for the ACAT-2 assay, it can be shown that if a cDNA sample contained 107 times more 
copies of ACAT-1 than ACAT-2 (i.e. an apparent ACAT-2/ACAT-1 ratio of   ~10-7), the error in 
estimating ACAT-2 abundance would be <1%, and hence negligible. 
 
Overall, if a sample gives an apparent ACAT-2/ACAT-1 ratio within the limits 10-7 to 104, neither 
the ACAT-1 nor ACAT-2 assay will be compromised by interference with cDNA from the other 
isoform. The actual ACAT-2/ACAT-1 ratios obtained from a variety of total cDNA samples of 
diverse origin (cf. Figures 2.5 and 2.6) ranged from ~0.005 (some liver and PBMC samples) to ~14 
(some duodenum samples), which are well within the interference limit for both the ACAT-1 and 
ACAT-2 assays. 
 
2.3.3 Validation of the multiplex assays of total cDNA from human samples using β-actin as 
reference  
 
2.3.3.1 Possible interference by genomic DNA in total cDNA samples  
 
The procedures used to isolate total RNA from human samples have the potential to carry over 
genomic DNA (gDNA) as a contaminant, and no steps were used to remove it e.g. by DNase 
treatment. Although the primers and TaqMan® probes for ACAT assays were designed to 
discriminate cDNA from its cognate gDNA sequence (cf. Sec. 2.2.4), the specificity of the assays 
for cDNA required validation.  Using 45ng of purified gDNA per multiplex assay (i.e. > twice the 
loading of 20 ng total cDNA used for routine qPCR assays), neither ACAT-1 nor ACAT-2 were 
detected in the gDNA sample by the multiplex assays (Ct > 45 cycles). Furthermore, “minus RT” 
controls run from time to time (using 20 ng samples of total RNA from liver as template without 
RT treatment) also failed to detect any signal for ACAT-1 or ACAT-2 amplification after 45 cycles 
of PCR.  
 
Similarly to the “minus RT” controls, “no template controls” consisting of the all PCR reagents but 
containing water instead of template, were incorporated in each qPCR run. The minus RT controls 
also failed to detect any contaminating DNA template carried over from previous runs (e.g. 
amplification products not destroyed by UNG treatment (cf. Sec. 2.2.5). These controls indicated 
that the procedures used to prevent cross-contamination (and hence false positives) were effective. 
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2.3.3.2 Genomic DNA interference in assays of β-actin  
 
Assay protocol, 
β-actin multiplexed 
with: 
Ct values for β-actin 
45 ng genomic DNA “minus RT cDNA”  
from 20 ng liver #6 RNA 
ACAT-1 35.7,  36.1,  36.2 >45 
ACAT-2 37.3,  37.2,  37.0 >45 
 
Table 2.4: Ct values for β-actin using the PDAR primer/probe kit supplied by Applied Biosystems 
in multiplex assays that include the primers and probe for each ACAT transcript as appropriate. 
Data for gDNA or “minus RT cDNA” samples from triplicate reaction tubes run on the same 
occasion are presented for the β-actin assays only. 
 
The manufacturers of the β-actin reference assay PDAR kit note that human gDNA can give an 
amplification signal.  Although the multiplex assays for ACAT-1 and ACAT-2 gave a positive signal 
for β-actin (Ct values ~36 cycles) with a large (45 ng) sample of purified human gDNA (Table 2.4), 
a 20 ng sample of the “minus RT cDNA” gave no amplification signal for β-actin (Ct>45 cycles) 
(Table 2.4). This compares with detection of a “plus RT cDNA” sample (derived from the same 
liver sample) being detected after ~23 cycles (cf. Fig 2.2). This (and other minus RT controls) 
indicates that any carry-over gDNA present in standard 20 ng samples of cDNA is insufficient to 
interfere with the assays of β-actin described in this thesis.  
 
2.3.3.3   Amplification kinetics of β-actin and ACAT targets during PCR 
 
One of the reasons for choosing β-actin as reference gene was its presumptive greater expression 
than ACAT genes. When designing the multiplex assays, limiting concentrations of primers for β-
actin were used (as recommended by the manufacturer), to minimise the possibility that optimum 
PCR efficiency for the ACAT component was not compromised by prior depletion of reagents 
during β-actin amplification. Using samples of total cDNA as template, it was confirmed that β-
actin transcripts were more abundant in all human tissue samples tested compared to either ACAT-1 
or ACAT-2 transcripts, i.e. they gave lower Ct values as shown in Fig 2.2 for liver #6.  
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2.3.3.4   Effect of sample size during PCR  
 
Real time qPCR is most efficient and reproducible when Ct values are small, but this requires larger 
amounts of total cDNA template which may be wasteful, and also increases the possibility that Taq 
inhibitors might carry over from the biological sample and interfere with optimum PCR conditions. 
To examine the effect of sample size on assays, a dilution series representing 150, 80, 40, 15 and 5 
ng total cDNA (prepared by mixing equal amounts of total cDNA from liver and duodenum, to 
equalise the relative abundance of ACAT-1 and ACAT-2 transcripts) was assayed by the standard 
multiplex assay protocols for ACAT-1 and ACAT-2. Assay results were plotted as Ct vs. log 
(amount cDNA) for ACAT-1, ACAT-2 and β-actin (Figures 2.5A, 2.5B and 2.5C, respectively), and 
used to deduce slopes and hence amplification efficiencies as indicated in the Fig. 2.5.  
 
Amplification efficiencies for β-actin were close to E= 1.00 (100%) as expected (cf. Fig 2.5C), i.e. 
101% for β-actin multiplexed with ACAT-1, 102% for β-actin multiplexed with ACAT-2). However 
contrary to expectations, amplification efficiencies were well above 100% for ACAT-1, (119.9%) 
and ACAT-2 (107.6%), i.e. the PCR amplification kinetics were apparently >2n, which is highly 
unlikely.  
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Figure 2.5:  Plots of Ct vs. log (amount cDNA) from TaqMan® based multiplex qPCR assays of 
ACAT-1 and ACAT-2 that include β-actin as reference.  The dilution series of cDNA (1.5, 5, 15, 40, 
80 and 150 ng) was taken from a pooled cDNA preparation obtained by mixing equal amounts of 
total cDNA from liver sample #8 and duodenal sample #A.  Mean values are presented from 2-4 
replicate reactions for each amount of cDNA assayed. E represents amplification efficiency for the 
relationship Xn = X0(1+E)
n for the number of amplified DNA copies (Xn) after n PCR cycles, 
starting from X0 copies of cDNA template. 
Slope = -2.92
R² = 0.988
E = 1.19
25
30
35
1 10 100 1000
C
t 
V
a
lu
e
ng cDNA 
ACAT-1
Slope=-3.15
R² = 0.989
E=1.07
25
30
35
1 10 100 1000
C
t 
V
a
lu
e
ng cDNA
ACAT-2 
A 
B 
C 
55 
 
The cause of apparent PCR efficiencies >2n is not known, but could result, for example, from 
factors such as interaction between the β-actin and ACAT components of the multiplex reaction 
mixtures, or dilution of Taq inhibitory materials carried over during extraction of RNA and 
preparation of total cDNA. For example, the presence of Taq inhibitors would cause greater 
inhibition with larger amounts of template, giving a decreased negative slope from Ct vs. log cDNA 
plots. Because amplification efficiency (E) is calculated from the relationship (1+E) = 10–(1/slope), 
this would result in an apparent PCR amplification efficiency of >2n, as observed in Fig. 2.5 where 
E values >1.00 indicate >2n amplification kinetics).  However, the effect of any Taq inhibitor would 
be expected to apply also to the β-actin assays, which approximated to 100% efficiency, which 
would seem to exclude such putative inhibitors. The issue of variable amplification efficiency will 
be discussed further in Chapter 3.  
 
Another approach to evaluating the effect of sample size on the multiplex assays was to calculate 
values for ΔCt [(ACAT-1) – (β-actin)] and ΔCt (ACAT-2) – (β-actin) for each amount of cDNA 
assayed (Table 2.5). These ΔCt values were used to calculate Ct values for [(ACAT-2) –(ACAT-
1)] and hence the ACAT-2/ACAT-1 mRNA abundance ratio for each amount of cDNA. The ΔCt 
values for [(ACAT-1) – (β-actin)] were most variable and tended to decrease slightly as the amount 
of cDNA assayed decreased, however none of these values were significantly different from each 
other (i.e. all comparisons were P>0.05). The ΔCt values for [(ACAT-2) – (β-actin)] were less 
variable for different amounts of cDNA, and none of these values were significantly different from 
each other. Mean values for Ct [(ACAT-2) –(ACAT-1)] were not significantly different from each 
other for samples in the range 1.5 – 40 ng total cDNA (P ≥ ~0.7 for all pair wise combinations using 
two-tailed t-test), indicating that samples in this size range gave very similar results (cf. Table 2.5 
for ACAT-2/ACAT-1 ratios derived from the Ct values). 
 
Based on the consistency of Ct and Ct values described above, the assay methods appeared to 
be suitable for routine assays of various human cDNA within the range 1.5-40 ng cDNA assayed 
(ratio range 1.62-1.75, Table 2.5), and 20 ng was selected for routine assays. Because assays of 
ACAT-1 gave somewhat more variable results than ACAT-2 (cf. Table 2.5), assays were repeated 
when necessary to obtain statistically reliable results.  
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ng cDNA 
Mean ΔCt ±  SD 
(ACAT-1) –(β-actin) 
Mean ΔCt ±  SD 
(ACAT-2) –(β-actin) 
Ratio ±  SE 
ACAT-2/ACAT-1 
150 9.17 ± 0.23 9.18 ± 0.02 1.01 ± 0.13 
80 9.45 ± 0.19 9.26 ± 0.15 0.87 ± 0.16 
40 8.50 ± 0.17 9.27 ± 0.08 1.70 ± 0.10 
15 8.62 ± 0.27 9.43 ± 0.17 1.75 ± 0.17 
5 8.46 ± 0.39 9.15 ± 0.05 1.62 ± 0.23 
1.5 8.14 ± 0.15 8.93 ± 0.20 1.73 ± 0.18 
Mean of all samples: 8.72  ± 0.49 SD 9.20  ± 0.16 SD  
 
Table 2.5: Results from multiplex qPCR assays of a dilution series of a pooled cDNA preparation as 
described in Fig. 2.5. ΔCt values were calculated from the Ct values of (ACAT-1 minus β-actin) or 
(ACAT-2 minus β-actin) for each reaction tube.  The mean values of ΔCt were used to calculate 
ΔΔCt [(ACAT-2) – (ACAT-1)] and hence the relative abundance ratios of ACAT-2/ACAT-1 (2-ΔΔCt) 
as described in Section 2.2.5. 
 
2.3.3.5 Examination of sizes of PCR products from ACAT-1 and ACAT-2 assays 
 
Amplification products of the ACAT-1 and ACAT-2 assay protocols (using reaction mixtures that 
omitted the β-actin reagents) gave products consistent with the expected size: ACAT-1 assay 89 
nucleotides, ACAT-2 assay 70 nucleotides (Fig. 2.6).  
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Figure 2.6:  Agarose gel electrophoresis of qPCR products from 20 ng of a mixed liver/duodenum 
cDNA sample (Fig. 2.5) using (a) the ACAT-1 assay protocol (Lanes 4 and 5), and (b) the ACAT-2 
assay protocol (Lanes 6 and 7). Reagents for the β-actin reference gene were omitted from these 
assays. A single PCR product of the expected size is apparent for each ACAT isoform. Lane 1 
represents a “GeneRuler 1 kb ladder” (Thermo Fisher Scientific, Australia). 
 
 
2.3.4   Survey of ACAT-1 and ACAT-2 expression in diverse human tissues. 
 
2.3.4.1 ACAT expression levels relative to β-actin 
Relative to β-actin, ACAT-1 and ACAT-2 were expressed as low-abundance transcripts in three 
different human tissues (liver, duodenum, and kidney; Fig. 2.7A, B) and PBMC (Fig. 2.8A, B). 
Expression levels varied considerably in different tissues and are shown on a logarithmic scale in 
Figs. 2.7A and 2.7B to depict all data visually. Both ACAT-1 and ACAT-2 transcripts were readily 
detected in all samples, including ACAT-2 in PBMC, at levels well within the range of sensitivity of 
the RT-qPCR technology as defined by the dilution series of cloned cDNA templates described in 
Section 2.3.2.1. The highest expression of the ACAT-1 transcript was observed in the liver and 
kidney samples, reaching a maximum abundance of only 1–2% that of the β-actin transcript. The 
highest expression of ACAT-2 was observed in duodenum samples, also reaching a maximum 
abundance of only 1–2% that of the β-actin transcript.  
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Because ACAT-1 expression relative to β-actin was more consistent and at generally higher levels 
than ACAT-2 in all of the tissue types examined except duodenum (see below), ACAT-1 was used as 
the reference transcript. Hence the expression of transcripts of the two ACAT isoforms relative to 
each other is presented as an ACAT-2/ACAT-1 ratio for each sample (Figs. 2.7C, 2.8C and 2.9C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7: The relative abundance of ACAT-1 and ACAT-2 transcripts in total RNA from different 
tissue samples was determined by real-time RT-qPCR and expressed relative to β-actin with 
standard errors for replicate determinations as described in Materials and Methods. Data for liver 
samples (#1–#17), duodenum samples (#A–#J), and kidney samples (#a–#c) are shown. The subject 
and patient characteristics from which these samples were taken are given in Materials and Methods 
and in Table 2.1. A: ACAT-1/β-actin. B: ACAT-2/β-actin. C: ACAT-2/ACAT-1. The y axes in A and 
B are on a log scale to display all data visually, whereas the y axis in C is on a linear scale to 
highlight the dramatic differences in relative expression between ACAT-2 and ACAT-1 in samples 
from different tissues. 
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2.3.4.2 Expression range among samples in different tissues  
 
The results shown in Figs. 2.7A and 2.8A indicate that ACAT-1 was expressed at appreciable levels, 
ranging from 132 to 2,194 x 10-5 (relative to β-actin) in samples from all tissues and cells examined, 
albeit clearly lower (relative to β-actin) in duodenum and PBMC than in liver and kidney. ACAT-2 
expression was more variable, ranging from 4 to 1,613 x 10-5 (relative to β-actin), with transcript 
levels being much higher (on average) in duodenum than in liver, kidney, and PBMC. Results 
obtained for a single sample of spleen obtained from an organ donor were similar to those for liver: 
ACAT-1/β-actin = 547 x 10-5; ACAT-2/β-actin = 15.0 x 10-5, ACAT-2 /ACAT-1 = 0.027.  
 
Figures 2.7C and 2.8C compare the ACAT-2/ACAT-1 ratio of all samples assayed, using a linear 
scale in Fig. 2.7C to demonstrate the dramatically higher expression of ACAT-2 over ACAT-1 
among the 10 duodenal samples (ACAT-2/ACAT-1 range 4.3 – 12.23) compared with the other 
tissue types assayed (e.g. ACAT-2/ACAT-1 range 0.006 – 0.58 among 17 liver samples).   
 
2.3.4.3 Comparative expression values for each tissue type 
 
Tests for significance for pair wise comparisons of each tissue type (except kidney, which was 
represented by only three samples) indicate that the mean mRNA abundance values for liver, 
duodenum and PBMC (Fig. 2.9A–C) were all significantly different from each other (P 0.05). For 
example relative to β-actin, ACAT-1 was on average about 3.3 times more abundant in liver than in 
duodenum, whereas ACAT-2 was on average about 9 times more abundant in duodenum than in 
liver (Fig. 2.10). Thus, when expressed as a percentage of total ACAT mRNA for the two ACAT 
isoforms, human liver constituted 90% ACAT-1 (range, 77–99% of total ACAT mRNA). 
Conversely, human duodenum constituted 77% ACAT-2 (range, 28–92% of total ACAT mRNA). 
ACAT-2 mRNA was more abundant than ACAT-1 mRNA in all duodenal samples examined except 
for sample C (Fig. 2.7B), in which 28% of total ACAT mRNA was ACAT-2. ACAT-2 levels in 
PBMC were exceedingly low compared with those in the other tissues examined (Fig. 2.9B).  
 
The most dramatic differences between tissue types were demonstrated by the mean ACAT-2/ACAT-
1 ratios (Fig. 2.9), which were far higher in duodenum (mean ACAT-2/ACAT-1 ratio of 3.27) than in 
PBMC (mean ACAT-2/ACAT-1 ratio of 0.015), liver (mean ACAT-2/ACAT-1 ratio of 0.112), and 
kidney (mean ACAT-2/ACAT-1 ratio of 0.180). Thus overall, the mean ACAT-2/ACAT-1 ratio was 
60 
 
about 29 times greater in duodenum than in liver, and about 218 times greater in duodenum than in 
PBMC. 
 
Figure 2.8:   The relative abundance of ACAT-1 and ACAT-2 transcripts in total RNA in peripheral blood 
mononuclear cells (PBMC) was determined by real-time RT-qPCR and expressed relative to β-actin with 
standard errors for replicate determinations as described in Materials and Methods.  Data for PBMC samples 
from healthy volunteers (#a–#d) and from patients with confirmed cholesterol gallstones with a strong family 
history of gallstones (#e–#g; see Table 2.1) are shown. A: ACAT-1/β-actin. B: ACAT-2/β-actin. C: ACAT-
2/ACAT-1. 
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2.3.5   Subgroup analysis of sample backgrounds 
 
The results obtained for liver, duodenal, and PBMC samples are grouped and numbered in Figs. 2.7 
and 2.8 according to patient/subject background (Table 2.1) to assist in the comparison of 
expression levels of ACAT-1 and ACAT-2 as elaborated below.  
 
2.3.5.1 Comparison of ACAT expression in liver samples.  
 
Sampling status. It is possible that sampling, storage and extraction methods could alter the 
relative levels of transcripts initially present in a living tissue, e.g. some transcripts may be more 
susceptible to degradation as a consequence of the treatment of the patient during sampling. 
However, no consistent or significant differences in the expression of either ACAT isoform were 
observed among liver samples obtained from organ donors (mean ± SE for samples #1–#10, #13, 
and #14: ACAT-1/β-actin = 801 ± 99 x 10-5; ACAT-2/β-actin = 60 ± 18 x 10-5; and ACAT-2/ACAT-1 
= 0.074 ± 0.022) compared with patients undergoing liver resection (samples #15–#17: ACAT-1/β-
actin = 876 ± 179 x 10-5; ACAT-2/β-actin = 64 ± 6 x 10-5; ACAT-2/ACAT-1 = 0.083 ± 0.026).  
 
Warm ischemia time, defined as a period of lack of blood flow to the tissue at 37°C before sample 
collection (Smith et al., 1989), varied between 21 and 120 min for samples #13–#17 (Table 2.1). As 
can be surmised from the data presented in Fig. 2.7, warm ischemia resulted in a higher mean level 
(but not statistically significant) of ACAT-1 transcripts (samples #13–#17: ACAT-1/β-actin = 967 ± 
164 x 10-5) compared with organ donor samples having no warm ischemia time (samples #1–#10: 
ACAT-1/β-actin = 740 ± 95 x 10-5). In contrast, ACAT-2 transcript levels were significantly higher 
in warm ischemia samples (samples #13–#17: ACAT-2/β-actin = 100 ± 29 x 10-5) compared with 
control liver samples having no warm ischemia time (samples # 1–#10: ACAT-2/β-actin = 41 ± 13 x 
10-5; P < 0.05).  This difference could be skewed by a subset of the “no-warm-ischemia” liver 
samples (especially samples #5 and #6) that showed particularly low levels of ACAT-2 compared to 
β-actin compared to the other liver samples (Fig. 2.7). 
 
Patient status including disease phenotype. Some liver samples within patient/subject subgroups 
exhibited ACAT expression levels very different from the mean values.  Samples #11 and #12 taken 
from patients with gallstones receiving the drug simvastatin had ACAT expression levels, 
particularly ACAT-2, that were markedly higher than other liver samples (ACAT-1/β-actin = 1,146 x 
10-5 and 2,194 x 10-5, ACAT-2/β-actin = 208 x 10-5 and 1,274 x 10-5 for samples #11 and #12, 
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respectively; Fig. 2.7).   These differences resulted in higher ACAT-2/ACAT-1 ratios for both 
samples (sample #11, 0.181; sample #12, 0.580).   Other samples showing increased ACAT-2/β-actin 
levels were sample #13 obtained from a 9 year old kidney donor (213 x 10-5) and sample #9 taken 
from a fatty donor liver sample (138 x 10-5), i.e., samples #13 and #9 were 5.9- and 3.8-fold higher, 
respectively, than the mean of the other organ donor samples (ACAT-2/β-actin for samples #1–#8, 
#10, and #14 = 36.0 ± 9.6 x 10-5).  
 
2.3.5.2   Comparison of ACAT expression in duodenal samples 
 
 Only small numbers of samples represented each subgroup, and apart from two exceptions, there 
appeared to be no consistent differences in levels of ACAT-1 or ACAT-2 transcripts among the 
subgroups of patients under investigation for iron deficiency, abdominal pain, weight loss, or 
anaemia. The most notable exception was a decreased ACAT-2 expression level (ACAT-2/β-actin = 
157 x 10-5) in duodenal sample #C taken from a 61-year-old female being investigated for iron 
deficiency. As noted in Sec. 2.3.4.2, the ACAT-2/ACAT-1 ratio was less than 1.0 for this sample 
(ratio value 0.39, i.e. ACAT-2 represented 28% of total ACAT mRNA), indicating that ACAT-1 was 
the major isoform, in contrast to all other duodenal samples which had ACAT-2 as the major 
isoform. Patient C was an insulin-dependent type 2 diabetic with chronic renal failure (Table 2.1). 
Another exception was patient #I, who had an extremely low level of ACAT-1 (relative to both β-
actin and ACAT-2, cf. Fig 2.7A and 2.7C) compared to the other duodenal samples. 
 
2.3.5.3   ACAT expression in PBMC from gallstone vs. gallstone-free patients 
Expression levels of ACAT-1 transcripts in PBMC from healthy (apparently gallstone-free) 
volunteers (ACAT-1/β-actin samples #a–#d: mean ± SE = 498 ± 55 x 10-5) were comparable to those 
of patients with confirmed cholesterol gallstones (samples #e–#g: 520 ± 47 x 10-5; Fig. 2.8A). In 
contrast, ACAT-2/β-actin expression levels (Fig. 2.8B) were 80% greater (P < 0.05) in PBMC from 
cholesterol gallstone patients (samples #e–#g: 9.5 ± 0.4 x 10-5) compared with healthy controls 
(samples #a–#d: 5.3 ± 1.0 x 10-5). When expressed as an ACAT-2/ACAT-1 ratio, the cholesterol 
gallstone patients had a ratio (0.018 ± 0.003) that was only 50% higher than that of controls (0.012 ± 
0.004; 0.1 > P > 0.05) as a result of the low ACAT-1/β-actin value for control sample #a. 
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Figure 2.9: Mean values (with standard errors) of the abundance of ACAT-1 and ACAT-2 transcripts 
in different tissue types derived from the data for individual samples presented in Figs. 2.7 and 2.8. 
A: ACAT-1/β-actin. B: ACAT-2/β-actin. C: ACAT-2/ACAT-1. Mean values are presented: liver, n = 
17; duodenum, n = 10; kidney, n = 3; PBMC, n = 7. Tests for significance (Student’s t-test for 
populations with unequal variance) were calculated for pair wise comparisons of each tissue type 
except for kidney, which was represented by only three samples; mean values for all other tissues 
were significantly different from each other (P 0.05). ACAT-1/β-actin: liver versus duodenum (P = 
0.0001), liver versus PBMC (P = 0.0024), duodenum versus PBMC (P = 0.007); ACAT-2/β-actin: 
liver versus duodenum (P = 0.0008), liver versus PBMC (P = 0.025), duodenum versus PBMC (P = 
0.0003); ACAT-1/ACAT-2: liver versus duodenum (P = 0.0165), liver versus PBMC (P = 0.011), 
duodenum versus PBMC (P = 0.0142). 
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2.4   Discussion  
 
2.4.1 Validation of the multiplex ACAT-1 and ACAT-2 assays with β-actin 
 
2.4.1.1 Specificity of the assays for various mRNA isoforms 
 
This chapter describes the development of two multiplexed, TaqMan®-based, RT-qPCR assays to 
determine the relative abundance of ACAT-1 and ACAT-2 mRNA relative to in human tissue and 
cell samples. Note that β-actin cancels out when calculating ACAT-2/ACAT-1 ratios, and the ratio 
values presented herein represent a true representation of relative abundance of ACAT-2 compared 
to ACAT-1 mRNA molecules, assuming equal reverse transcription efficiency, equal PCR 
efficiency, and equal detection sensitivity (i.e. emitted fluorescence per amplicon) for assays of 
each ACAT isoform. The assays were sufficiently sensitive to detect <10 copies (and probably a 
single copy) of cloned cDNA targets.  
 
When the PCR primers were designed, all known transcripts of ACAT-1 included the same ORF 
encompassing exons 2-16.  For ACAT-2, a sole 2.2 kb mRNA species had been identified (in human 
foetal liver samples, Oelkers et al., 1998, cf. Sec. 1.2.5) that included an ORF encompassing exons 
1-15 (Katsuren et al., 2001). The PCR forward primers for both ACAT-1 and ACAT-2 were designed 
across cognate splice junctions:  exons 5 and 6 for ACAT-1 with the reverse primer located in exon 
6; exons 4 and 5 for ACAT-2 with the reverse primer located in exon 5 (Sec. 2.2.4, 2.3.1). Hence at 
the time the assays were designed and applied to the survey described above, it was assumed that 
these primers would amplify all mRNA species of both ACAT-1 and ACAT-2. As far as we are 
aware, this situation still pertains for ACAT-1 (cf. Sec 1.2.3).  
 
In work published after completion of the assays described in this chapter, two additional 
ACAT-2 mRNA splice variants were reported in various human cell lines (Yao et al., 2005).  
Hence ACAT-2 can potentially be expressed as three known isoforms.  The original 2.2 kb mRNA 
species, representing the full length 522-amino acid protein encoded by exons 1-16, is now named 
ACAT-2a and is presumed to be most abundant (cf. Sec. 1.2.5, 1.2.6). The splice variants encode a 
502-amino acid protein that lacks exon 4 (ACAT-2b), and a 379-amino acid protein that lacks exons 
4,5,8,9,10 (ACAT-2c). These splice variants lack the exon 4/5 junction, and would not have been 
detected by the ACAT-2 assay protocol used in this chapter. Hence all assays of ACAT-2 reported in 
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this Chapter refer to the full length mRNA transcript ACAT-2a, and exclude the smaller splice 
variants ACAT-2b and ACAT-2c.  
 
Because our assay system detected only the full-length ACAT-2a splice variant, the data presented 
in this chapter would under-estimate ACAT-2/ACAT-1 ratios if the smaller ACAT-2b and ACAT-2c 
splice variants represented an appreciable fraction of the total ACAT-2 mRNA species in the 
samples assayed. In this regard, HepG2 cells (derived from human hepatocytes) and Caco-2 cells 
(derived from human intestines) expressed mostly ACAT-2a + ACAT-2b (ACAT-2a and ACAT-2b 
form a merged band after RT-PCR and gel electrophoresis) with ACAT-2c a minor component, 
compared to foetal liver and cancerous adult liver where ACAT-2c was similarly abundant to 
[ACAT-2a + ACAT-2b](Yao et al., 2005). Yao et al. (2005) did not examine intestines, and end-
point RT-PCR failed to detect any of the three ACAT-2 transcripts in healthy adult liver. If healthy 
adult liver resembles HepG2 cells rather than foetal or cancerous liver, and intestines resemble 
Caco-2 cells, the results presented in this chapter would approximate to the overall ACAT-2 
transcript abundance in each sample.  
 
Further research will be necessary to establish the relative amounts of each ACAT-2 isoform in 
various human tissues. Unless otherwise stated, the results of “ACAT-2” assays described in this 
thesis will be inferred as meaning ACAT-2a.   
 
2.4.1.2 Interference, linearity and reproducibility 
 
Under the conditions used for these assays, neither the ACAT-1 nor ACAT-2 assay suffered 
interference from contaminating genomic DNA.  Both the ACAT-1 and ACAT-2 assays gave very 
similar fluorescence signals from equal numbers of copies of cloned cDNA targets, and each was 
highly specific for its own cDNA target. Using multiplex assays, replicate qPCR amplification plots 
and Ct values for each sample were typically in good agreement, especially for ACAT-2, and gave 
smooth amplification plots similar to the data presented in Figure 2.2.  
 
Using multiplex assays of a dilution series of total cDNA, it was puzzling that apparent 
amplification efficiencies for ACAT-1 and ACAT-2 were >100% (ACAT-1, 120%; ACAT-2, 108%), 
while the β-actin assay approximated to the expected 100% efficiency. However it was 
demonstrated that total cDNA samples in the range 1.5-40 ng gave very similar values for Ct 
[(ACAT-2) –(ACAT-1)], suggesting that this represented the linear range and that the consistent ΔCt 
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and ΔΔCt values (used to calculate ACAT/β-actin and ACAT-2/ACAT-1 ratios) were more useful 
than PCR efficiency for validating multiplex assays.  
 
On some occasions it was noted that the ACAT-1 assay was more variable (i.e. less robust) than the 
ACAT-2 assay, and when this occurred assays were repeated until statistically significant results 
were obtained.  According to Primer Express software, the primers and probes designed for 
ACAT-1 (and ACAT-2) were the best options for TaqMan® based PCR at the time this work 
was initiated, and therefore represent the best compromise if one is to attempt to quantify 
ACAT transcripts via RT-qPCR using sequence in the vicinity of splice junction 5/6 (or 4/6). 
The issue of variable PCR efficiencies and reproducibility of the ACAT-1 assays etc. will be 
addressed further in Chapter 3. 
 
2.4.2 Relative expression of ACAT-1 and ACAT-2 (as ACAT-2/ACAT-1 ratio) in various tissues. 
 
 Expression levels of ACAT-1 and ACAT-2 transcripts relative to β-actin and values for ACAT-
2/ACAT-1 ratios were established for 17 liver, 10 duodenal, 3 kidney, 1 spleen, and 7 PBMC 
samples (Figs. 2.7 – 2.9). In liver, ACAT-1 mRNA levels were on average nine times more abundant 
than ACAT-2 (ACAT-2/ACAT-1 ratio = 0.112), whereas in duodenum, ACAT-2 transcripts were on 
average ~3 times more abundant than ACAT-1 (ACAT-2/ACAT-1 ratio = 3.27). These results 
demonstrated quantitatively that ACAT-1 was the predominant transcript isoform in all 
human liver samples assayed, and that ACAT-2 (actually ACAT-2a) was more abundant in 9 
of the 10 human duodenal samples. 
 
In kidney and spleen, relative levels of ACAT-1 and ACAT-2 expression were in the same range as 
liver (cf. Figures 2.7, 2.9). However, PBMC gave ACAT-2/ACAT-1 ratios that were significantly 
lower (mean value 0.015) than the other tissues assayed (cf. Fig. 2.8, 2.9). This is the first report of 
the presence of ACAT-2 transcripts in PBMC, and the ability to quantify them at low but readily 
detected levels opens the way for future analyses of both ACAT-1 and ACAT-2 transcripts in blood 
samples.  
 
In liver, our finding that ACAT-1 was on average ~9 fold more abundant than ACAT-2, is consistent 
with the results of Parini et al., (2004) who found an even higher (~27 fold) abundance of ACAT-1 
compared to ACAT-2 in human liver (mean ACAT-2/ACAT-1 ratio of 0.037), using RT-qPCR with 
SYBR® Green (in place of TaqMan®) to detect amplification products. Parini et al. (2004) also 
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found an ACAT-2/ACAT-1 ratio of ~0.2 for liver from African green monkey, suggesting that 
ACAT-2 mRNA appears to be more abundant in the livers of non-human primates. 
 
The apparently lower abundance of ACAT-2 mRNA compared to ACAT-1 mRNA in human liver, 
reported by both this thesis and Parini et al. (2004), is consistent with the results of Chang and co-
workers who have repeatedly reported very low (or apparently undetectable) expression of ACAT-2 
transcripts in human adult liver (cf. Yao et al., 2005; Chang et al., 2000). The consequence of low 
(and variable, cf. Sec. 2.4.3) expression of ACAT-2 compared to ACAT-1 in human liver will be 
discussed further in Sec. 2.4.5. 
 
2.4.3   Variable ACAT expression among individuals supplying each tissue/cell type 
 
When comparing expression of an ACAT gene relative to β-actin (as the reference housekeeping 
gene), it is assumed that β-actin is expressed at similar levels in samples of the same tissue type 
from different individuals (e.g. the 17 liver samples studied here).  
 
Among the 17 liver samples, ACAT-1/ β-actin ratios were relatively more consistent (cf. Sec. 2.3.4.2 
and Fig. 2.7), varying by 6.2-fold with the SD 50% of the mean value, compared with ACAT-2/β-
actin ratios, which covered a 320-fold range with the SD 200% of the mean. Although ACAT-1 
was on average ~9-fold more abundant than ACAT-2 (mean ratio 0.112), actual ACAT-2/ACAT-1 
ratios varied from 0.006 up to 0.58, representing a 97-fold range in livers from different individuals. 
 
The 10 duodenal samples gave somewhat less variable ACAT-1/β-actin ratios than liver, (Fig. 2.7), 
covering a 4.4-fold range, compared to the 6.2-fold range for liver. ACAT-2/β-actin covered a 10.3-
fold range for duodenum, compared to the 320-fold range for liver. Although ACAT-2 was on 
average ~3.3-fold more abundant than ACAT-1 in duodenum, actual ACAT-2/ACAT-1 ratios varied 
from 12.2 (sample #I) down to 0.39 (sample #C), i.e. a 31.3 fold range compared to the 97-fold 
range for liver. Hence although ACAT-2 was more variable than ACAT-1 in both liver and 
duodenum, the somewhat smaller range of variability shown with duodenum could result in part 
from the smaller number of samples examined (10) compared to liver (17).  
 
Little evidence was found for the coordinated regulation of ACAT-1 and ACAT-2, as demonstrated 
by the variability in ACAT-2/ACAT-1 ratios among different samples within a tissue type (Fig. 
2.7C).  Furthermore, a plot of ACAT-1 versus ACAT-2 expression levels within each tissue type 
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resulted in no association (plot not shown). These data provide additional evidence that ACAT-2 is 
more variable, and hence likely to be more highly regulated, than ACAT-1 in liver and duodenum, 
and are consistent with the notion that ACAT-1 is expressed relatively constitutively while ACAT-2 
expression is more highly regulated (cf. Ch 1, Sec. 1.3.3, but see Sec. 2.4.5.2 and Sec. 5.8.3 for 
further discussion of ACAT-1 regulation). 
 
Although ACAT-1 mRNA is known to be expressed in many cell types, including undifferentiated 
macrophages and fibroblasts (e.g. Cases et al., 1998, Oelkers et al., 1998, Wang et al., 1996), ACAT-
2 mRNA had not been detected in these cell types when the above work was started (e.g. Oelkers et 
al., 1998). The novel observation that ACAT-2 mRNA is present in PBMC, albeit at very low levels, 
indicates that the ACAT-2 enzyme may also have a physiological role in at least some subsets of 
peripheral cells and tissues represented in PBMC preparations (see below). Total ACAT activity has 
been determined previously in PBMC and shown to be increased in patients with hyperlipidemia 
(Dallongeville et al., 1992). Furthermore, Sakashita et al. (2003) reported the de novo expression of 
ACAT-2 in immature macrophages differentiated from monocytes in vitro (cf. Sec. 1.3.3). 
However, unlike ACAT-1, which appears to be involved in cholesteryl ester accumulation in 
macrophages (Wang et al., 1996, cf. Ch. 1 Sec. 1.3.3), the role of ACAT-2 in cell types such as 
macrophages represented in PBMC has yet to be determined (cf. also Sec. 5.7.2). 
 
2.4.4   Comparison of individuals representing different background groups and disease syndromes 
 
When collecting material for this study, samples were accessed from a range of individuals 
exhibiting various disease syndromes and from various physiological or physical backgrounds.  
Although the numbers of samples in some subgroups are too small to draw any firm conclusions (a 
common problem with human sampling), some differences or trends in ACAT expression levels 
were observed that might present hypotheses worth examining in future research. Two of the most 
interesting of these observations were the effect of warm ischemia time on ACAT-2 expression in 
liver samples, and expression levels of both ACAT isoforms in PBMC from patients with 
cholesterol gallstones. 
 
2.4.4.1 Warm ischemia: liver samples 
 
Perhaps surprisingly, the liver samples subjected to warm ischemia prior to snap freezing (livers  
#13-#17, Table 2.1) showed consistently higher (and statistically significant) levels of ACAT-2 
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mRNA relative to β-actin, compared with “control”, i.e. no warm ischemia, liver samples (livers #1-
#12). Similarly, ACAT-1 levels for the warm ischemic samples were also higher on average than for 
the control livers, but were more variable and not significantly different. This observation contrasts 
with a previous study (Smith et al., 1989) that showed total ACAT enzyme activity is markedly 
decreased by warm ischemia, with a half-life for the loss of activity of 57 min. Warm ischemia and 
its consequences are discussed further in Chapter 5 (Sec. 5.6).  
 
2.4.4.2   Cholesterol gallstones: liver samples  
 
One might expect mRNA levels of ACAT-1 or ACAT-2 to be decreased in liver, given that total 
hepatic ACAT enzyme activity is lower in patients with cholesterol gallstones (Smith et al., 1990, 
Smith et al ., 2000). However, only three liver samples from cholesterol gallstone patients were 
examined:  two of these patients had been taking the drug Simvastatin and showed elevated levels 
of both ACAT-1 and ACAT-2 relative to β-actin, and higher ACAT-2/ACAT-1 ratios (samples #11 
and #12, Figure 2.7A and 2.7B), compared to the other “control” livers. Only one other sample 
(liver #13) gave an ACAT-2/ACAT-1 ratio in the same range as livers #11 and #12, but liver #13 
was from a 9-year-old female kidney donor, consistent with previously studies that show human 
foetal livers express high levels of ACAT-2 that diminish to adult levels during childhood (Chang et 
al., 2000). The sole cholesterol gallstone patient not taking Simvastatin (liver #10, Figure 2.7) 
showed ACAT levels in the mid range compared to other liver samples (cf. also Sec. 4.4.4 in 
Chapter 4). However our work was intended as a pilot study, and the number of gallstone samples 
was too small to draw any firm conclusions. Further work using larger numbers of samples to 
examine ACAT levels in gallstone patients and the effect of Simvastatin on liver ACAT expression 
(comparing both ACAT-1 and ACAT-2), is warranted to test the trends described above (cf. Sec. 
5.7).  
 
Parini et al. (2009) assayed ACAT-2 mRNA levels (but not ACAT-1) relative to cyclophilin A (as 
reference housekeeping gene), together with ACAT-2 enzyme activity and ACAT-2 protein levels, in 
liver biopsies from 40 normolipidemic, non-obese gallstone patients in China, including some 
gallstone-free patients. Most interestingly, ACAT-2 enzyme activity was significantly lower in 
females than males, both among gallstone-free and gallstone patients (71-72% lower among all 
females compared to males). ACAT-2 protein levels were also significantly lower in female 
compared to male gallstone patients, although this gender difference did not apply to gallstone-free 
patients, and no differences in ACAT-2 protein were observed in gallstone vs. gallstone-free patients 
70 
 
of either gender. Although not statistically significant, ACAT-2 mRNA levels in gallstone patients 
were on average about twice that of non-gallstone patients for both males and females (with female 
levels about 10-20% lower than males). Despite the lack of statistical significance of the mRNA 
analyses, the trend clearly indicated higher ACAT-2 levels in the gallstone patients, in agreement 
with the trend shown in our much earlier study described herein (cf. Smith, Rangaraj et al., 2004). 
In our studies, none of our cohorts within any sampling strategy were large enough to detect any 
trends or statistically significant differences among males and females. 
 
In another study, 37 gallstone patients treated with statins for 4 weeks showed significantly reduced 
expression of ACAT-2, assessed by ACAT-2 activity, ACAT-2 protein and ACAT-2 mRNA levels, 
compared to gallstone patients treated with placebo (Parini et al., 2008). Statin treatment had no 
effect on ACAT-1 expression. However non-gallstone patients were not included in the study, 
which makes it difficult to compare the results of Parini et al. (2008) with our results, where two 
gallstone patients (livers #11 & #12) under long term treatment with simvastatin showed higher 
levels of ACAT-2 mRNA than non-gallstone patients. Contrary to our results and possibly the 
studies of Parini et al. (2008, 2009), liver #10, from a male gallstone patient not treated with statins, 
showed relatively low levels of ACAT-2 mRNA (but see Sec. 4.4.4.1 and 5.7.1). Because hepatic 
ACAT-2 mRNA levels varied up to 320 fold among human individuals (cf. Fig 2.7B), larger 
populations will be needed to assess baseline differences and variability among gallstone and non-
gallstone patients, and to determine the effect of statins on both cohorts.  
 
2.4.4.3 PBMC samples from gallstone and gallstone-free patients 
 
PBMC samples from three patients with confirmed cholesterol gallstones gave ACAT-2 mRNA 
levels that were 80% higher relative to β-actin (P<0.05) compared to four patients with no known 
history of cholesterol gallstones (Fig. 2.8B). PBMC cells typically include lymphocytes (70-90%), 
monocytes (10-30%) and dendritic cells (1-2%) (http://technical.sanguinebio.com/types-of-
immune-cells-present-in-human-pbmc/). The monocytes are of particular interest as progenitors of 
macrophages and foam cells which show elevated levels of ACAT enzyme activity during their 
differentiation from monocytes (Wang et al., 1996). Because foam cells are involved in the 
development of plaque, analysis of ACAT isoforms in PBMC would also be of interest in exploring 
the aetiology of atherosclerosis. 
 
71 
 
The elevated level of ACAT-2 mRNA we observed in PBMC from gallstone patients is converse to 
the decreased levels of total hepatic ACAT activity observed previously in patients with cholesterol 
gallstones by Smith et al. (1990) and Smith et al.(2000). However this work was done before the 
discovery of ACAT-2 and the contribution of ACAT-1 could have masked an increase in ACAT-2 
expression. 
 
The significance of the increased ACAT-2 expression in PBMC from cholesterol gallstone patients 
requires further investigation, using larger sample sizes to clarify any differences from “normal” 
patients. Our analyses of PBMC serve as an example that RT-qPCR methods such as those 
developed during this project may prove to be a useful non-invasive diagnostic tool, particularly for 
patients predisposed to cholesterol gallstones or atherosclerosis, with the potential for mass 
screening of blood samples for defects in lipid metabolism (cf. Sec. 5.5). 
 
2.4.4.4 Other samples of interest: duodenum 
 
Relative to β-actin, ACAT-1 showed a 4.4-fold range in relative mRNA abundance among the 10 
duodenal samples, in comparison to ACAT-2 which was more variable and showed a 10.3-fold 
range. However duodenal ACAT-2 abundance relative to β-actin was much less variable than in 
liver, which as noted above covered a 320-fold range among 17 liver samples. Overall ACAT-
2/ACAT-1 ratios for duodenum covered a 32-fold range, with a mean ACAT-2/ACAT-1 ratio of ~ 3.3 
(adjusted to a ratio of ~2 as explained in Ch. 5, Table 5.1). Although there were insufficient 
duodenal samples to detect statistically significant differences among sub-groups, the two samples 
with the most extreme ACAT-2/ACAT-1 ratios (highest and lowest, samples #I and #C respectively) 
were clearly divergent from the other 8 samples.  
 
Sample #C was the only duodenal accession to give an ACAT-2/ACAT-1 ratio of less than 1 (ratio 
value 0.39 → 0.26 after adjustment as shown in Ch. 5, Table 5.1). Thus ACAT-1 mRNA was ~4-
fold more abundant than ACAT-2, a consequence of an extreme deficiency in ACAT-2. This sample 
was taken from a 61-year-old female who was an iron-deficient, insulin-dependent type 2 diabetic 
with chronic renal failure. ACAT-2 is generally predominant in duodenum, and it is presumed that 
one or more of these multiple pathologies was responsible for (or a consequence of) the low 
duodenal ACAT-2 abundance. 
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Conversely to sample #C, sample #I from a 32-year-old male reflux patient was extremely deficient 
in ACAT-1 mRNA, resulting in the highest ACAT-2/ACAT-1 ratio among the 10 duodenal samples 
(ratio value 12.2 → 0.82 after adjustment as shown in Ch. 5, Table 5.1), i.e. ACAT-2 mRNA was 
~8-fold more abundant than ACAT-1. It is possible that ACAT-1 plays a previously unexpected role 
in duodenum that contributes to reflux, and two alternative, hypothetical mechanisms are suggested. 
Reflux could be a consequence of dietary or digestive imbalance e.g. resulting from a high 
fat/cholesterol diet, which could reduce the need for de novo cholesterol synthesis, which in turn 
could reduce the need for ACAT-1 expression. Alternatively, an inherent (genetic) deficiency in 
intestinal ACAT-1 expression could cause an imbalance in the enterocytic FC/CE ratio, leading to 
excessive levels of intracellular FC in enterocytes, which could cause irritation to the intestinal 
lining leading to reflux. 
 
2.4.5 Physiological significance of ACAT mRNA expression levels  
 
2.4.5.1 Relative abundance of ACAT-2 and ACAT-1 in liver and intestine 
 
Higher levels of transcripts in a tissue are generally (but not always) expected to lead to higher 
levels of their protein products (Kadota et al., 2003).  This issue is especially important for ACAT-2, 
where studies by T.Y Chang and co-workers have reported very low or undetectable levels of 
mRNA expression in adult human liver in some experiments (e.g. Chang et al., 2000; Yao et al., 
2005). Expression levels of the ACAT mRNA isoforms found in the present study for liver (where 
ACAT-1 represented a mean value of 90% of all ACAT isoforms), and intestine (where ACAT-2 
represented a mean value of 77% of all ACAT isoforms), are highly consistent with their cognate 
enzyme activities reported by Lee et al. (1998). Using assays of total ACAT activity before and 
after selective immunoprecipitation of ACAT-1 from solubilised microsomes, Lee et al. (1998) 
deduced that ACAT-1 represented 90% of total ACAT activity in whole human liver, and ACAT-2 
represented 81 % of total ACAT activity in human intestines.  
 
A converse correlation between ACAT protein and mRNA levels was found by Parini et al. (2004). 
Using pooled samples of liver microsomes derived from patients with gallstone disease, Parini et al. 
(2004) found that ACAT-2 enzyme activity (range 0.011-0.118 nmol/min/mg protein) was both 
higher and more variable than ACAT-1 activity (range 0.046-0.060 nmol/min/mg protein, 
i.e.ACAT-2/ACAT-1 activity ratios of 1.4, 2.2, 1.1 and 0.2 for the four pools of liver microsomes, 
mean ratio 1.23 ±0.83). As part of the same study, Parini et al. (2004) using another set of human 
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liver samples obtained from transplant patients with liver disease, found that ACAT-1 mRNA was 
~27 fold more abundant than ACAT-2 mRNA, suggesting that mRNA isoform levels were a poor 
predictor of the relative abundance of their cognate translation products (assuming that the two sets 
of liver samples used for enzyme and transcript analysis, taken from patients with quite different 
pathologies, are comparable).  
 
Our results demonstrated that ACAT-2 mRNA levels varied by ~320-fold among the 17 livers from 
different individuals, and a major strength of our work is the comparison of individual variation.  
Parini et al. (2008, 2009) examined larger cohorts of mostly gallstone patients for ACAT-2 
expression in liver, and focussed on differences among subgroups of patients (gallstone vs. controls, 
male vs. female, statin treatment vs. controls). From their SEM data, it appears that the range of 
individual variation for ACAT-2 was less extreme than in our study, and Parini et al. (2008, 2009) 
made no comments on individual variation. Our study possibly sourced samples from individuals 
covering a more diverse cross-section of society, rather than mostly gallstone patients who tend to 
show higher levels of expression of ACAT-2. The studies of Parini et al. (2008, 2009) and 
comparisons with our work are discussed further in Chapters 4 and 5. 
 
 The reports from Chang’s group cited above are based on limited numbers of human samples, and 
it is possible that the extremely low levels of ACAT-2 transcripts and protein they reported are not 
representative of most humans. In support of Chang’s results, two individuals in our study of 17 
liver samples (samples #5 and #6, cf. Fig, 2.7, from liver donors with no known pathological 
condition, noted in Sec. 2.4.4.2) showed extremely low expression of ACAT-2. The experiments by 
Parini et al. (2004) noted above are likewise limited by analysis of pools rather than individuals, and 
lack of comparison with non-pathological controls.  
 
Hypervariable expression of hepatic ACAT-2, including the occurrence of individuals with 
apparently extremely low expression, will be discussed further in Chapter 5 (cf. Sec. 5.8.2). 
 
2.4.5.2 Cell-specific differences in hepatic ACAT function 
 
Using immunofluorescence analysis (immunocytology) of marker enzymes and both ACAT 
isoforms in tissue slices from adult human liver, Parini et al. (2004) presented evidence that ACAT-
2 protein was exclusively confined to hepatocytes, whereas ACAT-1 was located primarily in 
Kupffer (macrophage) cells. They concluded that their results were consistent with the hypothesis 
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that ACAT-2 participates in the assembly and secretion of cholesteryl esters in hepatocytes (e.g. as 
VLDL), that ACAT-2 is highly regulated, and plays a critical role in the maintenance of cholesterol 
homeostasis in the liver of humans. This hypothesis is consistent with the undoubted predominance 
of ACAT-2 in intestinal enterocytes, which resemble hepatocytes in being sites of cholesterol 
packaging and secretion (as chylomicrons and VLDL, respectively).  
 
Although the proposed primary role of ACAT-1 is to esterify FC synthesised de novo and to 
regulate the intracellular balance between FC and CE, as suggested in Chapter 1 (Sec. 1.3.4 and Fig. 
1.4), it is possible that ACAT-1 can also supplement or substitute for  ACAT-2 when required (cf. 
Chapter 5, Sec. 5.8.2). In this regard, quantitative analysis of ACAT proteins directed towards 
revealing differences among individuals with various disease backgrounds etc., may provide 
additional information to the mRNA data presented in this chapter, and this will be addressed in 
Chapter 4. 
 
2.4.6 Postscript: ACAT-1 mRNA reproducibility and protein expression  
 
As noted in Sections 2.3.3.4 and 2.4.1 above, in practice the multiplex TaqMan® assay for ACAT-1 
was found to give variable results in some experiments, requiring re-assay until a statistically 
reliable result could be obtained.  This was perplexing given that the validation experiments using 
cDNA clones indicated that both the ACAT-1 and ACAT-2 assay protocols appeared to be 
sufficiently sensitive and efficient (within experimental error) for the survey of human tissue 
samples that form the basis of the current chapter. The primer/probe set for ACAT-1 appeared to be 
the best available option at the time they were designed. Chapter 3 describes the development and 
validation of improved assay protocols for ACAT-1 using newer TaqMan® technologies that were 
unavailable when the above work was initiated. 
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CHAPTER 3 
 
IMPROVEMENT OF THE qPCR ASSAYS FOR HUMAN ACAT cDNA  
 
3.1 Introduction 
 
3.1.1 Reproducibility and amplification efficiency of the ACAT assays? 
 
When the survey of human cDNA samples described in chapter 2 was well advanced, and the 
project was committed to the qPCR methods described in Chapter 2, it became apparent that the 
multiplex assay protocol for ACAT-1  was somewhat more variable than the assay for ACAT-2 (cf. 
Sec. 2.3.3.4 and 2.4.6).  To reduce the potential for error and confirm results, two or three 
independent assay runs were used routinely for most samples, and up to six independent assays 
were necessary for some samples to obtain statistically acceptable ACAT-2/ACAT-1 expression 
ratios.  
 
At the time the multiplex assays for ACAT-1 and ACAT-2 were designed, the PCR primers and 
TaqMan®  probes described in Chapter 2 represented the best options for optimal PCR efficiency 
and detection sensitivity according to the Primer Express software. Improvements to TaqMan® 
qPCR detection chemistries became available near the end of the survey of human ACAT transcript 
levels presented in Chapter 2.  Standard FAM -TAMRA TaqMan® probes as used in Chapter 2 can 
be improved by replacing the TAMRATM quencher dye with a non-fluorescent “NFQ” moiety and 
insertion of an “MGB” DNA-binding moiety prior to the NFQ moiety, to produce a FAM-MGB-
NFQ probe (cf. http://tools.lifetechnologies.com/content/sfs/manuals/cms_041280.pdf ). The MGB 
moiety binds non-specifically to the minor groove of dsDNA and strengthens the sequence-specific 
binding of the probe to the PCR product, thus making it possible to design shorter TaqMan® 
probes.  The NFQ moiety reduces background fluorescence “noise”, and hence provides increased 
detection sensitivity and precision (i.e. reproducibility among replicates). The use of a FAM-MGB-
NFQ probe enables greater flexibility when designing assays for specific targets, e.g. the reverse 
primer can be designed closer to the forward primer, thus opening up sequence that would 
otherwise be occupied by a FAMTM/TAMRATM based TaqMan® probe as used in Chapter 2.  
 
This chapter describes the development and assessment of a new TaqMan® probe and new PCR 
primers to minimise the variability observed with the original ACAT-1 assay. An extended period of 
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sickness interrupted progress during the work to be described below. During this interruption, a new 
384-well PCR machine “Model 7900 Sequence Detector’ was purchased and adopted in place of the 
original 96-well PCR machine “Model 7700 Sequence Detector”. An automated pipetting reaction 
tube setup system (EpMotion model 5075) was also purchased and used in place of manual reaction 
tube setup. Use of the new PCR machine resulted in unexpected disparities in the β-actin 
component of multiplex assays when comparing the ACAT-1 and ACAT-2 assays. Strategies were 
developed to compare data for additional samples assayed using the new TaqMan®  ACAT-1 assay 
method and the new 384-well PCR machine, with the historic data for samples assayed using the 
old TaqMan®  ACAT-1 assay method and the original 96-well PCR machine. 
 
3.2 Materials and Methods 
 
3.2.1 Liver samples 
  
In addition to liver samples #6 and #8 and duodenal sample #A (Chapter 2, Table 2.1 and Sec. 
2.2.1), three additional liver RNA samples  (from Dr. Grant Ramm, Queensland Institute for 
Medical Research, Herston, Queensland) were used for the work described in this chapter, as shown 
in the following text table: 
 
 
Sample label 
 
Tissue type 
 
Age  
(yr) 
 
 
Sex 
Subject/Patient 
group or 
investigation 
for: 
Warm 
Ischaemia 
Time (min) 
#A Liver 9.5 Male Removal of 
liver cyst 
0 
#B ” 9 Male Liver donor 0 
#C ” 42 Male Liver donor 0 
 
3.2.2 New Primers and MGB probe for ACAT-1 
 
In addition to the forward and reverse primers used for ACAT-1 assays described in Chapter 2 (Sec. 
2.2.4), abbreviated as 1F1 and 1R1 respectively, the following new forward (F) and reverse (R) 
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primers for ACAT-1 were designed as shown below (cf. Fig. 3.1 for 1F2 and 1R4), using Primer 
Express software version 5 (Applied Biosystems), cf. Sec. 2.2.4: 
 
Primer name Primer sequence 
ACAT1FWD2 (1F2) 5'-AAGGCGCTCTCTCTTAGATGAACT-3' 
ACAT1REV2 (1R2) 5'-TGCTGAGGATAAAGAGAATGAGGA-3' 
ACAT1REV3 (1R3) 5'-AAGTGTGCTGAGGATAAAGAGAATGA-3' 
ACAT1REV4 (1R4) 5'-GGAGGGCAATAAACATGTGATATATTG-3' 
 
Table 3.1: List of additional PCR primers designed for ACAT-1 (cf. also Sec 2.2.4).  
 
 
A new TaqMan® probe was designed for the ACAT-1 assay as indicated in Fig. 3.1.  The reporter 
dye (6-FAM) was attached to the 5’ end and the MGB and NFQ moieties were attached to the 3’ 
end. The probe was synonymous with the forward strand and had the sequence:  
5’-(6-FAM)-AAGTGGACCACATCAGA-(MGB-NFQ)- 3’ 
 
 
 
Figure 3.1: Forward strand cDNA sequence for ACAT-1, indicating position of the new qPCR 
primers (1F2 and 1R4) used with the new TaqMan® probe (an MGB probe). Amplicons were 74 
nucleotides in length. 
 
 
 
 
 
  tattgcaaggcgctctctcttagatgaactgcttgaagtggaccacatcagaacaatatatcacatgtttattgccctcctcat 
          
  
TaqMan® 
MGB Probe Forward primer (F2) Reverse primer (R4) 
Exon-Intron boundary 
hACAT1 
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3.2.3 RT-qPCR assays 
 
Instruments used for the RT-qPCR assays in this Chapter were either the 96-well ABI Model 7700 
Sequence Detector (Applied Biosystems) as used for the work described in Chapter 2, or the 384-
well ABI PRISM® 7900HT Sequence Detection Systems (Applied Biosystems) purchased during 
the work described in this Chapter. These will be referred to in the text as the “7700 PCR machine” 
and “7900 PCR machine” respectively. 
 
RNA was isolated from liver samples and converted to cDNA via reverse transcription reactions as 
described in Chapter 2, Sec. 2.2.5. PCRs used 20 or 25 ng of total cDNA per reaction tube unless 
otherwise stated. 
 
3.2.3.1 TaqMan® assays for ACAT isoforms multiplexed with β-actin 
 
Model 7700 PCR machine (96 well): 
Reaction mixtures (25μl final volume) were set up and assayed as described in Chapter 2, Sec. 
2.2.5. TaqMan® probes were at a final concentration of 0.2 μM, and primer concentrations were 
either 0.3 μM (as used in Chapter 2), or 0.9 μM in some experiments when specifically indicated in 
the Results.  The PDAR reagent for β-actin was added as described in Sec. 2.2.5. The PCR program 
using 45 cycles was the same as that described in Chapter 2 (Sec.  2.2.5. The updated “SDS 2.2 
software” was used to replace the SDS software system used for the work described in Chapter 2. 
 
Model 7900 PCR machine (384 well): 
Using reagents in the same concentrations as described in Chapter 2 Sec. 2.2.5 and above, an 
epMotion 5075 Automated Pipetting System (Eppendorf) was used to prepare 10μl (final volume) 
of reaction mixture prior to PCR. The PCR program for the 7900 PCR machine was the same as 
that described in Chapter 2 (Sec.  2.2.5) but used 50 cycles.  The updated “SDS 2.2.2” software was 
used with this instrument. 
 
PCR amplification efficiency (E) was estimated by two different approaches: (a) The “LinRegPCR” 
qPCR software measured the PCR amplification efficiency (as [1+E] values) of each individual 
reaction tube from the shape of its real time amplification profile, where (1+E)n represents the 
number of amplified copies per initial template copy after n PCR cycles, i.e. (1+E) = 2 for 
theoretical 100% PCR efficiency (i.e. E = 1.00 or 100%). (b) Amplification efficiencies were 
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calculated from the cDNA dilution series via plots of Ct vs. log (amount cDNA), using the 
relationship (1+E) = 10–(1/slope), as described in Sec. 2.3.3.4. 
 
3.2.4 Data analysis 
 
Data were collected and processed as described in Chapter 2 (Sec. 2.2.5) or as described in the 
Results.  Standard errors etc. were calculated as described in Sec 2.2.5 (Chapter 2). Amplification 
efficiency E values were calculated from fluorescence data capture during PCR using 
“LinRegPCR” software (Heart Failure Research Centre, Netherlands). 
 
 
3.3 Results and Discussion 
 
3.3.1 Attempts to design improved primers for multiplex TaqMan® assays of ACAT-1 using the 
FAM-TAMRA probe described in Chapter 2 
 
Using the original TaqMan®  protocol for ACAT-1 described in Ch. 2 (cf. Sec. 2.2.5), two new 
forward primers (1F2, 1F3) and one new reverse primer (1R2) were tested in all combinations with 
the original primers (1F1, 1R1) and the original FAM -TAMRA TaqMan®  probe, using assays 
multiplexed with β-actin.  Using a 20 ng sample of a pooled cDNA preparation obtained by mixing 
equal amounts of total cDNA from liver sample #8 and duodenal sample #A, all of the new primer 
combinations gave larger Ct values than the original 1F1-1R1 primer combinations (data not 
shown). It was concluded that none of the new primer pairs offered any advantage over the 
original 1F1-1R1 primers, and confirmed that the original 1F1-1R1 primer combination gave the 
most PCR-efficient amplification of the primer pairs tested. Note that Ct values for the β-actin 
component of the multiplex assays were very similar for all primer combinations tested (mean value 
26.00 cycles ± 0.26 SD), confirming the consistency of β-actin as a reference assay, and indicating 
that the choice of ACAT-1 primers did not affect the β-actin assay results.  
 
3.3.2 Design and use of a new MGB TaqMan® probe and new primers for ACAT-1   
 
Primer Express software was used to design a “new” FAM-MGB-NFQ TaqMan® probe (17 
nucleotides in length) that was 19 nucleotides shorter than the original “old” FAM-TAMRA probe 
(36 nucleotides). Multiplex assays using the original 1F1-1R1 primers with the new FAM-MGB-
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NFQ probe gave a mean ΔCt value for [(Ct ACAT-1) – (Ct β-actin)] of 7.11 cycles (Fig. 3.2), 2.60 
cycles less (P ≤0.05) than the mean ΔCt value for assays with the original FAM-TAMRA probe 
(9.71 cycles).  This increased sensitivity of 2.6 cycles using the new probe is attributed to its non-
fluorescent NFQ moiety, which quenches the FAMTM reporter dye more efficiently than the 
TAMRATM moiety of the old probe, resulting in a lower basal level of fluorescence during the PCR 
(http://tools.lifetechnologies.com/content/sfs/manuals/cms_041280.pdf ). Using the new MGB 
probe, all combinations of primers tested previously (Sec. 3.3.1) yielded smaller ΔCt values (P 
≤0.05) for [ACAT-1 - β-actin], i.e. enabled more sensitive detection, than the original assay using 
primers 1F1-1R1 and the old FAM-TAMRA probe (Fig. 3.2).   
 
Because the new FAM-MGB-NFQ probe was much shorter than the old probe, it was possible to 
design a new reverse primer (1R4) substantially closer to the forward primer than previously. 
Assays using the new 1R4 primer gave significantly (P ≤0.05) smaller ΔCt values for [ACAT-1 - β-
actin] compared to the other primer combinations tested when using the new MGB probe (Fig. 3.2).  
Primers 1F1-1R4 and 1F2-1R4 were most PCR efficient, with very similar ΔCt values of 6.44 and 
6.58 cycles respectively that were significantly less than ΔCt values for the other primer 
combinations but not significantly (P ≤0.05) different from each other (Fig. 3.2). Assays using the 
new primer pairs 1F2-1R4 or 1F1-1R4 detected ACAT-1 amplification products 0.53 - 0.67 cycles 
earlier compared to the new probe with the original 1F1-1R1 primers. This indicates that assays 
using the new FAM-MGB-NFQ probe with reverse primer R4 and forward primer 1F1 or 1F2 were 
more PCR-efficient  by ~0.6 of a cycle than assays using the old 1F1-1R1 primers with the new 
probe. 
 
In conclusion, assays using the new probe with primers 1F2-1R4 or 1F1-1R4 and the new FAM-
MGB-NFQ probe were both more sensitive (by about 2.6 cycles) and more PCR-efficient (by ~0.6 
of a cycle) than the original assay using primers 1F1-1R1 and the FAM-TAMRA TaqMan®  probe 
(an overall advantage of ~3.2 cycles). Examination of cycle-by-cycle amplification profiles using 
the qPCR software indicated that assays using primers 1F2-1R4 appeared to be less noisy and more 
uniform in shape than assays using primers 1F1-1R4. Hence the primer combination 1F2-1R4 
with the new MGB-TaqMan® probe was selected as the “new MGB” assay method for ACAT-
1 for the experiments described below.   
 
 No change was made to the “original” ACAT-2 assay, which continued to use the same primers and 
probes for the ACAT-2 target sequence as described in Chapter 2.  
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Figure 3.2:  ΔCt values [(ACAT-1) – (β-actin)] using various primer combinations for TaqMan® 
assays of ACAT-1 with the new FAM-MGB-NFQ probe (new MGB probe), compared to the 
original assay using primers 1F1-1R1 and the old FAM-TAMRA probe (old probe).  Assay 
protocols (Sec. 3.2.3.1) used the  ABI Model 7700 Sequence Detector with a 20 ng sample of a 
pooled cDNA preparation obtained by mixing equal amounts of total cDNA from liver sample #8 
and duodenal sample #A (Sec. 2.3.3.4, Chapter 2). Data are expressed as the mean value ± SD from 
3 replicate reactions.  Primer-probe combinations designated * gave results that were significantly 
different (P≤0.05) from the combination (1F1-1R4)/(MGB probe), while combinations designated † 
gave results that were significantly different from (1F2-1R4)/( MGB probe). T-tests between 
probe/primer combinations MGB/1F1-1R1 and MGB/1F2-1R4 gave a P value of 0.07, only 
marginally outside the 95% confidence limits. 
 
 
3.3.3 Consistency of the “new” vs. “old” TaqMan® assays of ACAT-1  
 
A dilution series of total cDNA from liver #8 was used to compare the “new” and “old” multiplex 
assays for ACAT-1 (Table 3.2). As expected, the new ACAT-1 assay gave a smaller mean ΔCt value 
of 5.66 ± 0.34 for [(ACAT-1) – (β-actin)] compared to the “old” assay with a mean ΔCt value of 
9.26 ± 0.49. Therefore, ΔΔCt values [(ΔCt new ACAT-1 assay) – (ΔCt old ACAT-1 assay)] ranged 
from 3.09 – 3.92 cycles (mean 3.60 ± 0.34), i.e. ΔCt values for the “new” assay were on average 
3.60 cycles less than ΔCt values for the “old” assay protocol for ACAT-1. This result is consistent 
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with the previous experiment using a different cDNA preparation (Sec.3.3.2), and confirmed that 
the new MGB assay is overall >3 cycles both more sensitive and efficient than the old FAM-
TAMRA assay. 
 
The new multiplex assay for ACAT-1 gave variable and highly anomalous PCR efficiency values 
for both ACAT-1 and β-actin using Ct vs. log (amount cDNA) plots and the “LinRegPCR” software 
(data summarised in Sec. 3.4.2).  A similar phenomenon was observed with the validation 
experiments for the original ACAT-1 assay (Sec. 2.3.3.4), and as suggested in Chapter 2 (Sec. 
2.3.3.4), values of ΔCt [(Ct target gene) minus (Ct reference gene)] (or ΔΔCt values derived 
from them) using a cDNA dilution series were used to assess the reliability of the new ACAT-1 
assay.  As shown in Table 3.2, the values for ΔCt [(ACAT-1) – (β-actin)] and ΔΔCt [(ΔCt new 
ACAT-1 assay) – (ΔCt old ACAT-1 assay)] were relatively consistent for different amounts of 
cDNA, and hence validate the new assay method for ACAT-1.  
 
 
ng cDNA 
“Old” ACAT-1 assay “New MGB” ACAT-1 
assay 
 
ΔΔCt difference: 
(ΔCt new assay) 
 – (ΔCt old assay) 
ΔCt   
(ACAT-1) – (β-actin) 
± SD 
ΔCt   
(ACAT-1) – (β-actin) 
± SD 
150 9.59  ± 0.21 5.77  ± 0.12     -3.82 
80 9.96  ± 0.69 6.04*           -3.92 
40 9.03  ± 0.53 5.59  ± 0.57     -3.44 
15 8.87  ± 0.60 5.78  ± 0.59     -3.09 
5 8.87  ± 0.37 5.12  ± 0.11     -3.75 
Mean ± SD 9.26  ± 0.49 5.66  ± 0.34     -3.60 ± 0.34 
 
Table 3.2:   ΔCt values [(ACAT-1) – (β-actin)] for TaqMan® assays of ACAT-1 comparing the 
“new” assay (primers 1F2-1R4, FAM-MGB-NFQ probe), with the “old” assay (primers 1F1-1R1, 
FAM-TAMRA probe). All assays were multiplexed with β-actin and used the 96-well model 7700 
PCR machine. Data represent mean values ± SD from different amounts of liver total cDNA 
derived from Liver #8, assayed in duplicate or triplicate. This experiment is designated Experiment 
#4 (02/02/04). *Replicate reactions failed.  
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Assay 
Date 
d/m/yr 
 
cDNA 
source  
 Mean ΔCt values  ± SD 
(ACAT-1) – (β-actin) 
ΔΔCt values ± SE 
“Old” 
ACAT-1 
assay 
“new” 
ACAT-1 
assay 
(ΔCt new 
ACAT-1)  
– (ΔCt old 
ACAT-1) 
(ΔCt ACAT-2)  
– (ΔCt old 
ACAT-1) 
1 20/05/03 Liver #8  6.36 ± 0.29 nd    - 5.45 ± 0.25 
4 02/02/04         “     9.26 ± 0.49 5.66 ± 0.34 -3.60 ± 0.27 nd 
5 22/12/04          “    7.13 ± 0.59 5.86 ± 0.19 -1.27 ± 0.43 6.75 ± 0.45 
6 08/04/05          “    6.88 ± 0.05 5.69 ± 0.29 -1.19 ± 0.13 7.15 ± 0.25 
 Mean ± SD 7.41  ± 1.3 5.74 ± 0.11  6.45 ± 0.89 
 
3 06/01/04 Pooled 
Liver #8  
+ 
Duodenum 
A 
9.71  ± 
0.30 
6.58 ± 0.40 -3.13 ± 0.29 nd 
 
 
Table 3.3:  Comparison of the “new” and “old” TaqMan® assays of ACAT-1 and the TaqMan® 
assay of ACAT-2 in five independent experiments using the 96-well Model 7700 Sequence 
Detector.  Reaction mixtures and assay protocols were as described in Table 3.2. All assays were 
multiplexed with β-actin and results are presented as ΔCt or ΔΔCt values ±SD as defined in the 
Table.  ΔCt data for Experiment 1 are taken from the survey of ACAT-2/ACAT-1 ratios presented in 
Chapter 2.  ΔCt data for experiment 3 are derived from mean ΔCt values from the data presented in 
Fig. 3.2.  ΔCt data for experiments 4 and 5 are derived from mean values from a dilution series of 
cDNA (5-150 ng) for the new ACAT-1 assay and duplicate assays for the old ACAT-1 assay (20 ng). 
The ΔΔCt data (final two columns) were derived from differences in ΔCt data (± SD) as specified 
in the Table, and the SE of the resulting value was calculated as cited in Sec. 3.2.4. 
 
Table 3.3 summarises the results of this and other experiments that compared the new and old 
assays for ACAT-1 using the original 96-well model 7700 PCR machine. Experiments 1, 4, 5 and 6 
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(Table 3.3), which all used cDNA derived from Liver #8, gave ΔCt values for [(ACAT-1) – (β-
actin)] that ranged from 6.36 – 9.26 cycles for the old ACAT-1 assay (range difference 2.9 cycles, 
mean ΔCt 7.41 ± 1.3 SD). The new assay method for ACAT-1 was more consistent, giving ΔCt 
values ranging from 5.66 – 5.86 cycles in experiments 4, 5 and 6 (range difference 0.2 cycles, mean 
ΔCt 5.74 ± 0.11 SD). These results illustrate the greater run to run reproducibility of the new assay 
method for ACAT-1 compared to the old ACAT-1 method.  The β-actin component of assays gave 
very similar Ct values in any experiment regardless of whether it was multiplexed with the new or 
old ACAT-1 assay (data not shown).  ACAT-2 was also assayed in experiments 1, 5 and 6, and data 
are included in Table 3.4 to enable comparison of ACAT-2/ACAT-1 ratios in other contexts (to be 
discussed in following Sections). 
 
3.3.4 Assays using the new 384-well 7900 PCR machine gave disparate Ct values with the β-actin 
reference in multiplex assays 
 
A new 384-well 7900 PCR machine (“ABI PRISM® 7900HT Sequence Detection Systems”) was 
adopted for routine use during an extended period of intermittent sickness. A disparity in Ct values 
was observed for the β-actin component of multiplex ACAT assays when using this instrument. β-
actin is more highly expressed than either ACAT-1 or ACAT-2 (cf. ΔCt values > 5 cycles in Table 
3.2), and the β-actin reagents were primer-limited in multiplex assays, to complete the β-actin 
amplification and ensure NTPs were not depleted prior to the detection of ACAT amplicons. These 
precautions were expected to avoid compromising the ACAT assays by the simultaneous assay of 
β-actin in a single reaction mixture. These presumptions appeared to hold when using the original 
96-well model 7700 PCR machine (cf. Sec. 3.3.1 and 3.3.3), but not with the new 384-well model 
7900 machine. 
 
Using the new - 7900 PCR machine, the β-actin component of multiplex assays varied by up to 
about two PCR cycles when assaying any particular sample depending on the ACAT component of 
the assays, and this disparity was greatest when comparing the new and old assays for ACAT-1 (data 
not shown). Taken at face value, these results could be explained if the primer/probe sets for the 
ACAT component of multiplex assays was able to alter the PCR efficiency for amplification of β-
actin, which is considered highly unlikely. The simplest explanation for the disparity in Ct values 
for β-actin is that the new PCR machine appears to be less able to distinguish fluorescence 
emissions from the β-actin and ACAT components of multiplex assays than the old PCR machine. 
After adoption of the new 384-well model 7900 PCR machine, further experiments continued to use 
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multiplexed assays, and the disparities in Ct valued for β-actin were not expected and only became 
apparent in retrospect. It was therefore necessary to ignore the β-actin component and only use Ct 
data from the ACAT component of multiplex assays when processing data.   
 
3.3.5 Assay of additional liver samples using the new 384-well 7900 PCR machine 
 
The new 384-well 7900 PCR machine was used for three experiments, the first of which 
(Experiment 7) used liver #8. A subsequent freezer breakdown caused the loss of sample #8 (and 
the other samples described in Chapter 2) after Experiment 7, and three additional liver samples #A, 
#B and #C were sourced for Experiments 8 and 9. 
 
Using the new model 7900 PCR machine, liver #8 (experiment 7) and livers #A, #B and #C 
(Experiments 8 & 9) were assayed by both the new and old methods for ACAT-1 and the original 
(and only) ACAT-2 assay method (Table 3.4). Values for ΔCt [(ACAT-2) – (ACAT-1)] obtained 
using either the old or new assay method for ACAT-1 sorted the four cDNA samples in the same 
order, highest for liver #C, followed by liver #8, liver #B, with liver #A lowest.  Comparing the new 
and old assays for ACAT-1, values of ΔCt [(new ACAT-1 assay) – (old ACAT-1 assay)] were 
remarkably similar for each sample, varying from -2.13 to -2.64 cycles (mean -2.42 ±0.21 SE) if an 
outlier value of -1.44 cycles for one of the replicate values for liver #A is ignored (Table 3.4).   
 
The above results indicate that for any given cDNA sample, the 384-well model 7900 PCR machine 
systematically detected ACAT-1 amplicons ~2.4 cycles earlier using the new ACAT-1 method than 
the old ACAT-1 method, i.e. the new ACAT-1 assay method enabled an overall increase in 
(sensitivity + PCR efficiency) of ~2.4 cycles.  This can be compared to the value of ~3.2 cycles 
found with the 96-well Model 7700 PCR machine using β-actin as reference gene (Sec. 3.3.2). 
Reproducibility of the old and new assays for ACAT-1 can be compared by SD values for ΔCt 
(ACAT-2) – (ACAT-1) between experiments 8 and 9 (Table 3.5). Although the SD was more 
variable for the old compared to the new ACAT-1 assay for liver samples #A and #C (± 0.54 vs. ± 
0.02, and ± 0.61 vs. ± 0.33, respectively), the converse was observed for liver sample #B (± 0.07 vs. 
± 0.13). Hence the old assay method for ACAT-1 was only marginally less reproducible than the 
new assay method for ACAT-1 in this series of experiments.  
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cDNA 
source 
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Assay 
Date 
d/m/year 
TaqMan®  assays: 
ΔCt values  ± SE: 
(ACAT-2) – (ACAT-1) 
TaqMan®  
assays: 
ΔCt  ± SE: 
(New  
ACAT-1)  
- (Old ACAT-1) 
“Old” ACAT-1 
assay 
“new” ACAT-1 
assay 
 Series II:  Model 7900 Sequence Detector: 
Liver #8 7 21/05/09 4.61  ±0.23 7.09  ±0.35  -2.48  ±0.23 
Liver #A  
        “ 
 
 
8 
9 
08/10/09 
11/11/09 
0.70  ±0.21 
1.47  ±0.12 
Mean:  
1.09 ± 0.54 SD 
2.87  ±0.11 
2.90  ±0.12 
Mean:  
2.89 ± 0.02 SD 
 -2.17  ±0.19 
 -1.44  ±0.08* 
Mean:  
-1.81 ± 0.52 SD 
Liver #B 
     “ 
 
 
8 
9 
08/10/09 
11/11/09 
3.98  ±0.29 
4.08  ±0.20 
Mean:  
4.03 ± 0.07 SD 
6.53    ±0.29 
6.72  ±0.20 
Mean:  
6.63 ± 0.13 SD 
 -2.55  ±0.10 
 -2.64   ±0.10 
Mean: 
-2.60  ± 0.06 SD 
Liver #C 
     “ 
 
 
8 
9 
08/10/09 
11/11/09 
4.89±0.24 
5.75  ±0.24 
Mean:  
5.32 ± 0.61 SD 
7.41  ±0.20 
7.88  ±0.18 
Mean:  
7.65 ± 0.33 SD 
 -2.52  ±0.18 
 -2.13   ±0.30 
Mean: 
-2.33 ± 0.28 SD 
    Overall Mean ΔCt all expts:   (New ACAT-1) - (Old ACAT-1): 
    *(omit ΔCt value from Liver #A, Experiment 9,  as an outlier): 
-2.28   ±0.42 
(-2.42   ±0.21) 
 
Table 3.4: Comparison of multiplex TaqMan® assays for ACAT-1 (new and old methods) and 
ACAT-2 using the 384-well model 7900 PCR machine. Assays used the reaction mixtures and assay 
protocols described in Sec. 3.2.3.1.  ΔCt values for the comparisons specified in the Table directly 
compare Ct values for the ACAT component of the multiplex assays (data for the β-actin reference 
were ignored). Three or four replicate reactions were run for each sample for each assay method.  
 
3.3.6 Which assay systems best compare relative expression of ACAT-2 and ACAT-1? 
 
Work described above enabled the development of a new, improved TaqMan® assay for ACAT-1, 
to be used in conjunction with the original assay for ACAT-2 to estimate the relative abundance of 
transcripts of ACAT-1 and ACAT-2. Assays using either the new or old method for ACAT-1 have 
been compared using two PCR machines. The choice of ACAT-1 assay and PCR machine will affect 
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values of data such as ΔCt or ΔΔCt for [(ACAT-2) – (ACAT-1)]. Benchmarking these choices 
against each other is best assessed by comparing data from assays of a common cDNA sample, such 
as liver #8 as shown in Table 3.5. 
 
 
All cDNA 
samples 
from  
Liver #8 
TaqMan®  assays 
96-well  “7700 PCR machine”: 
mean ΔΔCt values ± SD 
(ACAT-2) – (ACAT-1) 
 384-well “7900 PCR machine”: 
mean ΔCt values ± SE 
(ACAT-2) – (ACAT-1) 
(Expt No): 1. 
Old ACAT-1 
assay 
(= old ACAT 
assay system) 
2.  
New ACAT-1 
assay  
3. 
Old ACAT-1 
assay 
4. 
New ACAT-1 
assay  
(= new ACAT 
assay system) 
(1+5+6) 6.45 ±0.89    
(5+6)  8.18 ±0.23   
(7)   4.61 ±0.21 7.09 ±0.35 
 
Table 3.5:  Comparison of mean ΔΔCt or ΔCt values (as appropriate) for [(ACAT-2) – (ACAT-1)] 
using cDNA derived from Liver #8 when assayed using either the old or new ACAT-1 assay, and 
either the old 96-well Model 7700 PCR machine, or the new 384-well Model 7900 PCR machine, 
as specified in the Table. Data for experiments 1, 5 and 6 represent the mean value ± SD of the 
ΔΔCt or ΔCt values (as appropriate) from 2 or 3 independent experiments (cf. Table 3.3), and data 
for Experiment 7 represent the mean value ± SE from 3 or 4 replicate PCR reactions (cf. Table 3.4). 
 
Assay systems adopted for ongoing research should be capable of estimating ACAT-2/ACAT-1 
ratios with minimal need to verify by re-assay. Therefore the less-efficient old ACAT-1 assay (as 
used in Chapter 2) should be replaced by the new ACAT-1 assay in future. A higher throughput 
PCR machine such as the 384-well model 7900 instrument is also recommended. These options are 
represented in column 4 of Table 3.5 (new ACAT assay system), compared to the options 
represented in column 1 that were used for the work presented in Chapter 2 (old ACAT assay 
system).  
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3.3.7 Calculation of conversion factors 
 
Using the ΔΔCt values for [(ACAT-2) – (ACAT-1)] shown in Table 3.5, ACAT-2/ACAT-1 ratios 
were calculated for liver #8 (as a common sample) using  both the old ACAT assay system, and 
new ACAT assay system.  As shown in Table 3.6, these values have been used to calculate a 
“conversion factor” based on the comparison of ACAT-2/ACAT-1 ratios estimated by the new assay 
system and the old assay system. The conversion factor was:  [new TaqMan® System / old 
TaqMan® system] = 0.64. 
 
Mean values of (ACAT-2)/(ACAT-1) ratios for 
cDNA derived from Liver #8, assayed by various 
Assay systems as defined in Table 3.5 
“Conversion factor”: 
comparing  (ACAT-2)/(ACAT-1) 
ratios for assays using the new and 
old assay systems (as indicated): 
TaqMan®  assay systems Column 1 / Column 2: 
 
(7700, Old ACAT-1)    
/ 
(7900, New ACAT-1) 
1. 
Old ACAT-1 assay, 
Old 7700 PCR machine 
(old ACAT assay 
system) 
2. 
New ACAT-1 assay, 
New 7900 PCR machine 
(new ACAT assay 
system) 
 
0.0114 0.0073 1.56 
 
Table 3.6:  Comparison of (ACAT-2)/(ACAT-1) ratios for Liver #8 using mean values of ΔΔCt or 
ΔCt for [(ACAT-2) – (ACAT-1)] obtained by the different assay systems as defined in Table 3.5. 
Ratios were derived from the mean ΔCt or ΔΔCt values via the relationship 2 -ΔCt or 2-ΔΔCt as 
appropriate.  
 
 
 
The conversion factor can be used to transform ACAT-2/ACAT-1 ratios for additional liver samples 
obtained with the new ACAT assay system to their old ACAT assay system equivalents, so they can 
be compared directly with the ACAT-2/ACAT-1 ratios for samples listed in Chapter 2. Because the 
conversion factor is derived from the relationship: 
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Conversion factor  =   [ratio (ACAT-2)/(ACAT-1) using old ACAT Assay System] 
   [ratio (ACAT-2)/(ACAT-1) using new ACAT Assay System]  
therefore: 
[ratio (ACAT-2)/(ACAT-1) value equivalent to old ACAT assay system]   
 = Conversion factor x [ratio (ACAT-2)/(ACAT-1) given by new ACAT assay system]  
                                     
Hence an ACAT-2/ACAT-1 ratio obtained using the new TaqMan® ACAT assay system must be 
multiplied by the conversion factor of 1.56 to transform it to its equivalent value for the original old 
ACAT assay system. 
 
3.3.8 ACAT-2/ACAT-1 ratios of three additional liver samples assayed using the new ACAT assay 
system. 
 
 
cDNA source 
(ACAT-2)/(ACAT-1) ratios for cDNA derived from three new liver 
samples, assayed by the new ACAT assay system 
The new ACAT assay system used the new primer/probe set for ACAT-1 
and the new model 7900 PCR machine 
 (i) 
Ratio calculated from actual ΔCt 
data using the new ACAT assay 
system, cf. Table 3.4. 
(ii) 
Ratio transformed to its equivalent 
value for assay system 1(a)  
[Column (i) x 1.56] 
Liver #A 0.14 0.22 
Liver #B 0.010 0.016 
Liver #C 0.0050 0.0079 
 
Table 3.7: Comparison of (ACAT-2)/(ACAT-1) ratios for three new liver samples  #A, #B, #C, 
before and after adjustment to values equivalent to assays using the original assay system as used in 
Chapter 2.  The ratios were calculated via the relationships 2-ΔCt or 2-ΔΔCt as appropriate, and 
“transformed” as indicated in the Table to their old ACAT assay system equivalents using the 
conversion factor given in Sec. 3.3.7.   
 
The three additional liver samples (#A, #B and #C) were assayed by the new ACAT assay system, 
but not by the original ACAT assay system as used in Chapter 2. Table 3.7 presents the ACAT-
2/ACAT-1 ratios for these samples before and after conversion to their old ACAT assay system 
equivalents.  
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3.3.9 Estimation of errors: conversion of new ACAT assay system to values equivalent to the old 
ACAT assay system 
 
Errors can be estimated for the ACAT-2/ACAT-1 ratio of new liver samples after adjustment to their 
old ACAT assay system equivalents, by first combining errors for the various ΔCt and ΔΔCt 
components for [(ACAT-2) – (ACAT-1)] used in the calculation of conversion factors:  
 ΔΔCt values for liver #8 with new ACAT assay system = ± 0.35 SE (Table 3.5); 
 ΔCt values for liver #8 with old ACAT assay system = ± 0.89 SD (Table 3.5);  
 ΔCt values for new liver samples with new ACAT assay system ranged from ± 0.11 to ± 0.29 
(Table 3.4), giving a mean SE = ± 0.18.   
Combining all these components, the overall “ΔΔCt” SE for the new liver samples is: 
 {[(0.89)2 / 3] + (0.35) 2 + (0.18) 2}1/2     = 0.64 
 
Assuming exponential PCR of 2n, the errors are now defined by upper and lower limits of 2(+0.64) (= 
x 1.56) and 2(-0.64) (= x 0.64) of the mean value for the transformed ACAT-2/ACAT-1 ratio for livers 
#A, #B and #C. Hence the SE of the ACAT-2/ACAT-1 ratios of these liver samples after conversion 
to their old ACAT assay system equivalents are +56% to -37% of the mean value, which will be 
rounded up to +60% to -40%. 
 
3.3.10 Comparison of ACAT-2/ACAT-1 ratios of additional liver samples with samples presented in 
Chapter 2  
 
Fig. 3.3 compares ACAT-2/ACAT-1 ratios for all liver samples assayed during this investigation, 
including the 17 samples assayed using the “original” old ACAT assay system (reproduced from 
Fig. 2.7C in Chapter 2) plus the additional liver samples #A, #B and #C obtained using the new 
ACAT assay system after transformation to their old ACAT assay system equivalents.  
 
Liver #A, taken from a patient with liver cysts, gave a high ACAT-2/ACAT-1 ratio that fitted among 
the group of high-ratio livers assayed previously: samples #11 and #12 from patients treated with 
simvastatin, sample #13 from a 9 year old kidney donor, and sample #9 from a fatty liver donor. In 
contrast, livers #B and #C gave very low ratios and fitted among the group of predominantly 
“control” liver samples assayed previously (i.e. from organ donors with no apparent pathological 
condition or medical treatment régime).  
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Hence the assays using the new ACAT system, after transformation with a conversion factor, gave 
ACAT-2/ACAT-1 transcript ratios that appear to fit “within the same ball-park”, and even regions 
within the “ballpark” (as discussed above), as the ratios for livers presented in Chapter 2 that were 
assayed by the original, old ACAT assay system. This conclusion would not be altered if the large 
standard errors of +60% to -40% as estimated above are applied. It is concluded that the adjusted 
ACAT-2/ACAT-1 ratios for livers #A, #B and #C appear to represent a good fit with the ratios 
presented in Chapter 2, and justify the approach used to derive a conversion factor for such 
comparisons. 
 
 
 
Figure 3.3: ACAT-2/ACAT-1 mRNA ratios of all liver samples assayed by RT-qPCR during this 
study. Values for samples 1 to 17 have been taken from Fig. 2.7C, and used the original old ACAT 
assay system as described in Chapter 2. Values for three additional liver samples (#A, #B and #C) 
were assayed by the new ACAT assay system described in Chapter 3, and have been transformed 
using the conversion factor as defined in Sec. 3.3.7.  
 
3.4 Summary and Conclusions 
 
The current chapter describes the development and assessment of an improved TaqMan® assay for 
ACAT-1 (“new ACAT-1” assay).  The new and old ACAT-1 assays were used with the original 
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ACAT-2 assay to estimate ACAT-2/ACAT-1 mRNA ratios, using either the original “old” 96-model 
7700 PCR machine (as used in Chapter 2) or a new 384-well model 7900 PCR machine.   
 
3.4.1 The improved TaqMan® assay for ACAT-1 used a new FAM-MGB-NFQ probe and new 1F2-
1R4 primers (cf. Sec 3.3.2) 
 
The original multiplex TaqMan® assay method for ACAT-1 used a FAM-TAMRA TaqMan® probe 
and appeared to perform adequately in the validation experiments reported in Chapter 2.  This 
assay used the best available PCR primers for ACAT-1 at the time (i.e. before MGB probes 
became available), and it was only after regular use that its poorer reproducibility from run to 
run compared to the ACAT-2 assay became apparent. This problem was overcome by re-assay 
of samples until statistically reliable results were obtained. In work described in the current chapter, 
a new FAM-MGB-NFQ probe for TaqMan®  assays of ACAT-1 was developed and shown to be 
about 2.6 PCR cycles more sensitive (i.e. detected amplified products 2.6 cycles earlier) than the 
old FAM-TAMRA probe.  A new set of primers (1F2-1R4) improved the PCR efficiency of the 
TaqMan® assay of ACAT-1 by about 0.6 of a PCR cycle compared to the old 1F1-1R1 primers.  
Overall, the new TaqMan® assay for ACAT-1 resulted in a combined improvement in (sensitivity + 
efficiency) of >3 PCR cycles.  
 
3.4.2   PCR amplification efficiency (E) values were variable for multiplex assays of both the new 
and old TaqMan® assays of ACAT-1 (cf. Sec 3.3.3) 
 
One strategy for validating qPCR assay protocols is to demonstrate reproducible PCR amplification 
efficiency values that approach 100%. As noted above, the new multiplex TaqMan® assay for 
ACAT-1 was about 0.6 cycles more PCR-efficient than the old assay for ACAT-1 (cf. Sec. 3.3.2 and 
3.4.1). Ct values for the 20 ng samples of liver cDNA used in this experiment were about 28.0 
cycles using the new ACAT-1 assay, compared to 28.6 cycles for the old (less efficient) ACAT-1 
assay. Assuming the new assay method was 100% efficient (i.e. Enew = 1.00), Eold can be derived as 
follows: 
 
               (1+Eold)
28.6  =    (1+ Enew)
28    =  (1+ 1)28    =  228  
     taking logs of both sides and simplifying, 
             log (1+Eold)   =    (log 2) x (28/28.6) 
 =    (0.3010) x (0.97902)   =    0.29469 
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     where:    (1+Eold) =    1.971,     and Eold = 0.971 
 
Hence the old assay method for ACAT-1 was ~3% less efficient at amplifying cDNA targets than 
the new assay method. 
 
Attempts were made to quantify PCR amplification efficiency using two approaches: (i) using Ct 
vs. log (amount cDNA) plots from a dilution series of liver cDNA (5-150 ng cDNA), and (ii) from 
the shape of amplification plots of individual PCR reactions in the above cDNA dilution series, 
using “LinRegPCR” qPCR software.  Results (cf. Sec. 3.3.3) are summarised below: 
 
            % E from cDNA dilution series       .   
 How E was determined  Old ACAT-1 assay New ACAT-1 assay 
 (i) Ct vs. log (amount cDNA)  92%  (R2 = 0.99) 81%  (R2 = 0.98) 
 (ii) “LinRegPCR”qPCR software 61  ± 6 % (SD) 90  ± 12 % (SD) 
 
It is apparent that the above and other experiments (which used a dilution series to derive E values) 
gave data that were highly variable, showed no consistent correlation when comparing different 
assay methods, and bore little relationship to the near-100% efficiency expected for primers 
amplifying short DNA sequences. Furthermore, such E values for the old and new ACAT-1 assays 
showed no relationship to the 3% greater efficiency for the new assay method deduced from the 0.6 
cycle difference in Ct values for an equivalent 20 ng sample of cDNA, shown by our calculations 
above. The lack of a consistent correlation between E and the new vs old assays of ACAT-1 using 
cDNA dilution series confirms the similarly inconsistent PCR amplification efficiency results for 
TaqMan® assays presented in Chapter 2 (Sec. 2.3.3.4). Hence E values obtained from dilution 
series using the ACAT-1 component of multiplex assays were of little use for comparing or 
validating the new and old assays for ACAT-1.  
 
In retrospect, it is possible that the PCR efficiency (E) values for both the ACAT-1and β-actin 
components of multiplex assays were distorted when co-amplified from total cDNA templates in 
the same reaction mixture (cf. Sec 3.4.4). This notion is supported by the smaller (and more 
realistic) difference in E values of ~3% between the new and old assays of ACAT-1 deduced from a 
direct comparison of primer/probe sets. This value is similar to the ~5% difference in E values 
when cloned cDNA templates were used to compare the assay for ACAT-2 with the old assay for 
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ACAT-1 in the absence of the β-actin assay reagents (cf. Sec. 2.3.2.1). Hence it is recommended that 
multiplex assays should not be used to estimate E values.  
 
3.4.3 Validation of the new ACAT-1 assay using the original PCR machine  
 
Using the original 96-well model 7700 PCR machine, cDNA dilution experiments gave consistent 
ΔCt and ΔΔCt values that validated the linearity of the qPCR protocols (cf. Sec. 3.3.3). Comparing 
the new and old ACAT-1 assays within a single PCR run, ΔΔCt values demonstrated that although 
the new ACAT-1 assay was consistently more PCR-efficient and sensitive than the old ACAT-1 
assay, both assays were relatively reproducible within most experiments. However, the old ACAT-1 
assay was less reproducible when samples were assayed on successive, independent occasions, 
requiring time-consuming re-assays to achieve statistically acceptable results as reported in Chapter 
2. 
 
3.4.4  Multiplex TaqMan®  assays were compromised by adoption of the new 384-well model 7900 
PCR machine, which gave disparate Ct values for β-actin (cf. Sec. 3.3.4) 
 
After adoption of a new 384-well PCR machine, the β-actin component of multiplex assays gave 
disparate Ct values that varied by up to ~2 cycles when comparing different ACAT assays (e.g. old 
ACAT-1 vs. new ACAT-1 vs. ACAT-2) for any given cDNA sample. This disparity could result from 
differences in the spectral characteristics of the new model 7900 PCR machine compared to the 
original model 7700 instrument, possibly resulting in the fluors from the ACAT assays 
differentially interfering with detection of the VICTM dye used to detect β-actin. This phenomenon 
was not investigated further, and the problem was avoided by recording Ct values for the ACAT 
component of multiplexed TaqMan® assays, and the β-actin component was ignored. When 
calculating ACAT-2/ACAT-1 ratios using the new model 7900 PCR machine, it is assumed that the 
earlier amplification of primer-limited β-actin amplicons either did not affect the later detection of 
the ACAT component of multiplex assays, or any effect applied approximately equally to each 
ACAT isoform and cancelled out when calculating ACAT-2/ACAT-1 ratios.  
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3.4.5 Assay of additional liver samples using the new ACAT-1 assay and the new 384-well model 
7900 PCR machine  
 
Four liver samples, liver #8 used in much of the previous work, and three additional liver samples 
(#A, #B, #C) were assayed by both the old ACAT assay system (old ACAT-1 assay, original 
ACAT-2 assay, 96-well model 7700 PCR machine) and the new ACAT assay system (new ACAT-1 
assay, original ACAT-2 assay, 384-well model 7900 PCR machine). All four liver samples gave ΔCt 
values [(Ct new ACAT-1 assay) – (Ct old ACAT-1 assay)] that were remarkably similar to each 
other. This systematic difference between the new and old assays for ACAT-1 suggested it would be 
feasible to develop a conversion factor for comparing data from samples assayed by the different 
assay systems. 
 
Derivation of “conversion factors” to compare the new and old assay systems 
Comparison of data using liver #8 as a common cDNA source made it possible to derive a 
“conversion factor” to transform ACAT-2/ACAT-1 ratios obtained by the new ACAT assay system 
to values equivalent to ratios reported in Chapter 2 that used the old ACAT assay system. This 
enabled ACAT-2/ACAT-1 ratios for the three additional liver samples (#A, #B and #C) to be 
compared with the 17 liver samples reported in Chapter 2 (Sec. 2.3.4).  
 
The new samples fell into liver sub-groups that correlated with the medical status of the samples 
described in Chapter 2. Liver #A, from a patient with liver cysts, gave a high ACAT-2/ACAT-1 ratio 
that fell within the range for pathological samples: gallstone livers (#11, #12) and fatty liver (#13) 
assayed previously. New liver samples #B and #C, from liver donors, gave low ACAT-2/ACAT-1 
ratios that fitted within the group of organ donors with no apparent pathological condition or 
medical treatment régime. The derivation and application of the conversion factors to the new 
samples as described above represents a demonstration of the approach necessary to compare 
ACAT-2/ACAT-1 ratios obtained by new assay systems with historic data. 
 
Correction of ACAT-2/ACAT-1 ratios for inefficiency of the old ACAT-1 assay  
The old TaqMan®  assay for ACAT-1 was about 0.6 of a cycle less PCR efficient than the new 
ACAT-1 assay over 28 cycles, and hence under-estimated the “true” abundance of ACAT-1 target 
sequences in the cDNA sample. The relative abundance ratio (new ACAT-1 assay) / (old ACAT-1 
assay) for any cDNA sample is therefore 2-ΔCt x (apparent value), i.e.  20.6 x (apparent value)  =  
1.52 x (apparent value). Hence the ACAT-1 data presented in Chapter 2 (relative to β-actin) should 
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be multiplied by ~1.5 to estimate the “true” value of ACAT-1 abundance relative to ACAT-2.  
Assuming 100% PCR efficiency for both the ACAT-2 assay and the new ACAT-1 assay, the “true” 
ACAT-2/ACAT-1 ratios should be (1/1.5), i.e. ~67% of the values presented in Chapter 2 and Fig. 
3.4.  Adjustment of all ACAT-2/ACAT-1 ratios by this factor would not affect the interpretation of 
data as it applies equally to all samples assayed.  
 
3.4.6 Options for further improvement of RT-qPCR assays for ACAT-1 and ACAT-2 
 
Choice of primer/probe sets for ACAT-1 
The old primer/probe set for ACAT-1 should now be abandoned in favour of the new, more 
sensitive and PCR-efficient assay for ACAT-1 that uses a FAM-MGB-NFQ probe.  An additional 
TaqMan® assay using a FAM-MGB-NFQ probe targeting the unique N-terminal region of the 
hybrid ACAT-1 isoform (derived from chromosomes 1 and chromosome 7) should also be 
developed to reveal its relative abundance compared to the ACAT-1 isoform targeted by the assays 
described herein  
 
New primer/probe sets are required for ACAT-2 
Ideally, both the ACAT-1 and ACAT-2 assays should use TaqMan® probes of equivalent detection 
sensitivity. Hence a FAM-MGB-NFQ probe should be developed for the ACAT-2 assay, which we 
now know is specific only for isoform ACAT-2a, using the existing primers which we now know 
enable efficient and robust PCR. Two smaller isoforms (ACAT-2b and ACAT-2c) are now known 
that lack the splice junction used for the forward primer for the existing ACAT-2a assay, and splice-
specific TaqMan® assays for them should be developed for future surveys. 
 
Choice of PCR machine and format for TaqMan® assays  
Multiplex assays cannot be used with the 384-well model 7900 PCR machine due to the disparate 
Ct values for β-actin obtained when comparing assays of different ACAT isoforms, and should be 
abandoned in favour of “single-plex” assays that target only one gene sequence per reaction 
mixture.  Multiplex assays should be restricted to semi-quantitative screening work. The use of 
high-capacity 384-well PCR machines should be continued, to accommodate the extra reactions 
needed for assaying reference “housekeeping” genes and to provide better replication. 
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Choice of reference gene(s) 
In this study we used β-actin as reference and expressed the abundance of each ACAT isoform as 
ACAT/β-actin ratios. In this regard, Medhurst et al. (2000) used RT-qPCR to quantify β-actin 
expression per nanogram of purified poly(A)+ RNA, and showed that β-actin transcripts appeared 
to be several fold more abundant in duodenum than liver. Hence comparisons of ACAT-1 (or ACAT-
2) expression relative to β-actin in different samples of the same tissue type are more likely to be 
reliable than comparisons of samples from different tissue types.  This qualification should be borne 
in mind when comparing the expression of each ACAT isoform relative to β-actin in different 
samples and tissues, but does not apply to ACAT-2/ACAT-1 ratios where systematic errors, 
inefficiencies and other differences such as variation in β-actin abundance etc. apply equally to the 
assays of both ACAT-1 and ACAT-1 for each sample and cancel out. 
 
Rather than relying on a single reference gene such as β-actin, it is becoming customary to use a set 
of different housekeeping genes to compare the expression of functional genes of interest (such as 
ACAT-1 or ACAT-2), especially across different human tissues (e.g. Vandesompele et al., 2002; 
Radonic et al., 2004). Ribosomal RNA is another commonly-used reference. 
 
3.4.7 Quality control to compensate for run-to-run variability 
 
Newer detection chemistries and qPCR machines will continue to emerge, making it increasingly 
difficult to compare new with historic data e.g. for ACAT-2/ACAT-1 ratios.  In this regard, 
measuring the relative abundance of transcripts can be likened to measurements of enzyme 
activities in medical biochemistry laboratories, where the “units” of activity depend on defined 
assay chemistry and conditions (the units of enzymatic activity will vary if the assay conditions are 
changed). Transcript analysis requires: (1) purification of RNA, (2) RT enzymes to convert RNA to 
cDNA, (3) Taq polymerase enzymes for the PCR, (4) an appropriate chemistry for detecting 
amplicons, and (5) a convenient qPCR machine that cycles all reactions uniformly and detects 
fluorescence outputs from the chemistry.  Inherent in all of these parameters are variables that 
require choices and precise control of sample preparation/assay conditions to achieve consistent 
results.   
 
Medical biochemical laboratories include a “controlled assayed plasma” sample in all assays runs, 
to identify any changes in assay conditions from run-to-run and to normalise results for unknown 
samples if necessary.  For quantitative mRNA analysis therefore, it is recommended that a bulk 
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cDNA preparation be made, assayed carefully for ACAT-1 and ACAT-2 transcript abundance, and 
aliquots stored cryogenically (“control assayed cDNA” reference). Regular inclusion of this 
referenced cDNA would make it possible to correct for run-to-run variation from all sources during 
the qPCR reaction, although it would not eliminate variation from other sources during sample 
preparation prior to the qPCR. 
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CHAPTER 4 
 
MEASUREMENT OF ACAT PROTEIN(S) IN HUMAN TISSUE 
 
4.1 Introduction  
 
Having developed methods for quantifying and comparing transcript levels of ACAT-1 and ACAT-2 
in various human samples (cf. Chapters 2 and 3), the question arises: how do levels of their protein 
translation product(s) correlate with transcript abundance?  As reviewed in Chapter 1, ACAT-1 and 
ACAT-2 appear to be expressed as intrinsic membrane proteins located within the ER. ACAT-1 
expression appears to be ubiquitous in the human tissues that have been investigated (Sec. 1.2.4). 
However ACAT-2 expression appears to be highly variable, and appreciable expression in humans 
appears to be restricted to enterocytes in the intestines, hepatocytes, and macrophages in the later 
stages of maturation (Sec. 1.2.6). 
 
ACAT-1 has been shown to exist as two isoforms, a 550 amino acid protein with a calculated size 
of ~65 kDa encoded entirely on chromosome 1, and a larger, chimeric 591 amino acid protein 
encoded on both chromosomes 1 and 7 (Chapter 1, Sec. 1.2.3). The larger isoform possesses a 
unique 41-amino acid sequence at its N-terminus fused to the same 550 amino acid sequence 
present in the smaller isoform. Hence both isoforms should be detectable using antibodies raised 
against epitopes present in the smaller isoform.  When subject to SDS-PAGE, the smaller and larger 
isoforms both migrate faster than predicted (due to their hydrophobic character) and are observed to 
have apparent sizes of 48-50 kDa and 56 kDa respectively (cf. Sec. 1.2.4). The larger 56 kDa 
isoform appears to be absent from most human tissues that have been investigated (or possibly 
present in trace amounts), but can be induced in some cultured cell lines after various treatments (cf. 
Sec. 1.2.4). No differences in function have yet been assigned to the two isoforms. 
 
Comparatively less is known about ACAT-2, which in its complete form (isoform ACAT-2a) 
represents a 59.9 kDa protein (calculated size) consisting of 522 amino acids deduced from its full 
length cDNA sequence (Chapter 1, Sec. 1.2.5, 1.2.6). The full-length ACAT-2a isoform migrates 
with an apparent size of 46 or 48 kDa during SDS-PAGE (Sec. 1.2.6). Several alternatively spliced 
variants of this gene have been described: ACAT-2b (which lacks exons 4 & 5) with a calculated 
size of 502 amino acids; and ACAT-2c (which lacks exons 4, 5, 8, 9, 10) with a calculated size of 
379 amino acids. Hence all three isoforms should be capable of detection using antibodies raised 
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against epitopes present in their shared N-terminus (encoded by exons 1-3). Any differences in 
function among the various isoforms of ACAT-2 are as yet unknown. 
 
 This Chapter investigates the use of one anti-hACAT-1 polyclonal antiserum and four anti-
hACAT-2 polyclonal antisera obtained from commercial or other sources in attempts to detect 
ACAT-1 and ACAT-2 proteins in human and rat tissues. A further anti-ACAT-2 polyclonal 
antiserum (raised against an African green monkey epitope) was developed during this 
investigation. The ACAT-1 antiserum was found to be considerably more reliable than any of the 
ACAT-2 antisera, and was used to quantify levels of ACAT-1 protein (using β-actin as reference) in 
22 human liver samples.  These ACAT-1 protein levels were compared with levels of ACAT-1 
transcripts in 16 of these samples that were examined previously in work described in Chapter 2.  
 
 
4.2 Materials and Methods 
 
4.2.1 Additional liver samples 
 
Liver samples #2-17 inclusive (cf. Table 2.1, as used for the transcript analyses described in 
Chapter 2) were included in the protein work described in this chapter (the supply of liver sample 
#1 was exhausted). Most of these samples were available in relatively limited supply, so an 
additional six liver samples (#18-23 inclusive) were sourced by J. Smith (cf. Sec. 2.2.1 for source 
institutions) to assist method development. These liver samples had the following accession 
profiles:  
 #18 (68 yr male, 75 min warm ischemia time, liver resection) 
 #19 (18 yr male, 0 min warm ischemia time, liver donor) 
 #20 (18 yr female, 0 min warm ischemia time, liver donor) 
 #21 (43 yr male, 0 min warm ischemia time, liver donor) 
 #22 (unspecified) 
 #23 (14 yr male, 24 min warm ischemia time, kidney donor) 
  
Samples of rat liver (male Wistar) were provided by S. Mason (School of Chemistry and Molecular 
Biosciences, UQ). 
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4.2.2 Source of antibodies 
The six primary polyclonal rabbit antisera used in this study are listed in Table 4.1. All were raised 
against amino acid sub-sequences of ACAT-1 or ACAT-2. A primary mouse anti-actin antiserum 
and secondary goat anti-rabbit and goat anti-mouse antisera were used for the detection and analysis 
of ACAT-1, ACAT-2 and β-actin, and were sourced and used as described in Sec. 4.2.5. 
 
Antiserum Amino acid sequences of peptides used to raise each antiserum  
1  a Commercial ACAT-1 polyclonal 
antiserum 
K6 MSLRNRLSKSRENPEED23 
 
2  b Commercial ACAT-2 polyclonal 
antiserum 
P3 GGARLRLQRTEGLGGER20 
 
3.  c, h ACAT-2 polyclonal antiserum 
obtained from JL Smith and J deJersey 
(RB3) 
CA59 RRGEGIQAPSFSS73 (15 mer) 
4.  d, h ACAT-2 polyclonal antiserum 
obtained from JL Smith and J deJersey 
(RB4) 
CQ256 LRELLDRAMREAIQ270 (16 mer) 
5.  e ACAT-2 polyclonal antiserum supplied 
by L Rudel  
 
M1EPGGARLRLQRTEGLGGERERQPCGDGNTETHRAPDLV 
QWTRHMEAVKAQLLEQAQGQLRELLDRAMREAIQSYPSQD 
KPLPPPPPGSLSRTQEPSLGK100 
6.  f  GST-ACAT-2 fusion  antiserum 
G28 N T E T H R A P D L V K W T R H ME A V K A Q L L E Q A Q 
G Q L R E L L D R A MW E A I Q S Y P S Q D K P P P L P P P D S L 
S R T Q E P S L G99 (African green monkey ACAT-2 sequence) 
Table 4.1:  Primary polyclonal antisera for ACAT-1 and ACAT-2 sourced or developed for this 
investigation. All of these antibodies were raised in rabbits. Amino acid residues are numbered 
using the full deduced cDNA sequence of each ACAT isoform. 
 aAntiserum 1:  anti ACAT-1, Cayman Chemicals, Ann Arbor USA, Cat. #100028, 
bAntiserum 2:  anti-ACAT-2, Cayman Chemicals, Ann Arbor USA, Cat. #100027. 
cAntiserum 3:  anti-ACAT-2, “RB3” developed by J. Smith and J. deJersey in our laboratory prior 
to start of the work described in this thesis.  
dAntiserum 4:  anti-ACAT-2, “RB4” developed by J. Smith and J. deJersey in our laboratory prior 
to start of the work described in this thesis. 
eAntiserum 5:  anti-ACAT-2, a gift from L. Rudel. 
fAntiserum 6:  anti-ACAT-2, Developed as part of the work described in this thesis. 
h The first residue, “C”, was added during preparation of  protein expression vector. 
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4.2.3 Whole tissue homogenates and subcellular fractionation 
 
1g of frozen human liver was pulverised using a pre-chilled mortar and pestle, dispersed in 9 
volumes of cold homogenising buffer (300 mM sucrose, 20 mM HEPES, 10 mM EDTA, 1 mM 
EGTA, pH 7.4), and broken up in a homogenising tube with 10 upward and downward strokes.  At 
the end of the second stroke 5 µl PMSF (0.1 mM) was added. Small, replicate aliquots (500 µl) of 
homogenate were frozen and retained for future analysis, and various subcellular fractions were 
isolated as described in Fig. 4.1. Protein was estimated in the whole homogenate and all fractions 
using a micro-bicinchoninic acid assay method (adapted from 
http://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Bulletin/bca1bul.pdf) and modified 
to include 0.1% (w/v) SDS (Morton et al., 1992) with bovine serum albumin as standard. Rat liver 
homogenates were prepared similarly to the human liver homogenates. 
  
 
Figure 4.1: Subcellular fractionation of liver preparations. (Adapted from Touster et al., 1970). 
 
 
4.2.4 SDS-PAGE and Western Blotting 
 
Polyacrylamide gels (10 % unless otherwise specified, 0.75 mm thick) were cast and run using the 
Biorad Mini Protean® apparatus via standard procedures (Bio Rad MINI PROTEAN® 
Electrophoresis Cell Instruction Manual). Whole liver homogenate or subcellular fractions were 
mixed with an equal volume of 2x gel loading buffer (0.125 M Tris-HCl, 4% SDS, 20% v/v 
glycerol, 0.2 M DDT, 0.02% bromophenol blue, pH 6.8), heated to 100 ºC for 90 seconds and 
allowed to cool to room temperature, then loaded on to gels.  BIO-RAD SDS-PAGE Standards 
Homogenate (H) centrifuged 
 at 1000g for 10 min at 4 ºC. 
Nuclei pellet P1- Resuspended  
in 5 mM HEPES  
Supernatant S1 - centrifuged  
at  33000g for 7.5 min at 4 
ºC 
Mitochondrial lysosomal pellet P2-  
resuspended in 5 mM HEPES  
Supernatant S2 - centrifuged  
at 78000g for 100 min at 4 ºC 
Retained supernatant S3  
Microsomal pellet P3- resuspended 
 in 5 mM HEPES 
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Broad range protein size marker Cat # 161-0318, Control 300000925 (3.5 µl) was used in one or 
more lanes. Stacking gels were run at 34 mA for 5 min and resolving gels at 32 mA for 
approximately 45- 60 min.  
 
Gels not intended for Western transfer were stained by placing them in about 30 mL of Coomassie 
blue staining solution (0.025% brilliant blue R, 40% v/v methanol, 7% v/v acetic acid) using an 
orbital shaker for 30 min, then destained with two washes of an aqueous solution containing 10% 
acetic acid and 10% methanol. 
 
Western blots (WB) were prepared by transfer of proteins from the gel to nitrocellulose membranes 
(PROTRAN®, Perkin Elmer, Rowville, Victoria, Australia) using a Bio-Rad semidry protein 
transfer cell (cat #170-3940) using the manufacturer’s instructions. Membranes were checked for 
successful protein transfer using Ponceau S reversible stain (Sigma-Aldrich, Castle Hill, NSW, 
Australia) and destained with MilliQ water.  Residual gels were checked for quantitative protein 
transfer of proteins to the WBs using the Coomassie blue staining solution described previously. 
The residual gels gave no stain for proteins in the size range expected for ACAT-1 and ACAT-2 or 
smaller. 
 
4.2.5 Detection of antigen-antibody complexes in Western blots (WBs)  
 
4.2.5.1 Probing for ACAT proteins with primary rabbit antibodies 
 
Using an orbital shaker, WB membranes were blocked for 1 hr at room temperature using half 
strength (1.5%) cold water fish scale gelatine (supplied as 3% solution by Sigma-Aldrich, Castle 
Hill, NSW, Australia, and diluted to 1.5% using PBS buffer). PBS buffer was prepared from PBS 
tablets, Amresco USA. Unless otherwise stated, ACAT protein was detected using a 1: 5000 
dilution (in PBS) of a primary rabbit anti-ACAT antiserum (cf. Table 4.1), and incubating the 
membrane overnight at 4 ºC (cold room) in a sealed polythene bag on the orbiting shaker platform. 
The membrane was then washed 4 x (5 min.) with 0.1% Tween in PBS. 
 
4.2.5.2 Qualitative detection of ACAT proteins in WBs probed with rabbit antibodies 
 
The next morning the probed WB membrane (i.e. after Step 1) was washed 4 x (5 min.) with 0.1% 
Tween 20 (Ajax Fine chemicals (Taren Point, NSW, Australia) in PBS, then incubated in the dark 
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at room temperature (nominally 22-23 ºC) for 45 min with goat anti-rabbit IgG antiserum (Alexa 
Fluor® 700 Goat Anti-Rabbit IgG [H+L] from Molecular Probes [Invitrogen], Mt. Waverley, 
Victoria, Australia, Cat # A 21076)) as a 1: 15,000 dilution in PBS. The membrane was then 
washed 4 times with 0.1% Tween 20 in PBS every 5 min and once with PBS for 2 min to remove 
excess Tween. ACAT proteins were then detected using an Odyssey infrared scanner (John Morris 
Scientific) at scanning intensities 4 and 5 using the 700 nm channel. Images were reproduced in 
black and white (e.g. Fig. 4.3 for ACAT-1 detection in human liver preparations). 
 
4.2.5.3 Quantitative analysis of ACAT-1:  
 
a) Probing for β-Actin:  The next morning (after Step 1) the WB membrane was incubated with 
a 1:15,000 dilution of primary mouse anti-actin antiserum (Sigma-Aldrich (Castle Hill, 
NSW, Australia) for 1 hr at room temperature using a revolving Falcon tube. The membrane 
was then washed 4 x (5 min.) with 0.1% Tween 20 in PBS.  
b) Simultaneous detection of ACAT-1 and β-actin:  The doubly-probed WB membrane (after 
Step 3) was incubated in the dark at room temperature (nominal 22-23 ºC) for 45 min with a 
mixture of goat anti-rabbit antiserum (cf. Step 2), and goat anti-mouse antiserum (IR Dye 
800® Goat Anti-Mouse IgG [H&L] from Li-Cor Biosciences [Lincoln, NE, USA], code- 
610-132-121), each used as a 1: 15,000 dilution in PBS. The membrane was then washed 4 
times with 0.1% Tween 20 in PBS every 5 min and once with PBS for 2 min to remove 
excess Tween. Proteins were then detected using the Odyssey infrared scanner at scanning 
intensities 4 and 5 using both 700 nm and 800 nm channels for ACAT and actin 
respectively. A typical image of a scanned WB membrane loaded with whole tissue 
homogenates of various liver samples is presented in Fig. 4.2. When required, ACAT-1 and 
β-actin bands on WBs were quantified as “integrated intensity units” (= arbitrary scan units) 
using the Odyssey software (ODYSSEY Infra Red Imaging System, Application Software 
version 1.2).  
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Figure 4.2: Image of Western blot doubly fluor-stained for ACAT-1 (red) and β-actin (green) as 
described in Sec. 4.2.5. Samples of whole liver homogenates equivalent to 30 μg protein (liver 
samples #3, 5, 15, 9,7 ,16, 11 and 14 from left to right in the figure) were loaded and subjected to 
SDS-PAGE, transferred to WB, stained and imaged as described in Sec. 4.2.5.  
 
4.2.6 Modification of the antigen-antibody detection procedure for blocking experiments 
 
Homogenate of liver #14 equivalent to 500 μg of protein was loaded into one long well in a gel, and 
after SDS-PAGE and transfer to a WB (Sec. 4.2.4), the WB was visualised with Ponceau S and split 
into 6 strips. Two of these strips  (Blot A and Blot B) were probed as described in Sec. 4.2.5, Steps 
1 and 2, with Step 1 being modified by including ACAT-1 Blocking peptide (Cat# 10005090), 
Cayman Chemicals, Ann Arbor USA) in the probing solution containing primary rabbit anti-ACAT 
antiserum, as follows. For Blot A, aliquots (6 μL) of the primary anti-ACAT antiserum solution (as 
supplied by the manufacturer, cf. Sec. 4.2.5) and the blocking peptide solution were mixed and 
incubated at room temperature for 2h, then diluted 1:500 with PBS prior to the overnight incubation 
as detailed in Step 1 of Sec. 4.2.5. Blot B was treated similarly to Blot A except that the blocking 
peptide solution was omitted and replaced with 6 μL of PBS. 
 
4.2.7 Antiserum 6 production using ACAT-2-GST fusion protein (cf. Sec. 4.3.2.3) 
 
Recombinant plasmid pGEX-5x-2-ACAT2, supplied by J. Smith, included the GST (glutathione-S-
transferase) sequence with an insert encoding portion of the African green monkey ACAT-2 
sequence shown in Table 4.1 (item 6). The plasmid was transformed into competent E. coli cells 
(DH5) via standard procedures.  Bulk cultures of the transformed E. coli (prepared by adding 
overnight starter to 500 mL LB/Ampicillin medium in 2L conical flasks) were incubated for 2 h at 
37 ºC using an orbital shaker at 200 rpm. When the absorbance (600 nm) reached 0.8-1.0, 125 µl of 
1.0 M IPTG (from Applichem, Germany) was added to the remainder, and incubation continued for 
a further 2.5h and the cells were harvested by centrifugation (5,000 rpm for 25 min at 4 ºC and 
stored at -80 ºC until needed). 
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GST-ACAT2 peptide was purified from the harvested E. coli cells after resuspension in 20 mL 
chilled PBS by sonication followed by addition of 0.8 mL 25% Triton X-100 detergent (Sigma-
Aldrich, Castle Hill, NSW, Australia).  The lysate was centrifuged at 17,000 rpm for 30 min. and 
the supernatant loaded on to a glutathione-linked agarose column (BioRad) to purify the GST-
fusion protein using the manufacturer’s instructions. The GST-fusion protein was eluted with 15 
mL TCB buffer (50 mM Tris HCl 0.15 mM NaCl, pH 7.5) containing 5 mM reduced glutathione, 
and protein was quantified by A280.  
 
Two rabbits were each injected with 0.2 mg of the fusion protein in Freund’s adjuvant (Sigma-
Aldrich, Castle Hill, NSW, Australia) (initially in complete adjuvant but followed by boosters in 
incomplete adjuvant at 2-4 week intervals) using standard procedures. Crude antisera were prepared 
from each rabbit using standard procedures. 
 
4.2.8 Quantitative estimation of ACAT-1 and β-actin protein in human liver samples 
 
Whole human liver homogenates were prepared, subjected to SDS-PAGE, transferred to WBs, and 
probed with anti-ACAT-1 antiserum 1 as described in Sections 4.2.4 and 4.2.5. To assist 
consistency, a bulk homogenate of each liver sample was divided into aliquots and frozen, and an 
aliquot thawed each time the sample was required. After trials to determine the optimal amount of 
liver homogenate (cf. Fig. 4.8 in Sec. 4.3.3), an aliquot representing 30 μg protein for each liver 
homogenate was used for all quantitative determinations unless otherwise stated.  
 
The 22 human liver samples (#2-23 incl., cf. Sec. 4.2.1) were distributed as subsets among three 
gels per assay run (8 liver samples per gel designated subset A, subset B or subset C, including 
Liver #14 loaded on each gel as an internal reference). Each set of 3 subsets was run on four 
independent occasions (Trials). After PAGE, protein was transferred to a WB, then probed with 
antibodies to visualise and quantify the ACAT-1 and β-actin bands as described in Sec. 4.2.5. 
Quantitative scan data (“raw data” as arbitrary scan units) were used to calculate the ACAT-1/β-
actin ratio for all liver samples loaded on each WB, as described in Sec. 4.2.9.  
 
4.2.9 Calculation of “raw” and “corrected” ACAT-1/β-actin ratios 
 
“Raw ACAT-1/β-actin ratios” for each sample on a WB were obtained by first using the raw scan 
data for ACAT-1 and β-actin for that sample.  The “normalised raw ACAT-1/β-actin ratio” for 
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each sample was obtained by dividing by the ACAT-1/β-actin ratio for Liver #14 on that WB, as 
described in Sec 4.2.8 (cf. Fig. 4.10). 
 
“Corrected ACAT-1/β-actin ratios” were calculated to compensate for gel-to-gel and WB-to-WB 
variability both within and between Trials. This was achieved as indicated in Table 4.2 based on the 
assumptions and considerations detailed in Sec. 4.3.4.2. Using Western Blot “B” in Trial 1 as an 
example, the raw scan data for ACAT-1 (column (1) of Table 4.2) were summed and averaged over 
all 8 samples to give a mean value of 63.34 scan units. Similar mean values were calculated for WB 
“B” in all 4 Trials, and the average value for all 4 Trials was found to be 43.21 scan units; this value 
was used to “correct” the raw values for each sample on that gel (i.e. to compensate for run-to-run 
variability) as shown in Column (2) of Table 4.2. The raw β-actin data were corrected in a similar 
fashion to ACAT-1 (Columns (3) and (4)). These corrected values for β-actin varied from gel to gel, 
despite the same amount of each liver sample being loaded in each gel. However each sample 
should contain the same amount of β-actin in all 4 gels. 
 
To obtain a single value for β-actin for each sample in all 4 gels, it was assumed that the same 
amount of each liver (and hence amount of β-actin) was loaded for each liver sample # in all 4 WBs 
containing that sample (this also assumes minimal error when dispensing equal aliquots of the 
thawed liver homogenate for each trial, and also assumes equal transfer of protein from gels to WBs 
after SDS-PAGE). Hence the “average corrected value for β-actin” for each liver sample # was 
calculated for all 4 cognate WBs as indicated in column (5) of Table 4.2.  These values were used to 
calculate the overall “corrected ACAT-1/β-actin ratio” for each liver sample in each Trial via the 
quotient: [column (2)]/[column (5)] (data shown in Fig. 4.11). 
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Western Blot "B", Trial 1: Arbitrary WB scan units 
 
(1) (2) (3) (4) (5)  Av. 
corrected 
β-Actin, 
all 4 Trials 
 
Raw data ACAT-1 Raw data β-Actin 
Liver No. ACAT-1 corrected β-Actin corrected 
3 36.99 25.23 5.70 18.79 19.30 
5 52.81 36.03 3.85 12.69 14.98 
15 63.57 43.37 4.27 14.08 14.90 
9 75.45 51.47 7.23 23.84 21.28 
7 61.29 41.81 5.49 18.10 20.26 
16 97.18 66.30 7.03 23.18 18.45 
11 73.61 50.22 5.91 19.49 17.81 
14 45.83 31.26 1.99 6.56 9.66 
      Av. WB “B”: Trial 1 63.34 
 
5.18 
  Av. “B”: all 4 Trials 43.21 
 
17.08 
  
      Correction factor: x (43.21/63.34) x (17.08/5.18) 
  
Table 4.2: Procedure to obtain “Corrected ACAT-1/β-actin ratios”, using the raw data obtained 
from Western blot “B” in Trial 1 as an example (Table adapted from an Excel spreadsheet). ’Av. 
WB “B”/ Trial 1‘ represents the average value in arbitrary scan units (raw data) for all liver 
samples for this WB (Blot B/Trial 1) in columns (1) (ACAT-1) and (3) (β-actin). ’Av.  “B” all 4 
Trials‘ represents the mean of these averages for each sample from the “B” subsets of WBs in all 4 
Trials. “Corrected” values for each liver (columns (2) and (4)) were calculated using these average 
values as a “Correction factor”, as indicated in the Table. Column (5) represents the mean 
corrected value for β-actin for each liver # averaged over the 4 Trials. 
 
4.3 Results and Discussion 
 
4.3.1 A commercially-available antiserum specific for ACAT-1  
 
At the time this investigation was started, an anti-ACAT-1 antiserum was commercially available 
(Cayman Chemicals, Ann Arbor USA) that was reported by the supplier to be highly specific for 
human ACAT-1 protein (cf. Ch.1, Sec. 1.2.4).  Named antiserum 1 in Table 4.1, this antiserum was 
raised in a rabbit against a synthetic peptide representing amino acids 6-23 deduced from the full 
cDNA sequence of ACAT-1.  
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To examine the properties of antiserum 1, subcellular fractions were prepared from whole tissue 
homogenates derived from liver #14 (Table 2.1) as described in Sec. 4.2.3. Western blots after SDS-
PAGE (WB) using this antiserum detected a single band (Fig. 4.3) that was most intense in 
fractions P1 (nuclear fraction), P2 (lysosomal/ mitochondrial fraction) and P3 (microsomal 
fraction), and much less intense in the post-microsomal supernatant (S3) and the whole tissue 
homogenate (Fig. 4.3). The size of this protein was found to be 48.0 ± 0.3 SE kDa (range 47-49 
kDa) based on 6 independent gels and WBs, similar to the 48-50 kDa range reported by other 
workers (Sec. 1.2.4). 
 
 
 
   
Figure 4.3: ACAT-1 in Western Blots. WBs of various subcellular fractions from human liver #14 
(cf. Fig. 4.1) were probed with anti-ACAT-1 antiserum 1 (Table 4.1) and imaged as described in 
Secs. 4.2.3 and 4.2.4. H: whole liver homogenate (equivalent to 30 μg protein).  P1: Nuclear pellet; 
P2: Mitochondrial/lysosomal pellet; P3: Microsomal pellet, S3: “Retained” Supernatant; (all 
subcellular fractions equivalent to 50 μg protein).  
 
 
When tested on multiple occasions, antiserum 1 reproducibly gave a single intense band of ~48 kDa 
with all 22 human liver samples tested (e.g. Figs. 4.2; 4.4B; 4.5; 4.6E/F). When used to probe rat 
liver, antiserum 1 detected a relatively weak band of the same 48 kDa size as human liver (Fig. 4.5), 
and a very faint band that was slightly larger by an estimated 5-10 kDa.   
 
The specificity of the positive bands for ACAT-1 shown in Fig. 4.3 was examined by incubating 
WBs containing samples of whole liver homogenate with a “blocked anti-ACAT-1 antiserum” 
(rabbit anti-ACAT-1 antiserum 1 mixed with its cognate synthetic peptide epitope), prior to visual 
detection using the goat anti-rabbit antiserum. No signal was detected after treatment with the 
blocking agent (Fig. 4.4, Lane A) compared to the “unblocked” treatment (Lane B). This 
H P1 P2 P3 S3 
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demonstrates that ACAT-1 antiserum 1 does not bind to proteins other than those homologous to 
the N-terminal epitopes of ACAT-1 described in Table 4.1.  
        
ACAT-1 detected as 
antibody 
was not blocked 
by blocking peptide
ACAT-1 not detected
as antibody was
blocked
A B
 
                 
Figure 4.4:  Specificity of the anti-ACAT-1 “antiserum 1” (Table 4.1) for ACAT-1 protein. A whole 
homogenate of liver #14 (equivalent to 500 μg of protein) was subjected to SDS-PAGE and 
transferred to a WB (Sec. 4.2.4).  The WB was split into 6 strips, and 2 strips were probed as 
described below (the other strips were used for other experiments). Lane A (“blocked Ab”): the 
WB was incubated with a “blocked anti-ACAT-1 antiserum” (Sec. 4.2.6) containing the synthetic 
ACAT-1 peptide used to generate the antiserum (Sec. 4.2.6). Lane B (“Control” unblocked Ab): 
the WB was treated with anti-ACAT-1 antiserum in the absence of the synthetic ACAT-1 peptide. 
 
4.3.2 Attempts to obtain antisera that detect ACAT-2 in human liver 
 
4.3.2.1 Overview of approaches for obtaining and assessing ACAT-2 specific antisera 
 
Table 4.1 lists a total of five rabbit antisera reported or developed to detect ACAT-2 that were 
examined during this investigation. The locations of the antigenic peptides within the full-length 
(deduced) ACAT-2 protein sequence from which these preparations were derived are indicated 
Table 4.1. Salient features of experiments designed to assess these preparations are summarised 
below. 
 
 
 
 
 
 
 
 
 
111 
 
4.3.2.2 ACAT-2 antiserum 2 (sourced from Cayman Chemicals) 
 
Figure 4.5: Western blot analysis to detect ACAT-1 and ACAT-2 proteins in a microsomal fraction 
from human liver (Liver #6, 30 μg protein per lane) and rat whole liver homogenate (50 μg protein) 
after SDS-PAGE and transfer to WB. The WB was split in half and one half was probed with 
antiserum 1 (ACAT-1), lanes 1 and 2, as described in Sec. 4.2.4, 4.2.5 and Table 4.1. The other half 
of the WB was probed with antiserum 2 (ACAT-2), lanes 4 and 5.  A protein ladder (Sec. 4.2.4 was 
loaded in Lane 3 and was split in half as indicated in the figure; the “50 kDa” size marker was 
ovalbumin, actual size 50.4 kDa. 
 
Antiserum 2 , raised against residues 3-20 of the full amino acid sequence of human ACAT-2, 
failed to detect any signal against a WB of liver #6 (Lane 5, Fig. 4.5). However the same liver 
sample on the same WB reacted strongly with antiserum 1 (raised against residues 6-23 of ACAT-
1), and detected the expected ~48 kDa band for ACAT-1 (Lane 1, Fig. 4.5) as noted in the previous 
section.   Preparation 2 was reported by the suppliers to detect ACAT-2 as a 60 kD protein in 
human fibroblasts, and a 49 kD protein in human Jurkat cell lysates, but the suppliers did not 
mention human liver (https://www.caymanchem.com/pdfs/100027.pdf).  The data reported by 
Cayman appear to be unreliable, and the consensus is that liver ACAT-2 is expressed as a 46-48 
kDa protein when examined by SDS-PAGE (Cf. Sec. 1.2.6). Because ACAT-2 antiserum 2 showed 
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no evidence of clear detection of an ACAT-2 band of the expected size in human liver sample #6 in 
this experiment (Fig. 4.5), and liver #18 in another experiment (data not shown), it was not 
investigated further. 
 
Interestingly, antiserum 2 detected antigenic products in rat liver:  an intense band of ~-16 kDa, a 
weaker band of ~-4 kDa and a very faint band of ~-80 kDa (Fig. 4.5, Lane 4).  This result is 
contrary to other work that has reported a ~50 kDa protein as the major band for ACAT-2 in rat 
liver (cf. Sec. 1.2.6). The failure to detect bands of expected size for both human and rat liver 
caused us to abandon further work with antiserum 2. 
 
4.3.2.3 ACAT-2 antisera 3, 4 and 5 
 
Antisera 3 and 4 were developed by prior work (J. Smith and J. de Jersey) in our laboratory to target 
human epitopes of ACAT-2 downstream from the N-terminus (preparation 3: residues 59-73; 
preparation 4: residues 256-270, cf. Table 4.1), but were untested prior to this investigation. 
Preparation 5, a gift from L Rudel, was raised against residues 1-100 of the full-length human 
ACAT-2 amino acid sequence.  Multiple banding patterns were observed with each of these three 
ACAT-2 antibodies after Western analysis of liver #14 (see Fig.4.6), compared to the single ~46-48 
kDa band for ACAT-2 expected from the literature (cf. Sec. 1.2.6). However the expected single 
~48 kDa band for ACAT-1 (Sec. 4.3.1) was observed when strips of the WB were probed with 
antiserum 1 for ACAT-1 (Lanes E, F in Fig. 4.6), indicating that the WB had been prepared 
correctly, and that the proteins do not appear to be degraded. Band intensity varied greatly from 
experiment to experiment for preparations 3, 4 and 5, and were very faint in other experiments that 
examined liver #18, (data not shown), and Fig. 4.6 represents the most clearly-defined banding 
patterns observed for anti-ACAT-2 probing experiments using these three antisera.  
 
Size markers were not loaded on the WB shown in Fig. 4.6, but the ACAT-2 bands could be 
compared with the single intense ACAT-1 band (~48 kDa) obtained using antiserum 1 (cf. Fig 4.6 
lanes E, F). The major ACAT-2 band (possibly a doublet shown as bands 4a and 4b in Fig 4.6) 
observed after using antisera 3 or 4 (RB3 and RB4 respectively) was estimated to be somewhat 
smaller than the ACAT-1 band, consistent with these antibodies detecting band(s) similar to the 46 
or 48 kDa band reported by other workers for the full-length ACAT-2a isoform (cf. Sec. 1.2.6). 
Preparation 5 supplied by L. Rudel (R-A2-5) produced a weaker band of similar size to band 4b 
found using preparations 3 and 4, but the major ACAT-2 band using preparation 5 (band 1 or 2 in 
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Fig. 4.6) was much larger in size. It is possible that bands 4a and 4b using RB3 and RB4 could 
represent a fused doublet of ACAT-2a and ACAT-2b respectively (cf. Sec. 4.3.2.4 and 4.4.1). 
 
 
Figure 4.6:  Western blot analysis of a whole homogenate from human liver #14 (300 µg protein) 
loaded into a single large well. After SDS-PAGE and WB transfer (cf. Sec 4.2.4, 4.2.5), the 
membrane was cut into 8 strips designated Lanes A-H, that were probed with antiserum 1 (ACAT-
1, Lanes E and F); antiserum 3 (ACAT-2: RB3, Lanes A and B); antiserum 4 (ACAT-2: RB4, 
Lanes C and D); and antiserum 5 (Rudel ACAT-2: R-A2-5, Lanes G and H). No space was 
available for loading protein size markers on the gel.  
 
In addition to the major 4a and 4b bands noted above, many other bands, both smaller and larger, 
were observed after probing with antisera 3 (RB3), 4 (RB4), and 5 (R-A2-5), including some 
common and some unique bands. The unique bands detected by each antiserum could (for example) 
be a consequence of each preparation being raised against a different epitope of the ACAT-2 amino 
acid sequence and detecting different non-ACAT-2 (i.e. non-specific) targets in the liver 
homogenate. For reasons outlined above, none of the smaller or larger bands could be interpreted as 
corresponding to ACAT-2a or ACAT-2b, and the larger bands could represent non-ACAT-2 
antigens or adducts bound to an ACAT-2 isoform. It is also possible that one of the smaller-sized 
bands (e.g. band 5, cf. Sec. 4.3.2.4) could represent ACAT-2c, although the smaller (and weakly-
RB4 RB3 ACAT1 R-A2-5 
A and C-1:1000 
B and D-1:2000 
G-1:2000 
H-1:4000 F-1:10000 
E-1:5000 
A B C D E F G H 
1 
 
2 
3 
4a 
4b 
114 
 
staining) bands could also represent non-ACAT-2 antigens or degradation products of an ACAT-2 
isoform.  
 
The cause of the complex and inconsistent banding patterns from experiment to experiment (and 
within experiments) noted above was not resolved, and pending further work, it was decided not to 
use preparations 3, 4 and 5 for further analysis of ACAT-2 protein levels in human liver. These 
problems were compounded by the limited amount of each human liver sample available, and it was 
not possible to use a single liver sample in all experiments, so some of the variability observed may 
have been caused by differences among livers from different human individuals in different 
experiments. 
 
4.3.2.4 ACAT-2 antiserum 6 
 
Antiserum 6 was made as part of this investigation using a cloned African green monkey sequence 
from ACAT-2 (residues 28-99, cf. Table 4.1, item 6), in an expression vector developed by J. Smith 
in our laboratory.  Antisera were prepared in two rabbits against a GST-fusion protein containing 
the African green monkey insert of ACAT-2 (Sec. 4.2.7). The crude antisera were used to probe 
WBs of whole liver homogenates from three human individuals (livers #15, 7, 12) after SDS-
PAGE. Complex banding patterns were observed for the antiserum from each rabbit (Fig. 4.7).  The 
antiserum from rabbit 2 gave less intense bands and mostly detected smaller proteins than the 
antiserum from rabbit 1 which appears to have greater potential for further analysis.  
 
Although mostly the same bands were detected in all three liver samples using the antiserum from 
rabbit 1, the relative intensity of bands differed considerably (Fig. 4.7). Liver #15 reacted most 
strongly to the antiserum from rabbit 1, with the most intense band at ~34kDa (band 3). The next 
most intense bands for liver #15 were possibly a merged doublet of a ~47 kDa band (band 2b) and 
~49 kDa band (band 2a), followed by a ~54 kDa (band 1). A number of much weaker bands were 
observed between the ~34 and ~47-49 kDa bands for liver #15.  The size markers (not shown) did 
not stain sharply in this WB, and the deduced sizes in liver preparations are approximate and could 
vary by up to ~2 kDa.  Bands 1, 2 and 3 were much weaker for livers #7 and #12, and the large 
band 1 appeared to be absent from liver #7 and was relatively weak for liver #12.  
 
The above results suggest that individuals may differ substantially in both the overall level of 
ACAT-2 protein(s) expressed in liver, and the relative expression of different isoforms of ACAT-2 
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or other non-ACAT antigens or ACAT-2 degradation products detected by preparation 6. Note that 
the apparently greater abundance of ACAT-2-positive proteins in liver #15 compared to liver #12 is 
converse to the relative abundance of ACAT-2 transcripts, where liver #12 gave a much higher 
ACAT-2/β-actin mRNA ratio than liver #15 (Fig. 2.7B in Chapter 2).  
 
As noted in Sec. 1.2.6, other groups of workers cite sizes of ~46 kDa (Chang & coworkers) or ~48 
kDa (Rudel, Parini and coworkers) for ACAT-2 that presumably represent the full length ACAT-2a 
isoform (cf. Sec. 1.2.6). In a later publication, Parini et al. (2009) showed images of unsized WBs 
from 37 human individuals, all of which gave the same common band (presumably the ~48 kDa 
band for ACAT-2a cited frequently in the literature), and some individuals also gave a doublet of 
the presumptive ~48 kDa band together with a smaller-sized band that varied considerably in 
intensity. Although not stated by the authors, the two bands shown by Parini et al. (2009) for some 
individuals could correspond to the band 2a/2b doublet shown in Fig. 4.7. ACAT-2a (522 amino 
acid residues) and ACAT-2b (502 residues) differ by only 20 amino acids, and would be expected 
to run as a merged or open doublet depending on the conditions of SDS-PAGE and Western 
transfer. The ~34 kDa band 3 in Fig. 4.7 could possibly represent ACAT-2c, and the identity of the 
~54 kDa band 1 is not known. Bands that could possibly correspond to ACAT-2a, ACAT-2b and 
ACAT-2c were also observed using antisera 3, 4 and 5 (Sec. 4.3.2.3) but not antiserum 2 (Sec. 
4.3.2.2). 
 
The GST-ACAT-2 fusion protein had a calculated size of ~34 kDa (composed of a ~26 kDa GST 
sequence with an ~8 kDa ACAT-2 insert). The fusion protein preparation used to raise the 
antibodies gave multiple bands when tested by Western analysis, none of which appear to coincide 
with the bands observed after probing human liver samples, and the major bands (<30 kDa) were 
smaller than those observed with the liver samples (Fig 4.7). In this regard, the GST portion of the 
fusion protein is derived from the parasite Schistosoma japonicum, and hence antibodies raised 
against it were not expected to cross-react with GST from other species including humans (cf. 
http://www.millipore.com/catalogue/item/05-782?cid=BIOS-A-BIOC-1228-1205-RC). However it 
is possible that antibodies raised against E. coli proteins in the GST-ACAT-2 preparation used to 
make preparation 6, could have reacted with other (unknown) proteins present in human liver. 
The presence of multiple bands additional to those ascribed to ACAT-2a and ACAT-2b above, such 
as the prominent ~34 kDa band 3 seen in all three livers (rabbit 1, Fig. 4.7), have not been reported 
by other workers (cf. Sec. 4.4.1).  Time was running out to complete further antiserum development 
and validation work, and due to intermittent sickness it was not possible to finalise such studies 
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within the time-frame of the project (data not shown). Other work (described below) was 
directed towards using anti-ACAT-1 antiserum 1, which gave a single and reproducible ~48 
kDa band on WBs that was suitable for the quantitative analysis of ACAT-1 protein in human 
liver samples. 
 
 
 
Figure 4.7:  Western blot analysis of whole homogenates from human liver samples #15, #7 and 
#12 (60 μg protein/sample) after SDS-PAGE and Western transfer (Sec. 4.2.4). The WBs were 
probed (Sec. 4.2.5) with crude ACAT-2 antisera derived using a synthetic GST-fusion peptide 
derived from African green monkey as antigen (cf. Sec. 4.2.5, 4.2.7).  Lanes labelled “GST-ACAT-
2 peptide” represent the GST-linked synthetic peptide purified from the E. coli expression vector, 
after probing with the crude antisera. Protein ladder: BIORAD Pre-Stained SDS-PAGE Standards, 
Broad Range Catalogue 161-0318 CONTROL 300002325. 
 
 
 
 
1 
2b 
2a 
3 
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4.3.3 Survey to quantify ACAT-1 and β-actin in 22 human liver samples 
 
Preceding sections showed that antiserum 1 raised against ACAT-1 gave a single, clear band with 
homogenates of human liver. Whole human duodenum samples were unavailable (Chapters 2 and 3 
present data for transcript levels using duodenal RNA samples supplied by collaborators, cf. Sec. 
2.2.1), and hence the survey was limited to ACAT-1 in the 22 human liver samples that were 
available at the time, including 16 of the livers surveyed for ACAT transcripts in Chapter 2 (Livers 
#2-17 inclusive as listed in Table 2.1) and the six additional liver samples listed in Sec 4.2.1 (Livers 
#18-23 inclusive).  
A. ACAT-1 
 
B. β-actin 
 
Figure 4.8:  A serial dilution of a whole homogenate from human Liver #18 representing different 
amounts of total protein was subjected to SDS-PAGE, transferred to WBs, and the ACAT-1 (A) and 
β-actin (B) bands scanned and quantified as arbitrary scan units as described in Sec. 4.2.8. 
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To determine the optimal amount of liver for quantifying ACAT-1 protein, three independent WBs 
each representing a serial dilution of a whole homogenate from Liver #18, were prepared and 
scanned to quantify the ACAT-1 and β-actin bands as described in Sec. 4.2.8 (cf. Fig. 4.2).  As 
evident from Fig. 4.8, which presents data from one of these WBs as an example, plots for both 
ACAT-1 and β-actin were generally near-linear up to about 30 μg protein, then became more 
variable.  
 
4.3.4 Data analysis to compare ACAT-1 and β-actin from WB scans 
 
Aliquots of whole homogenate representing 30 μg protein from each liver were distributed among 
three polyacrylamide gels (“A”, “B” and “C”), with each gel containing a subset of 8 different 
samples (including liver #14 as a common sample in each gel). Each set of samples (22 livers 
distributed among the 3 gels) was run on four independent occasions (Trials 1, 2, 3 and 4), 
transferred to cognate WBs, and scanned to quantify ACAT-1 and β-actin as described previously. 
 
 
 
Figure 4.9:   Quantitative analysis of ACAT-1 and β-actin protein in human Liver #14 using SDS-
PAGE and WB as described in Sec. 4.2.4, 4.2.5, 4.2.8.  Results are presented as arbitrary 
“integrated intensity” scan units (raw data) produced by scans of the ACAT-1 and β-actin bands on 
the three WBs (A, B and C) in each of four independent experiments (Trials).  Each data point 
represents the value obtained from liver #14 as the common sample loaded in each of the 3 WBs in 
each trial. 
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4.3.4.1 “Raw” ACAT-1/β-actin values 
 
To assist the development of strategies to compensate for WB to WB variability, Liver #14 was 
included as a reference in each WB.   Figure 4.9 presents the raw data (in arbitrary scan intensity 
units) for all samples of liver #14 in all 4 Trials.  Scan values for both ACAT-1 and β-actin showed 
considerable variability among the 3 gels/WBs within any one trial (especially Trial 1), even though 
all three gels (A, B and C) in each trial were run at the same time (SDS-PAGE), and their cognate 
WBs incubated with antisera at the same time under apparently identical conditions albeit in 
separate reagent containers (cf Sec. 4.2.5). Considerable variation was also observed between trials 
(cf. Fig. 4.9). As will be shown below, this variation within and between Trials created 
difficulties in calculating mean ACAT-1/β-actin ratios for each sample. 
 
 
 
 
Figure 4.10:  Raw ACAT-1/β-actin ratios normalised to liver #14, derived from scans of each WB 
after probing for ACAT-1 and β-actin (cf Sec. 4.2.9). The 22 liver samples (#2-23 incl.) were 
distributed as subsets among three WBs (A, B and C), and each set of subsets was run on four 
independent occasions (Trials). Liver #14 was loaded on each WB, and the raw ACAT-1/β-actin 
ratio for each sample # was normalised by dividing by the ACAT-1/β-actin ratio for Liver #14 
loaded on that WB. 
 
Gel/WB 
A 
Gel/WB 
B 
Gel/WB 
C 
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Figure 4.10 shows the raw ACAT-1/β-actin ratios for all 22 livers in all four Trials, normalised to 
the ACAT-1/β-actin ratio for Liver #14. Many sets of samples in particular Trial/WB combinations 
showed a systematic bias, e.g. WB “C” in Trial 2 where all samples gave much higher values than 
the same liver samples in WB “C” in the other trials. This suggested that liver #14 gave an 
anomalously low value for the ACAT/actin ratio in WB “C”/Trial 2, resulting in anomalously high 
ratio values (normalised to #14) for all the other samples in WB “C”/Trial 2. In this example, it 
appears that this bias is a consequence of random experimental error in determining the ACAT/actin 
ratio for Liver #14 in WB “C”/Trial 2. Other examples of such bias are evident in Fig. 4.10. 
 
4.3.4.2 “Corrected” ACAT-1/β-actin values 
 
As noted above, a systematic bias in a subset of ACAT-1/ β-actin ratios can arise if a random error 
for liver #14 distorts the normalised ratios for all other samples present on the same WB. To 
overcome this bias, an alternative approach was developed to obtain “corrected” ACAT-1/β-actin 
ratios, using all the data for all samples in each WB to adjust values without relying solely on Liver 
#14, as described in Sec 4.2.9 and Table 4.2. These calculations produced “corrected” scan values 
for both ACAT-1 and β-actin for each sample, as indicated in columns (2) and (4) of Table 4.2 
respectively, by processing the raw scan data as summarised below.  
 
a) The “average raw value” (as arbitrary scan units for both ACAT-1 and β-actin), was 
calculated and summed over all samples in each WB including Liver #14.  
b) Each WB designated as WB “A” contained the same subset of samples in all 4 Trials 
(similarly for subsets “B” and “C”). A correction factor was derived for ACAT-1 for each 
WB in that subset, using the quotient: (average raw value for all samples in all 4 trials in the 
subset) / (average raw value for all samples in the WB), as described in Sec. 4.2.9 and Table 
4.2.  
c) A similar correction factor was derived for β-actin. 
d) The correction factors was applied to all samples on each WB. This provided the “corrected 
values for ACAT-1” and β-actin for each sample on each WB. 
The above approach assumed that the average raw value for all 8 livers on a WB “evened out” 
random experimental variability (up or down) among individual livers within that WB. 
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Finally, to further minimise Trial-to-Trial bias among subsets of liver samples, it was necessary to 
assume that the same amount of each liver sample was loaded in its cognate gel position in all 4 
Trials (cf. assumptions in Sec. 4.2.9 and Table 4.2).  To obtain corrected ACAT-1/β-actin ratios 
based on this assumption, the following further calculations were carried out: 
e) The “average corrected value for β-actin” for each liver sample # was calculated, using data 
from all 4 cognate WBs, as indicated in column (5) of Table 4.2. This provided a single 
value for β-actin for each sample that could be applied to all 4 Trials. 
f) The “corrected value for ACAT-1” for each sample [column (2) in Table 4.2], was divided 
by the “average corrected value for β-actin” for that sample [item (a) above], to obtain the 
corrected ACAT-1/β-actin ratio for each sample.                                
 
Figure 4.11 summarises the corrected ACAT-1/β-actin ratios (calculated as described above) over 
all four Trials.  Compared to the raw ratios shown in Fig. 4.10, the corrected ratios in Fig. 4.11 
generally show less variation, and no subsets of samples show a systematic bias.   
 
 
 
Figure 4.11:  “Corrected ACAT-1/β-actin ratios” for each liver sample surveyed by WB analysis 
during this project. Ratio values were obtained by adjusting the “raw” scan units (cf. Fig 4.10) using 
correction factors derived from replicate subsets of liver samples (designated A, B or C) over 4 
independent Trials as described in Sec. 4.2.9. Each data point represents the corrected value from 
one WB in each Trial, without normalising by the value for Liver #14 in that WB. 
Gel/WB 
A 
Gel/WB 
B 
Gel/WB 
C 
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4.3.4.3 Comparison of ACAT-1/β-actin ratios using data normalised with Liver #14 
 
The corrected ACAT-1/β-actin ratios for all liver samples shown in Fig 4.11 were further 
“normalised” by dividing by the mean value for Liver #14 within that subset (i.e. from 4 Trials). 
This gave corrected values comparable to those presented for the raw ACAT-1/β-actin ratios 
presented in Table 4.10.  Fig. 4.12 presents a side-by side comparison of the mean raw vs corrected 
values of ACAT-1/β-actin for all WB/Trial combinations, all normalised by Liver #14.   
 
For most samples, the corrected ACAT-1/β-actin ratios (normalised by Liver #14) were generally 
similar or slightly smaller than the raw ratios (Fig. 4.12). However, the overall profile (pattern 
among samples) was similar for both the raw and corrected ratios. Hence samples were ranked 
similarly using either the raw or corrected ACAT-1/β-actin ratios, highest to lowest, with liver #14 
giving the highest ratio values by both criteria, and liver #17 lowest. 
 
 
 
 
Figure 4.12:  Comparison of the mean “raw” and “corrected” ACAT-1/β-actin ratios for each liver 
sample surveyed by WB analysis over four independent Trials (n = 4). The “raw” values represent 
the mean ratio ±SE for each liver sample (normalised by Liver #14) as presented in Fig. 4.10. The 
“corrected” values represent the mean ratios ±SE for each liver sample presented in Fig. 4.11 after 
normalising these ratios by dividing by the average ratio for Liver #14 loaded on that WB (A, B or 
C). 
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The most interesting outcome of using corrected values was the improvement in the standard 
error of the mean ACAT-1/β-actin ratio for each sample. Using corrected values for each 
sample, the SE of the mean ratio for each sample averaged 16% for the 21 samples across the 
4 Trials, compared to 32% for the raw ratios (ignoring the errors for Liver #14, which are not 
applicable to the raw values for this sample). This large reduction in SE averaged across all 
samples (except #14) validates the assumptions that were made when calculating the corrected 
ratios. The approach described above appears to minimise bias and variability originating from 
random experimental errors in the estimation of values for a common reference sample (e.g. Liver 
#14) used to normalise values for other samples, and may be useful for quantitative WB analysis in 
other applications. 
 
Using the corrected values for ACAT-1/β-actin normalised by liver #14 (Fig. 4.12), ACAT-1 was 
least abundant in sample #17 (ratio value 0.16), and most abundant in sample #4 (1.27), i.e. a 7.9-
fold difference among the 22 liver samples.  Since only samples 2-17 had previously been assayed 
for ACAT-1 mRNA abundance (Chapter 2), and these 16 samples will be the focus of the following 
sections. 
 
4.3.5 Comparison of WB and RT-qPCR data for ACAT-1/β-actin ratios 
 
Livers #2-17 inclusive as used herein were also surveyed for transcript levels in the work described 
in Chapter 2.  The final questions arising from the work described in this chapter were therefore:  
1. whether ACAT-1 protein levels show any correlation with ACAT-1 transcript levels, and  
2. whether relative ACAT-1 protein levels correlated with any pathological condition(s) from 
the individuals supplying the liver samples.   
 
4.3.5.1 Comparison of ACAT-1 protein (WB) and transcript (RT-qPCR) analyses 
 
The relationship between the protein and transcript analyses was explored by plotting ACAT-1/β-
actin ratios for the Western blots and RT-PCR against each other, using both the raw WB data (Fig. 
4.13A) and the corrected WB data (Fig. 4.13B) normalised against Liver #14. Trendlines indicated 
no correlation between WB and RT-PCR, with R2 values of 0.018 and 0.045 respectively for plots 
using the raw and corrected data (Fig. 4.13). The trendlines in each plot were quite flat (slopes of 
0.129 and 0.216 for the raw and corrected plots respectively), and close to the “average” value of 
0.63 (for RT-qPCR / Liver #14) from all liver samples, shown as a dashed red line on each plot 
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(Fig. 4.13). It thus appears that levels of transcripts were distributed randomly around this average 
value regardless of the actual level of ACAT protein in any liver sample. 
 
   
 
Figure 4.13:  Scatter plots of the “raw” (Fig. 4.13A) and “corrected” (Fig. 4.13B) ACAT-1/β-actin 
ratios for various liver samples obtained by WB analysis (proteins, X-axis), vs the ACAT-1/β-actin 
ratios for the same sample obtained by RT-qPCR analysis (transcripts, Y-axis, cf. Fig. 2.7 in 
Chapter 2). The solid black trendlines were drawn using the Microsoft Excel program. The dashed 
red lines represent the average ACAT-1/β-actin ratios obtained by RT-qPCR for all samples 
presented in each Figure (Livers #2-17 inclusive). 
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4.3.5.2 ACAT-1 protein levels and pathological status of human liver samples 
 
Table 4.3 compares quantitative data for ACAT-1/β-actin ratios with the known pathological and 
accession etc. status of each of the 16 human liver samples assayed by both WB and RT-qPCR. 
Liver samples were ranked highest to lowest for each of the analytical criteria listed in Table 4.3. 
No correlation was readily apparent between values of these data with the age, sex, pathology, 
warm ischemia time and other sampling circumstances, except for the presence of gallstones 
in the individuals supplying the sample, as described below.  
 
Table 4.3 ranked the three “gallstone livers” (#10, #11, #12) relatively highly (highest to lowest)  
among all 16 liver samples by their WB (as 1/WB) and RT-qPCR values separately:  1/WB - ranked 
3th, 5th and 8th for livers #10, #12 and #11 respectively, and RT-qPCR - ranked 1st, 5th and 8th for 
livers #12, #11 and #10 respectively.  However when these criteria were combined as a 
transcript/protein ratio (i.e. RT-qPCR/WB quotient), the three “gallstone livers” (samples #12, 
#10, #11) were ranked 2nd, 3rd and equal 4th  for livers #12, #10, and #11 respectively out of the 16 
liver samples (highest to lowest). This indicates that the protein and transcript data when taken 
together (as a RT-qPCR/WB quotient) provide the best correlation with a gallstone phenotype. This 
correlation is consistent with an inverse relationship between relatively high transcript and 
low protein levels for ACAT-1 in the livers of human individuals with known gallstone 
phenotypes among the samples included in this study. 
 
“Non-gallstone” livers #17 and #8 gave RT-qPCR/WB quotients that fell among the “gallstone” 
livers and were ranked 1st and equal 4th respectively. Interestingly, liver #8 was only ranked 9th by 
1/WB, and although ranked 3rd by RT-qPCR for ACAT-1 was ranked lowly (12th) for ACAT-2 
mRNA. However liver #17 gave the highest RT-qPCR/WB quotient in the survey (ranked 1st), and 
was ranked 1st also by 1/WB, and 4th by RT-qPCR for ACAT-1. Liver #17 (and possibly liver #8) 
may therefore be the sample(s) that disprove the correlation, or alternatively the individuals 
supplying these livers, especially liver #17, could be at risk of gallstones, or may have undetected or 
incipient gallstones, or gallstones were not formed due to diet and lifestyle (discussed further in 
Sec. 4.4.4). 
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Liver 
# 
ACAT-1 analysis criteria: 
Values and rank 
 
 
 
Patient/sample profile 
RT-qPCR/WB 1/WB RT-qPCR 
value rank value rank value rank 
17 4.94 1 6.17 1 0.80 4 (58F, 120 min) liver resection 
12 3.91 2 2.64 5 1.48 1 (65M, 0 min) gallstone patient + 
Simvastatin 
10 1.89 3 2.90 3 0.65 8 (22M, 0 min) L donor (visual 
gallstones) 
8 1.31 4 1.61 9 0.82 3 (14F, 0 min) L donor 
11 1.31 4 1.69 8 0.77 5 (72F, 0 min) gallstone patient + 
Simvastatin 
7 1.16 6 1.71 7 0.68 7 (38M, 0 min) L donor 
2 1.10 7 2.95 2 0.37 14 (37M, 0 min) L donor 
6 1.02 8 2.51 6 0.41 12 (43F, 0 min) L donor 
14 1.00 9 1.00 14 1.00 2 (61F, 24 min) kidney donor 
9 0.99 10 1.41 11 0.71 6 (50F, 0 min) L donor (>60% fat) 
16 0.76 11 1.29 12 0.59 9 (55F, 90 min) liver resection 
5 0.68 12 1.41 10 0.49 11 (41M, 0 min) L donor 
3 0.68 13 2.78 4 0.25 15 (48M, 0 min) L donor 
15 0.49 14 1.27 13 0.38 13 (71M, 75 min) liver resection 
13 0.43 15 0.88 15 0.49 10 (9F, 21 min) kidney donor 
4 0.19 16 0.79 16 0.24 16 (48F, 0 min) L donor 
 
Table 4.3: Comparison of ACAT-1/β-actin ratios for all 16 human liver samples (Livers #2-17 
inclusive) assayed by both RT-qPCR (transcripts) and WB (protein) during this project. Corrected 
WB values (presented as 1/WB) and RT-qPCR/WB values (normalised by Liver #14) are derived 
from the data presented in Figs. 4.12 and 4.13. RT-qPCR values for ACAT-1/β-actin represent data 
shown in Fig. 4.13 (i.e. taken from Fig 2.7). Data within each category (1/WB, RT-qPCR and RT-
qPCR/WB) were separately ranked 1-16, highest to lowest value, then all liver samples were sorted 
by their RT-PCR/WB rankings as indicated in the Table. Sample profiles indicate: (age in years, 
sex, warm ischaemia time), patient description and pathology. Data for livers associated with 
gallstones are indicated in yellow.  
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An additional six liver samples (#18-23 inclusive, listed in Sec. 4.2.1) were surveyed only by WB 
analysis. None of the individuals supplying these livers were of known gallstone phenotype (cf. 
Sec. 4.2.1). Livers #19-23 gave relatively low 1/WB values for ACAT-1/β-actin ranging from 1.03-
1.49 that fell among values for most of the “non-gallstone” livers listed in Table 4.3. However, 
Liver #18 gave a high 1/WB value of 3.21 that would have ranked second highest among the livers 
listed in Table 4.3 (i.e. between livers #17 [6.17] and #2 [2.95]), and higher than all three gallstone 
livers using 1/WB as sole criterion (liver #2 was only ranked 14th by RT-qPCR). Unfortunately, 
liver #18 was accessed after the transcript analyses, and RT-qPCR/WB values are unavailable for 
comparison with the gallstone livers. 
 
 
4.4 Summary and conclusions 
 
4.4.1 Detection of ACAT-1 and ACAT-2 by various antisera 
  
This chapter describes the use of SDS-PAGE and Western Blot analysis to assess one polyclonal 
antiserum raised against an N-terminal epitope of human ACAT-1, four polyclonal antisera raised 
against various epitopes of human ACAT-2, and the development and assessment of one polyclonal 
antiserum raised against an N-terminal epitope of ACAT-2 from African green monkey. The five 
ACAT-2 antisera gave complex and variable banding patterns with human liver samples. Hence 
none of these antisera was considered sufficiently well characterised to be used for quantitative 
analysis. However, the ACAT-1 antiserum was found to be specific for its target epitope, 
reproducibly detecting a single protein of ~48 kDa in human liver similar to other reports in the 
literature, and was deemed suitable for the quantitative analysis of this protein in various liver 
samples.  
 
Previous research has indicated that liver preparations expressing detectable amounts of ACAT-2 
give a single band after SDS-PAGE and Western analysis, with the band size variously reported as 
46 or 48 kDa (cf. Sec. 1.2.6). Our failure to detect any bands at all with antiserum 2, and multiple 
bands with preparations 3, 4 and 5, was puzzling, although each of the latter three preparations gave 
a band or bands that could correspond to the 46 or 48 kDa band reported by others. Some of our 
difficulty in detecting ACAT-2 reproducibly may have been caused by using liver samples from 
different individuals in successive experiments, a consequence of limited supply of stored samples. 
ACAT-2 protein abundance in human liver appears to vary greatly among individuals (cf. Sec. 1.2.6 
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and Sec. 4.3.2.4), and it is possible that the livers selected for some experiments may have been of 
low ACAT-2 abundance.  
 
As noted above, prior to and during the work reported in this chapter, the literature reported only a 
single band representing ACAT-2a in human liver. For example, Parini et al (2004) presented 
images of WB of livers from 10 individuals (diseased livers from transplantation patients), each of 
which gave only a single ~48 kDa ACAT-2 band with no evidence of smaller or larger bands (cf. 
Chapter 1, Sec. 1.2.6).  Later work by Yao et al. (2005) reported that ACAT-2 can be expressed as 
three splice variants of differing size, ACAT-2a, ACAT-2b and ACAT-2c, with the full-length 
ACAT-2a isoform representing the 46/48 kDa protein reported earlier. However, Yao et al. (2005) 
detected no ACAT-2 expression in the adult human liver samples they used, and detected 
expression of all three splice variants only in cultured human cell lines or foetal/cancerous liver.   
Yao et al. (2005) did not report the size of the three ACAT isoforms (cf. Sec. 1.2.6).  
 
A subsequent publication by Parini et al. (2009) presented images of WBs stained by an anti-
ACAT-2 antiserum, that show livers from some individuals gave a doublet rather than a single band 
after SDS-PAGE.  Although Parini et al. (2009) did not comment on the size and pattern of ACAT-
2-staining bands among the 37 gallstone and control patients they investigated, it is possible that the 
doublets shown in their images represent ACAT-2a and ACAT-2b or ACAT-2a and ACAT-2c. Our 
examination of the images of single/doublet bands presented by Parini et al. (2009) provided no 
evidence for any correlation between banding pattern and possession or absence of gallstones. The 
bands observed in some of our experiments (Sec. 4.3.2.3 and 4.3.2.4) could represent ACAT-2a and 
ACAT-2b, and smaller-sized bands found in these experiments could possibly represent ACAT-2c. 
Further research is necessary to define the status of the variable ACAT-2 banding patterns observed 
in liver samples from different individuals.  
 
4.4.2 Quantitative analysis of ACAT-1 protein in human liver samples 
 
Antiserum 1 was used to quantify ACAT-1 protein in a total of 22 human liver samples on WBs 
after SDS-PAGE, using β-actin as internal (endogenous) reference. Because each WB could 
accommodate only 8 liver samples, liver #14 was included in each WB as a control. Initially, “raw” 
ACAT-1/β-actin ratios were calculated using the direct scan data (“integrated intensity units”) 
from each sample.  However considerable variability was observed among raw values for the four 
replicate WBs containing each sample (indeed, ACAT-1 and β-actin appeared to vary 
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independently of each other on replicate WBs). After “normalising” ACAT-1/β-actin ratios for all 
samples on a WB by division with the ratio for liver #14 on that WB, subsets of samples still 
showed considerable variability and systematic bias.  
 
It was possible to minimise the systematic bias among raw ACAT-1/β-actin ratio values, and halve 
the SEM among replicates of each sample, by adjusting the raw scan data for both ACAT-1 and β-
actin, and hence calculate “corrected” ACAT-1/ β-actin ratios. This was achieved by using data 
from all samples on each WB (rather than the single sample of liver #14 on that WB) to make 
adjustments for WB to WB variability averaged over the four replicates for each sample, as detailed 
in Sections 4.2.9 and 4.3.4.2. It is considered that the assumptions used to make the corrections (cf. 
Sec 4.3.4.2) were validated by the halving of SE values of the mean ACAT-1/ β-actin values from 
32% to 16% (averaged over all liver samples except #14), as evident in Fig. 4.12 which compares 
the “raw” and “corrected ACAT-1/ β-actin ratios. This approach may be useful in other applications 
requiring quantitative Western analysis. 
 
4.4.3 Comparison of ACAT-1 protein and transcript abundance in human liver 
 
Sixteen of the 22 human liver samples assayed for ACAT-1 protein (WB analysis) had previously 
been assayed for ACAT-1 transcripts (RT-qPCR analysis).  Scatter plots of ACAT-1/β-actin ratios 
showed no correlation between ACAT-1 protein and transcript abundance (R2, 0.045, cf. Fig. 
4.13B), and transcript levels appeared to be distributed randomly around an average value 
regardless of the actual level of ACAT-1 protein in any liver sample.  
 
The lack of a statistically significant correlation in Fig. 4.13 suggested either that the errors in 
determining relative transcript and/or protein levels were too large, or that the correlation between 
the actual transcript and protein levels at the instant of taking a liver sample is relatively loose, e.g. 
due to delays in the signal transduction response of transcript synthesis (via de novo gene 
expression) to sensing lower ACAT-1 protein levels. In this regard, the half-life of ACAT-1 protein 
turnover appears to be very short (~30 min) compared to ACAT-2 (~6 h) (Temel et al., 2003, cf. 
Sec 5.8.1), suggesting it is possible that ACAT-1 mRNA levels are capable of rapid change e.g. in 
response to dietary or diurnal stimuli (cf. Chapter 2, Sec 2.4.5). 
 
It is currently envisaged that ACAT-2 regulation is biologically more important than ACAT-1, 
given the wide range of ACAT-2 levels observed in different tissues and individuals (cf. Chapter 1, 
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Sec. 1.3.3). Given the above results however, it is possible that regulatory mechanisms leading to 
ACAT-1 homeostasis or otherwise may turn out to be more important than previously envisaged 
(discussed further in Sec. 5.8.3). More precise data or further analysis of new livers in future 
research would assist the above ideas and hypotheses to be tested.  
 
4.4.4 Comparison with sample profile (pathological and accession status etc.) 
 
4.4.4.1 Gallstone patients 
 
Analyses of 16 human liver samples enabled comparison of the relative abundance of both ACAT-1 
protein and ACAT-1 mRNA. These livers were ranked, highest to lowest, by the quantitative values 
for each of the analytical criteria involving ACAT-1:  protein (1/WB); mRNA (RT-qPCR); 
protein/mRNA quotient ([RT-qPCR]/[WB]). Rankings were matched against the accession profiles 
of each liver sample (Table 4.3). The three liver samples with a gallstone phenotype (#12, #11 and 
#10) were ranked highly by their [RT-qPCR]/[WB] quotients (2nd, equal 4th and 3rd  respectively for 
highest quotient values), and only a little less highly by the criteria RT-qPCR and 1/WB 
individually (cf. Table 4.3 and Sec. 4.3.5.2). This indicates that the gallstone livers may show a 
propensity for (relatively) higher ACAT-1 transcript to protein ratios compared to most of the non-
gallstone livers.  
 
Using the data presented in Chapter 2 (cf. Fig. 2.7C, Sec 2.3.4), when the above 16 livers were 
ranked by their transcript values, highest to lowest, the three gallstone livers (#12, #11 and #10) 
were ranked 1st, 5th and 8th respectively by their ACAT-1/β-actin ratios, 1st, 3rd and 11th respectively 
by ACAT-2/β-actin, and 1st, 3rd and 13th respectively by ACAT-2/ACAT-1 transcript ratios.  Liver 
#10 is the only one of the three gallstone livers that was not accessed from a patient being treated 
with Simvastatin, and taken at face value, could imply that the two gallstone patients receiving 
Simvastatin showed higher ACAT transcript ratios (as described above) than gallstone patient #10. 
Despite its low ranking by ACAT transcript ratios, liver #10 was ranked relatively highly by criteria 
using ACAT-1 protein levels: 3rd by 1/WB and 3rd by its [RT-qPCR]/[WB] quotient. This indicates 
the potential importance of measuring both transcripts and proteins when examining patients with a 
gallstone phenotype.  
 
One non-gallstone liver (#17) was ranked 1st for ACAT-1 by its 1/WB data (i.e. least abundant for 
ACAT-1 protein), and 1st by [RT-qPCR]/[WB] quotient for ACAT-1 (transcript/protein ratio). This 
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might indicate that this patient is at risk of gallstones or perhaps has not developed them for dietary 
or lifestyle reasons, However, liver #17 was ranked more lowly by its ACAT-2 data: 9th by its 
ACAT-2/β-actin transcript ratio, and 11th by its ACAT-2/ACAT-1 transcript ratio, which makes the 
suggestion of gallstone risk less compelling.  Liver #14 was subjected to the longest warm ischemia 
time of all the liver samples, which could have contributed to it having a low level of ACAT-1 
protein (cf. Chapter 5, Sec. 5.6).   
 
The trends and correlations noted above for gallstone patients may be misleading due to the small 
sample size (3 gallstone phenotypes among 16 patients) and the errors inherent in determining 
quantitative data via RT-qPCR and WB analysis. Hence it would be premature to draw any firm 
conclusions using the data presented herein. Furthermore, ACAT transcript/protein levels could also 
be affected by syndromes other than propensity to produce gallstones. ACAT gene expression was 
quantified using β-actin as an internal “housekeeping” reference for both transcripts and protein, 
and comparison with further housekeeping genes would be advisable in future research. 
Nonetheless, the above correlations and trends represent useful hypotheses for future research, and 
it would be of interest to conduct a new and larger survey that includes more livers from gallstone 
and control patients. The analytical procedures developed during this investigation represent a 
useful resource for continuing research requiring analysis of ACAT gene expression. 
 
4.4.4.2 Child liver and patients with fatty liver and liver cysts 
 
Other patients showing high ACAT-2/ACAT-1 mRNA ratios were sample #13 (from a 9-year-old 
female kidney donor) ranked 2nd, and sample #9 (from a 50-year-old female liver donor with fatty 
liver) ranked 4th.  ACAT-2 expression is known to be high in foetal livers and in young children and 
does not represent a pathological condition (cf. Ch 2, Sec.  2.4.4.2). However, samples #13 and #9 
were both ranked lowly by their ACAT-1 mRNA and protein (1/WB) data. 
 
A further liver sample (#A) from a patient with liver cysts, presented in Chapter 3, gave a high 
ACAT-2/ACAT-1 ratio that fitted between the two gallstone/simvastatin patients. However this 
sample was not included in the ACAT-1 protein assays. 
  
132 
 
4.4.5 Practical considerations in relation to future directions 
 
4.4.5.1 Minimising experimental errors 
 
Although this chapter demonstrates how errors can be minimised by using data from all samples on 
a WB to obtain “corrected” values for antiserum reactive bands on a WB (cf. Sec. 4.2.9 & 4.4.1), 
the scope exists to minimise gel-to-gel, blot-to-blot and run-to-run variation in band intensity.  
Stricter control of incubation conditions with staining reagents (e.g. more practice runs to 
standardise manipulation variables between gels and runs), and better temperature control (e.g. 
temperature-controlled cabinet rather than relying on constant air-conditioning, treatment) would be 
beneficial. 
 
4.4.5.2 Sampling 
 
WB analysis of ACAT-2 protein would be assisted by obtaining a single, bulk liver sample pooled 
from individuals with different backgrounds for method development and assessment, rather than 
relying on the small amounts of each test liver that restricted comparison among the experiments 
reported herein.  Several bulk samples may need testing to identify livers with high anti-ACAT-2 
reactivity. Human duodenum with its high ACAT-2/ACAT-1 transcript ratio compared to liver 
would be useful to complement the liver samples for anti-ACAT-2 antiserum method development. 
 
When possible, blood samples (and PBMC cells) should be obtained from each organ donor to seek 
correlations with classes of disease phenotype (e.g. gallstone vs non-gallstone livers), and hence 
identify non-invasive approaches to ACAT-expression analysis. Little is known of within-organ 
variability of ACAT expression, and preferably >1 sample should be taken from different, defined 
sections of each organ (e.g. liver lobes, & surface vs interior), to obtain representative data for each 
patient. 
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1 Overview of work completed 
 
To recapitulate, Chapter 2 describes the development of multiplex TaqMan® based RT-qPCR 
assays to quantify mRNA levels from ACAT-1 and ACAT-2 relative to β-actin, and their application 
to the analysis of 38 samples from 37 human individuals (17 liver, 10 duodenal, 3 kidney, 1 spleen, 
and 7 PBMC samples).  The samples represented various diseases and controls. Chapter 3 describes 
the adoption of newer RT-qPCR technologies that made it possible to design an improved assay for 
ACAT-1 that was applied to the analysis of an additional 3 liver samples. Chapter 4 describes the 
assessment of six antisera for Western analysis of ACAT-1 and ACAT-2 protein in human liver 
samples, and the use of one of these antisera to quantify ACAT-1 protein (relative to β-actin) in 16 
of the 17 liver samples assayed by RT-qPCR in Chapter 2, together with an 6 additional liver 
samples. 
 
After completion of the transcript abundance assays described in Chapter 2, a new report was 
published (Yang et al., 2004a) which demonstrated that ACAT-1 was expressed as two protein 
isoforms translated from four mRNA species, all of which would have been detected by the 
TaqMan® assays for ACAT-1 mRNA described in chapters 2 and 3, and by the ACAT-1 protein 
assay described in Chapter 4. Another new report (Yao et al., 2005) indicated that ACAT-2 was 
expressed as three splice variants (both mRNA and protein), of which only the full-length and 
probably most abundant isoform (ACAT-2a) would have been detected by the TaqMan® assays 
described in Chapters 2 and 3. The two smaller isoforms, ACAT-2b and ACAT-2c, which lack one 
or more of the exons targeted by the PCR primers, would not have been detected by the TaqMan® 
assays described herein. Hence unless otherwise stated, the results of our ACAT-2 assays refer only 
to the ACAT-2a isoform. Apart from Yao et al. (2005), other workers who have used RT-PCR to 
detect ACAT-2 mRNA and Western analysis to detect ACAT-2 protein, have not reported which of 
these splice variants were targeted by their assays. 
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5.2 Issues associated with quantifying expression levels of ACAT mRNA  
 
Estimation of the absolute abundance of any mRNA species as number of molecules in a sample is 
subject to variables such as degradation of RNA during sample collection and RNA purification, 
incomplete reverse transcription of mRNA molecules using random hexamers, and <100% PCR 
amplification efficiency with some assays. However, if one assumes that such variables apply 
equally to all mRNA species being assayed, it is possible to compare the relative molar abundance 
of any set of mRNA species of interest (such as ACAT-1, ACAT-2 and β-actin) relative to each 
other.   
 
During the comparison of assay methods described in Chapter 3, the original ACAT-1 assay was 
found to be ~3% less PCR efficient than the new ACAT-1 assay, and presumably ~3% less PCR 
efficient than the original (and only) ACAT-2 assay. As detailed in Sec. 3.4.5, it was calculated that 
the new assay method for ACAT-1 gave values for mRNA abundance that were ~50% higher than 
values using the old ACAT-1 assay. Hence the ACAT-2/ACAT-1 ratios for mRNA cited in 
Chapter 2 should be multiplied by a factor of ~0.67 to give a better estimate of the ACAT-
2/ACAT-1 molar ratio of any particular sample. This factor applies to all samples, and hence 
does not affect the interpretation of data when comparing fold differences of ACAT/β-actin and 
ACAT-2/ACAT-1 ratios among various samples and tissues. 
 
Table 5.1 summarises the ACAT-2/ACAT-1 ratios for the five tissues surveyed in Chapter 2 (before 
and after adjustment by the correction factor deduced in Chapter 3), and provides our “best 
estimate” of the mean molar ratio of each ACAT isoform in each tissue, given the assumptions 
described above. Because β-actin (as reference housekeeping gene) is more likely to vary in 
expression among different tissues than between different samples of the same tissue (cf. Sec. 
3.4.6), the expression of ACAT-2 is also compared with ACAT-1 when comparing liver and 
duodenum. Hence as a fraction of total ACAT mRNA, ACAT-2 was on average about 10 times 
more abundant in duodenum (69% of total ACAT mRNA) than in liver (7%).  
 
Table 5.2 summarises the fold difference among samples of each tissue for the abundance of ACAT-
1 and ACAT-2 mRNA relative to β-actin, and for ACAT-2 relative to ACAT-1. This illustrates the 
hypervariability of ACAT-2 among liver samples compared to both β-actin (320-fold) and ACAT-1 
(97-fold). In duodenum ACAT-2 was far less variable relative to β-actin (4.4-fold), but relative to 
ACAT-1, ACAT-2 showed a 31-fold range that was skewed by one sample (sample #I, cf. Sec. 
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2.4.4.4) that gave a particularly low value for ACAT-1/β-actin.  PBMC showed the least variability 
among samples for both ACAT-1 and ACAT-2.  
 
 
Tissue No. samples Av. ACAT-2/ACAT-1 ratio ACAT-2 as % of total ACAT 
mRNA (from corrected ratios) Ch. 2 value *Corrected 
Duodenum 10 3.27 2.19 69% 
Kidney 3 0.18 0.121 11% 
Liver 17 0.112 0.075 7.0% 
Spleen 1 0.027 0.018 1.8% 
PBMC 7 0.015 0.010 0.99% 
 
Table 5.1: Mean values of ACAT-2/ACAT-1 mRNA ratios for the survey of human tissues presented 
in Chapter 2. *Ratio values have been corrected by the efficiency factor of 0.67 derived in Chapter 
3 (Sec. 3.4.5). 
 
 
Tissue No. samples Fold range between samples, highest/lowest 
ACAT-2/β-actin ACAT-1/β-actin ACAT-2/ACAT-1 
Duodenum 10 10.3 x 4.4 x 31.3 x 
Liver 17 320 x 6.2 x 97 x 
PBMC 7 3.1 x 2.1 x 4.0 x 
 
Table 5.2: Fold differences in relative abundance of ACAT-1 and ACAT-2 mRNA among different 
samples of each tissue (from survey presented in Chapter 2). 
 
The three kidney samples, taken from apparently normal tissue adjacent to cancerous kidney tissue, 
gave expression values for ACAT-1/β-actin, ACAT-2/β-actin, and ACAT-2/ACAT-1 that were within 
the same range as the 17 liver samples (Table 5.1). Raised levels of cholesterol and total ACAT 
activity have been demonstrated in cancerous human kidney, and raised cholesterol content has 
been demonstrated in cancerous kidney from rat (Clayman et al. 1983, 1986). However, it is 
possible that these results are not representative of normal kidney, and expression of ACAT-2 may 
have been induced by the adjacent cancerous tissue. Unlike liver, kidney has not been a tissue of 
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much interest to researchers, and a role for ACAT-2 in normal kidney is not known. Further 
analysis of diseased and control kidney is warranted. 
 
As noted in Sec. 2.4.3, no evidence was found for the coordinated regulation of ACAT-1 and ACAT-
2, as demonstrated by the variability in ACAT-2/ACAT-1 ratios among samples of differing 
physiological or disease within a tissue type (liver). 
 
5.3 Quantitative analysis of ACAT-1 protein in human liver 
 
A novel procedure was developed for calculating mean ACAT-1/β-actin protein ratios that 
minimizes the highly variable raw data from scans of band intensity in replicate Western blots. The 
range of values for ACAT-1/β-actin was very similar for the protein assays (~6-fold among 16 
samples) compared to the previous survey of mRNA (~8-fold range for ACAT-1/β-actin among 17 
samples, 16 of which were included in the survey of ACAT-1 protein). Scatter plots of mRNA vs. 
protein abundance showed no significant correlation between ACAT-1 protein and transcript 
abundance (R2 = 0.045). These results suggest that on average, human liver tends to maintain (i.e. 
fluctuate around) a relatively consistent ACAT-1 protein level that appears to show little 
relationship to the ACAT-1 mRNA level.   However when the data were expressed as 
mRNA/protein ratios for ACAT-1 (cf. RT-qPCR/WB quotients in Ch. 4), the patients known to 
possess gallstones were grouped together, as discussed below. 
 
5.4 Patients with gallstones: liver samples  
 
Gallstone formation is thought to be favoured when hepatic ACAT activity is low, resulting in 
ratios of hepatic FC/CE that are relatively high (cf. Sec. 1.4.2.3 ).  Such changes could 
“increase the availability of FC within the hepatocyte for efflux into the bile”, resulting in 
increased secretion of FC into the bile and gallstone formation.  The above hypothesis was 
proposed by Smith et al. (1990), who found that total ACAT enzyme activity was 2-3-fold 
higher in the liver of control patients compared to patients possessing gallstones.  
 
ACAT-2 expression in gallstone patients. 
The mRNA abundance data from Chapter 2 show that samples #12 and #11 from gallstone patients 
aged 65 and 72 were ranked 1st and 3rd respectively among the 17 liver samples for both ACAT-2/β-
actin and ACAT-2/ACAT-1 ratios. These two patients had been taking simvastatin for 3 weeks prior 
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to taking the liver biopsy. Parini et al. (2008) have shown that treatment with statins causes a 
significant decrease in ACAT-2 gene expression (assessed by mRNA, protein and enzyme activity), 
which suggests that ACAT-2 expression may have been even higher if these individuals had not 
been taking this drug. A third gallstone liver sample in our study (#10), from a male gallstone 
patient not taking statins, ranked more lowly for mRNA levels: 11th for ACAT-2/β-actin and 13th for 
ACAT-2/ACAT-1 ratio. However sample #10 was from a 22-year-old male, who may have had an 
early-onset predisposition for gallstone formation, compared to the aged patients taking Simvastatin 
whose gallstones may have resulted from dietary and/or other factors.    
 
In a study using human liver biopsies from gallstone and control patients (reviewed in Sec. 2.4.4.2), 
Parini et al. (2009) examined ACAT-2 protein levels (assessed by WB analysis) and ACAT-2 
enzyme activity. No significant difference was observed between female gallstone and non-
gallstone patients, or male gallstone and non-gallstone patients, even though ACAT-2 enzyme 
activity was on average about two-fold higher in male gallstone patients compared to gallstone-free 
males.   Although also not statistically significant, Parini et al. (2009) also found that ACAT-2 
mRNA levels in gallstone patients were on average twice that of non-gallstone patients for both 
males and females (cf. Sec. 2.4.4.2), a finding consistent with the trend for higher ACAT-2 mRNA 
abundance in the aged gallstone patients observed in our work.   
 
On the basis of our study and that of Parini et al. (2009), there appears to be little evidence that 
ACAT-2 expression is lower in the liver of gallstone patients compared to controls, and some trends 
favour higher ACAT-2 expression.  The finding that ACAT-2-/- knockout mice were protected from 
gallstone formation when fed a high cholesterol diet does not apply here, because the lack of 
intestinal ACAT-2 suppressed the uptake of dietary cholesterol, and hence shielded the liver from 
diet-induced hypercholesterolemia (cf. Sec. 1.4.2.3). Hence there is little evidence to support the 
possibility that lower hepatic ACAT-2 expression favours gallstone formation.  
 
ACAT-1 expression in gallstone patients.  
ACAT-1 expression was not examined in the study of Parini et al. (2009) described above.  As 
summarized in Sec. 4.3.5.2, our study showed that all three human individuals with a known 
gallstone phenotype tended to have a relatively high mRNA/protein quotient for ACAT-1 in 
liver, i.e. ACAT-1 protein levels were low compared to ACAT-1 mRNA levels in the gallstone 
patients compared to non-gallstone controls.  Furthermore, ACAT-1 protein relative to β-actin was 
low to average in the gallstone patients compared to the non-gallstone controls. Although we have 
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insufficient data to warrant tests for significance, this trend is consistent with the hypothesis that 
lower hepatic ACAT expression (as ACAT-1 protein) may contribute to a propensity for gallstone 
formation. Furthermore, all three gallstone patients in our study showed relatively high ACAT-
2/ACAT-1 mRNA ratios, i.e. ACAT-1 mRNA as a fraction of total ACAT mRNA was relatively 
low compared to non-gallstone controls, also consistent with the suggestion that relatively low 
ACAT-1 gene expression may be associated with a propensity for gallstone formation. However 
studies on single ACAT-1-/- knockout mice appear to be inconclusive, because FC/CE ratios and 
total ACAT activity were similar in both knockout and control mice  (Meiner et al., 1996, cf. Sec. 
1.4.1.2).  We are not aware of any attempts to induce gallstone formation in mice by selective 
inhibition of hepatic ACAT-1, perhaps because double knockout ACAT-1-/- mice exhibited 
cytotoxic effects in macrophages, and because single knockout ACAT-2-/- mice showed resistance 
to gallstone formation. 
 
Does ACAT-1 have a role in the production of biliary cholesterol? 
Very recently, it has been shown that targeted knockdown of ACAT-2 in mice resulted in the 
increased hepatic FC being secreted into intestines by the novel TICE pathway via plasma 
lipoproteins rather than via the bile (cf. Chapter 1, Sec. 1.4.1.5).  This suggests that ACAT-2 may 
not be responsible for regulating the pool of endogenous hepatic FC destined for biliary secretion, 
and that another pool of FC + CE is the source of FC secreted into bile. This raises the further 
possibility that ACAT-1 controls the size of the “micro-pool” of FC within hepatocytes that 
regulates the amount of FC secreted into bile. Such a hypothesis is consistent with the apparently 
lower expression of ACAT-1 in gallstone patients observed in our study.  
 
Multiple factors, including genetic and lifestyle components (e.g. diet) are likely to contribute to 
gallstone formation (cf. Sec. 1.4.2).  Levels of ACAT-1 expression (whether intrinsic or induced by 
other factors) are possibly one such component, and it cannot be assumed that all components 
resulting in gallstone formation will affect ACAT-1 expression in the same way. Hence 
correlations and trends may not meet statistical significance when examining and comparing 
members of populations.  
 
5.5 Patients with gallstones: PBMC samples 
 
One of the reasons for investigating PBMC is that marker enzymes in blood cells are expected to be 
far more uniform and representative of the whole person than small tissue biopsies taken at random 
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from large organs such as liver or intestine. PBMC is composed largely of lymphocytes and 
monocytes (progenitors of macrophages) where ACAT-1 predominates, and the extremely low level 
of ACAT-2 mRNA compared to ACAT-1 mRNA in all PBMC samples (cf. Tables 5.1 and 5.2) 
agrees with predictions. It is possible that genetic or lifestyle/dietary factors that regulate ACAT 
gene expression in liver may also affect ACAT expression in other cell types including those that 
contribute to PBMC.  
 
In Chapter 2 it was reported that on average, PBMC from gallstone patients expressed almost twice 
(P<0.05) the ACAT-2 mRNA levels relative to β-actin, compared to controls with no history of 
gallstones (i.e. presumed to be gallstone-free). ACAT-2/ACAT-1 ratios were also much higher for 
the gallstone patients compared to controls, especially if an anomalous non-gallstone sample 
(sample #a, cf. Fig. 2.8) is ignored. These results indicate that ACAT-1 mRNA appears to represent 
a smaller fraction of total ACAT mRNA in the PBMC from the gallstone patients compared to the 
non-gallstone controls.  This trend agrees with the analyses of ACAT mRNA in liver samples 
from gallstone patients, where ACAT-1 tended to represent a smaller fraction of total ACAT 
mRNA compared to controls, consistent with the suggestion that relatively low ACAT-1 gene 
expression may be associated with a propensity for gallstone formation. 
 
The above correlations are consistent with the possibility that differences in ACAT expression in 
PBMC reflect expression patterns in other cell types such as those present in liver. Larger surveys 
of PBMC from gallstone and control patients who also provide liver samples would make it 
possible to establish more firmly whether ACAT-1 or ACAT-2 expression levels show a positive or 
negative correlation with a predisposition towards gallstone formation or other disease such as 
CHD.  PBMC samples are relatively non-invasive and highly suited to large surveys. 
 
5.6 Warm ischemia time for liver samples 
 
Warm ischemia time, defined as a period of lack of blood flow to the tissue at 37°C before sample 
collection and snap-freezing (Smith et al., 1989), varied between 21 and 120 min for liver samples 
#13–#17 (Table 2.1). The five liver samples subjected to warm ischemia had levels of ACAT-2 
mRNA that were 240% higher on average P<0.05) than the 12 control samples that had been snap-
frozen after taking the biopsy. ACAT-1 mRNA levels were 31% higher on average but not 
significantly different from controls, in apparent agreement with ACAT-1 protein levels that were 
35% higher than controls (P ~0.05).  Unfortunately, it was not possible to obtain data on ACAT-2 
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protein levels. Interestingly, the sample with the lowest level of ACAT-1 protein level (liver 
#17, from a liver resection patient) had been subject to warm ischemia for the longest time 
after taking the biopsy (120 min.), which runs counter to the trend for the other warm 
ischemia livers. 
 
The trends towards increased expression of both ACAT-1 (as mRNA and protein) and ACAT-2 (as 
mRNA) during warm ischemia as summarised above, were opposite to predictions, based on the 
definitive study by Smith et al. (1989) who assayed total ACAT enzyme activity in liver (before it 
was known that the ACAT-1 and ACAT-2 isoforms exist), and showed that ACAT activity 
decreases during warm ischemia. However, the sample backgrounds of the sets of individuals 
compared for warm ischemia vs. controls were different: controls included liver donors and 
gallstone patients, whereas warm ischemia included liver resection patients and livers from kidney 
donors, cf. Table 2.1. Hence it is possible that (at least some of) the differences described above are 
a function of innate differences in ACAT expression that are not related to warm ischemia. In the 
absence of a time-lapse study on the effect of warm ischemia on ACAT mRNA and ACAT protein 
expression on the same liver samples, such as that employed by Smith et al. (1989), warm ischemia 
should be avoided or minimized when taking samples. Warm ischemia will be discussed in relation 
to protein turnover in Sec. 5.8.1. 
 
5.7 Summary: trends from our pilot study require verification 
 
A number of trends have been reported for samples with different pathologies and sample treatment 
backgrounds, including data from liver and PBMC from gallstone patients and warm ischemia 
summarized in this chapter.   Other samples from patients with pathological phenotypes (duodenal 
reflux/iron deficiency cf. Sec. 2.4.4.4; liver cysts cf. Sec. 3.4.5; fatty liver cf. Sec. 4.4.4.2) also 
showed some interesting correlations. However, these trends may be misleading due to the small 
sample sizes. Hence it would be premature to draw any firm conclusions using the data presented 
herein. Nonetheless, the trends reported above (and others described below) represent useful 
hypotheses that can be tested by future research. 
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5.8 Functional aspects of differences in ACAT gene expression among individuals 
 
5.8.1 Discordance between mRNA and protein levels of ACAT isoforms in liver 
 
In this study, we made a “best attempt” at measuring the actual molar ratios of mRNA for ACAT-
2/ACAT-1 in various samples. Hence for 17 samples of human liver, we estimated that ACAT-1 
mRNA was on average actually ~13 times more abundant than ACAT-2 mRNA (deduced from 
Table 5.1). Parini et al. (2004) using RT-qPCR protocols with no published account of their relative 
sensitivity for ACAT-1 and ACAT-2, reported that ACAT-1 mRNA was on average  ~27 times more 
abundant than ACAT-2 mRNA in human liver (cf. Sec. 2.4.5.1) – a value that is within the same 
“ballpark” as our results.   
 
Compared to mRNA assays which can be benchmarked against cloned cDNA, it is more difficult to 
measure molar ratios of ACAT-1 and ACAT-2 proteins in a tissue sample. When comparing 
relative concentrations of each ACAT protein isoform, assays of enzymatic activity appear to 
provide the best indicator currently available for assessing relative abundance (despite 
qualifications about whether some ACAT protein molecules in a sample are present in inactive 
forms etc.). On this basis, Lee et al. (1998) estimated that hepatic ACAT-1 enzymatic activity was 
about 9 times greater than ACAT-2 activity, while somewhat conversely, Parini et al. (2004) 
estimated that hepatic ACAT-2 enzymatic activity on average was slightly greater than ACAT-1 
activity (mean ACAT-2/ACAT-1 activity ratio 1.23 ±0.83, cf. Sec. 2.4.5.1). 
 
Based on the fragmentary evidence cited above (the studies by different authors used liver samples 
from quite different sets of pathological etc. backgrounds) it appears that in human liver, ACAT-2 
enzyme activity (and presumably protein content) is maintained at higher levels compared to 
ACAT-1 than might be predicted from mRNA abundance assays alone (a general conclusion 
drawn by Parini et al., 2004, who compared mRNA levels from transplantation patients with 
diseased livers, with enzyme activities in livers from “gallstone” cholecystectomy patients). Indeed, 
although higher levels of transcripts in a tissue are generally expected to lead to higher levels of 
their protein products, this is not always the case (Kadota et al., 2003), and ACAT gene expression 
may represent such an example.  The extreme hypervariability of ACAT-2 mRNA in the liver of 
different individuals is another issue that compromises such comparisons, and will be considered 
separately below (Sec. 5.8.2). 
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The puzzle of why a relatively higher ACAT-2 enzyme activity (and presumably protein content) 
appears to be supported by a lower mRNA level compared to ACAT-1 is possibly explained by 
each gene and its expression products being controlled by different regulatory mechanisms at the 
transcriptional, translational, and/or post-translational levels. Higher levels of ACAT-1 mRNA 
could, for example, be a prerequisite for a more rapid turnover (synthesis and degradation) of 
ACAT-1 protein compared to ACAT-2 (cf. Ch. 1, Sec. 1.3.3). Put another way, if ACAT-1 protein 
turns over faster than ACAT-2, relatively higher levels of ACAT-1 mRNA might be needed to 
maintain biologically effective levels of its protein product compared to ACAT-2 mRNA.  
 
Consistent with the above hypothesis, Temel et al. (2003) cited unpublished experiments using 
cultured AC29 (mouse) cells that exclusively express either ACAT-1 or ACAT-2 (from African 
green monkey), and reported a half life of only ~30 min for ACAT-1 protein compared to ~6h for 
ACAT-2, based on [35S]Met/Cys labelling and immunoprecipitation. In another publication, half 
lives of 20-30 min for ACAT-1 and >6h for ACAT-2 were cited for (presumably human) ACAT 
genes expressed in an ACAT-deficient Chinese hamster ovary cell line (Parini et al., 2004). This 
can be compared with the study of Smith et al. (1989) who showed that total hepatic ACAT enzyme 
activity (ACAT-1 + ACAT-2) is markedly decreased by warm ischemia, with a half-life for the loss 
of activity of 57 min., a value consistent with the turnover rates cited by Temel et al. (2003).  
During warm ischemia blood flow stops and liver tissue is maintained at 37 ºC, a situation where de 
novo protein synthesis could be expected to decline much more rapidly than protein degradation, 
and the rate of loss of total ACAT activity would be somewhere between that of ACAT-1 and 
ACAT-2, i.e. somewhere between 30 min and 6 h, e.g. the 57 min reported by Smith et al. (1989), if 
the human ACAT isoforms turn over at rates comparable to those reported by Temel et al. (2003) 
and Parini et al. (2004). 
 
5.8.2   ACAT-2 hypervariability in relation to liver function in humans 
 
As summarized in Sec. 5.2, the hypervariable expression of ACAT-2 mRNA (320 fold range 
relative to β-actin, 97-fold range relative to ACAT-1) among 17 human liver samples from 
different individuals is perhaps the most definitive finding of our survey. 
 
Three individuals in particular (liver samples #5 and #6, cf. Sec. 2.4.5.1; and liver sample #C, cf. 
Sec. 3.3.10 and Fig. 3.3), from liver donors, had extremely low ACAT-2 mRNA levels relative to 
ACAT-1, and some of the other samples were almost as low, a finding consistent with reports of 
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other workers who have reported extremely low levels of ACAT-2 mRNA and protein in the 
samples they analysed (cf. Sec 2.4.5.1). Rudel et al. (2005) suggest some of the reports of inability 
to detect ACAT-2 mRNA or protein(s) could have been caused by sample degradation after taking 
the biopsy or post-mortem; however warm ischemia time was minimized when most of our samples 
were taken and snap frozen (cf. Table 2.1). Hence the extremely low level of ACAT-2 mRNA we 
observed in some liver samples is not believed to represent an artefact of sample degradation after 
collection. The consequence of such low levels of ACAT-2 on cholesterol function in liver will now 
be considered. 
 
As reviewed in Chapter 1 (Sec. 1.3.4), it is now generally accepted that ACAT-2 plays a primary 
role in producing CE for packaging into lipoprotein particles in both liver (hepatocytes) and 
intestine (enterocytes), for export to the blood. Consistent with this hypothesis, Parini et al. (2004) 
demonstrated (via immunohistochemical examination) that in human liver, ACAT-2 protein appears 
to be strongly predominant in hepatocytes, whereas ACAT-1 protein appears to be strongly 
predominant in Kupffer (macrophage) cells (cf. sec. 2.4.5.2).  Parenchymal cells (hepatocytes) have 
been estimated to occupy almost 80% of the total liver volume, while non-parenchymal cells 
(including Kupffer cells) contribute only 6.5% to the liver volume 
(http://www.ncbi.nlm.nih.gov/pubmed/11729749).   
 
Given the ubiquity of ACAT-1 in many human tissues including liver, the high level of ACAT-1 
mRNA and protein expression we and others (e.g. Lee et al., 1998) have observed in total liver 
biopsies from some sets of liver samples, and the relatively small liver volume occupied by Kupffer 
cells compared to hepatocytes, we suggest it is unlikely that ACAT-1 is quarantined exclusively in 
Kupffer cells within liver.  Hence it is likely that hepatocytes express both ACAT-2 and ACAT-1 
(cf. Chang et al., 2006).  Because ACAT-1 appears to be primarily involved in accepting FC 
synthesized de novo for conversion into non-toxic CE, and regulating intracellular levels of FC and 
CE in cells where ACAT-1 predominates and ACAT-2 expression is extremely low (such as 
macrophages and adrenal glands), it is highly likely that ACAT-1 also contributes to the conversion 
of de novo-synthesized FC to CE in hepatocytes.   
 
Given the apparently specific role of ACAT-2 in packaging CE for trafficking in the blood, the 
apparent deficiency in ACAT-2 expression observed in some human individuals is puzzling, as all 
humans presumably need to participate in cholesterol packaging and trafficking.  An analogous 
situation occurs with ACAT-2-/- single knockout mice which are apparently healthy when fed 
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balanced diets (Buhman et al., 2000, cf. Sec. 1.4). It is therefore possible that ACAT-1 may also 
be able to participate (at least in part) in some of the roles that have been proposed for 
ACAT-2 in hepatocytes and enterocytes (such as lipoprotein assembly), if such roles are 
essential for viability.  
 
The information summarised above is consistent with the hypothesis that ACAT-2 plays a 
primary, but perhaps not exclusive, role associated with CE trafficking in hepatocytes. However 
alternative explanations are possible, and regulatory mechanisms that control tissue 
specificity of ACAT-2 expression could ensure that the level of hepatic ACAT-2 enzymatic 
activity is adequate to provide sufficient CE for lipoprotein particle assembly and trafficking 
etc. For example, if a liver donor is quiescent and drip-fed a low-fat diet of soluble nutrients for an 
extended period prior to taking a liver biopsy (such as at least some of the liver donors used in our 
study), the need for bulk CE synthesis and trafficking would be reduced, which could lead to a 
downturn in ACAT-2 expression.  Dietary regulation of hepatic ACAT-2 in primates has been 
demonstrated by Rudel et al. (2002), who found that a high fat/cholesterol diet fed to cynomolgus 
monkeys for 10 weeks induced hepatic ACAT-2 enzyme activity 3-fold, with a lesser increase in 
mRNA abundance of ~35%. However, this response to dietary cholesterol was not found with 
African green monkeys. It is possible that humans vary in their response to dietary cholesterol (or 
lack of cholesterol), and the “low ACAT-2” mRNA values we found in some liver samples may 
represent the end result of a low cholesterol diet fed to individuals who respond similarly to the 
cynomolgus monkeys. 
 
An alternative route for CE trafficking is to package FC into plasma lipoprotein particles in 
hepatocytes, followed by export of the particles into the plasma where LCAT can esterify the FC to 
produce CE (similarly to the export of FC from peripheral cells to HDL where it is esterified to 
CE). Hence ACAT-2 is not absolutely required for the conversion of FC to CE, or the export of FC 
and its movement as CE around the body.  
 
5.8.3 Is ACAT-1 expression more highly regulated than implied by its ubiquitous tissue-specific 
distribution? 
 
Based on the much lower expression of ACAT-2 compared to ACAT-1 in almost all human tissues 
except intestine, foetal liver, and some adult liver samples, it is generally considered that ACAT-2 
is the more highly regulated ACAT isoform.  However the apparently higher turnover rate of 
145 
 
ACAT-1 protein (cf. sec. 5.8.1) suggests that ACAT-1 could in fact be more highly regulated than 
ACAT-2, requiring a much higher level of mRNA to maintain (or modify?) cellular levels of 
ACAT-1 protein. For example, relatively rapid ACAT-1 turnover may be necessary to restrict its 
location to specialised parts of the ER or other subcellular structures. Restriction of ACAT-1 to 
specialised intracellular compartments or domains would prevent it from interfering with pockets of 
FC where CE is not wanted, and would prevent it from interfering with domains where exclusive 
ACAT-2 function is required. Alternatively, perhaps ACAT-1 protein varies diurnally or in 
response to other short-term stimuli such as dietary diversity, and the need for de novo synthesis of 
FC and its storage as CE (associated with ACAT-1) might be lessened when the liver and other 
tissues receive CE from the blood after meals? This would be difficult to study in humans and other 
primates, requiring successive (invasive) biopsies over relatively short periods of time, but perhaps 
such differences could be detected in PBMC? 
 
In contrast to ACAT-1, regulation of ACAT-2 could be tissue-specific and over a longer term e.g. 
over days rather than hours as demonstrated for cynomolgus monkeys (cf. Rudel et al., 2002; also 
Zhang et al., 2010, reviewed in Sec. 1.3.3.2), consistent with its putatively slower turnover rate and 
requiring relatively lower mRNA levels to maintain the ACAT-2 protein at appropriate levels for 
the function of specific tissues and cell types. This would assist such tissues to maintain FC/CE 
trafficking infrastructure at levels appropriate to their needs. 
 
5.9 Future Directions 
 
5.9.1 Analysis of ACAT-1 and ACAT-2 isoform diversity and expression 
 
The current study was designed before it was known that hACAT-1 is expressed as two protein 
isoforms (via four mRNA species) and ACAT-2 as three protein isoforms (via three mRNA 
species). As far as we are aware, workers other than  Yao et al. (2005) have not critically examined 
their expression in a variety of human tissues (cf. Sec. 4.4.1), and no studies appear to be available 
on their expression among individuals of varying background status and pathology. Such a study is 
overdue. Such screening programs typically take a single, small biopsy for analysis, and assume 
that this sample approximates to the ACAT status of the whole liver. In this regard, although Smith 
et al. (1990) found that different lobes of livers from gallstone and control patients showed similar 
levels of total ACAT activity, this may not apply to ACAT-2 mRNA levels, or to the livers of 
patients showing extremely low levels of ACAT-2 expression. 
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It is becoming standard practice to use a number of housekeeping genes as reference to compare the 
relative abundance of test genes in different samples and tissue types, and reference genes 
additional to β-actin should be included whenever possible. RT-qPCR assays for the different 
ACAT mRNA isoforms should use the same fluorescence detection technology (preferably using 
TaqMan® detection with FAM-MGB-NFQ probes, given the greater variability with SYBR® green 
detection, cf. Mouillesseaux et al., 2003; http://www.ncbi.nlm.nih.gov/pubmed/19023979; 
Matsenko et al., 2008; Cao & Shockey, 2012). This would better enable comparison of the actual 
molar ratios of the various mRNA target molecules in a sample. Recommendations for improving 
the protein assays are discussed in Chapter 4 (Sec. 4.4.5), and the inclusion of enzyme assays 
specific for ACAT-1 and ACAT-2 should be considered (although such assays are unlikely to 
distinguish the different size variants of each ACAT isoform). 
 
There has been a tendency in recent research to focus on ACAT-2 analysis, perhaps because 
suppression of its expression has been shown to reduce the severity of atherosclerosis and gallstone 
formation in test animal systems, with the ultimate goal of developing new drugs based on ACAT-2 
inhibition. However, we found little evidence to implicate ACAT-2 expression levels with gallstone 
formation, and identified trends and recent literature that suggest lower ACAT-1 expression may be 
involved in regulating levels of FC secreted into the bile (cf. Sec. 5.4). Although strong suppression 
of ACAT-1 activity has not been shown to combat atherosclerosis and gallstone formation, partial 
inhibition of ACAT-1 has been shown to be effective in suppressing atherosclerosis (Sec. 1.4.1.2), 
and ACAT-1 may nonetheless play a role in conditioning these pathotypes. Hence, research on the 
expression and regulation of ACAT-1 should not be abandoned (cf. also Sec. 2.4.4.4 on a possible 
role for ACAT-1 in intestinal pathology).  
 
5.9.2 Cell biology of ACAT-1 and ACAT-2 in hepatocytes 
 
The particular roles (if any) where ACAT-1 could supplement or replace ACAT-2 function within 
the intracellular infrastructure require further clarification. For example, what and where among 
organelles are the intracellular locations of ACAT-1 and ACAT-2 in hepatocytes, do their locations 
overlap, and how do they interact with the various pools of FC and CE within the cell such as the 
source(s) for VLDL packaging, the sources for biliary secretion, the reservoirs for receipt of CE/FC 
from HDL, the reservoirs for receipt of CE/FC from chylomicrons, and the reservoirs for receipt of 
FC from de novo synthesis?  Literature exists on aspects of these issues, e.g. some locations of 
ACATs within the ER, machinery for packaging FC and CE into chylomicrons [enterocytes] and 
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VLDL [hepatocytes], machinery for synthesis of HDL by hepatocytes and movement of FC/CE 
from macrophages into HDL and subsequent movement into hepatocytes and conversion to bile, 
e.g. Chang et al. (2001); Lee et al. (2000); Fryer et al. (2013); Sakashita et al. (2010); Urano et al. 
(2008); Khelef et al. (2000). A review of this cellular infrastructure and its relationship to 
cholesterol trafficking etc. is beyond the scope of this thesis.  
 
5.9.3 ACAT gene regulatory mechanisms 
 
It is difficult to examine the regulation of ACAT genes in living humans.  Further studies are 
needed on ACAT mRNA/protein turnover and cholesterol uptake/conversion kinetics in the 
presence and absence of cholesterol, inhibitors and modulators, designed to probe ACAT regulatory 
mechanisms and signaling pathways. If protocols for such studies can be established with model 
systems such as cultured cells, or tissue slices from test animals, they can be applied to fresh human 
samples (e.g. from organ donors) when they become available. Screening programs for ACAT 
mRNA and protein expression could be better designed whenever possible, e.g. (a) take multiple 
samples from the same organ/tissue whenever possible to investigate intra-organ variability, (b) 
take a blood sample from each tissue sample donor to compare tissue expression patterns with 
PBMC, (c) human aortic samples (control and atherosclerotic) and other macrophage-rich tissues 
from surgical interventions should also be capable of accession and should be considered for 
inclusion in screening programs, (d) accumulate samples from sufficient numbers of patients to 
assist statistical analysis of results. 
 
5.9.4 Significance and impact of this study 
 
In summary, the current project was conceived as a pilot study to detect patterns of ACAT-1 and 
ACAT-2 gene expression in samples from diverse human patients of known pathotype, and hence 
identify which of the hypotheses inherent in the work described and discussed above, are worthy of 
further research. The range of expression of ACAT mRNA isoforms among human individuals, 
published during the first phase of this study (Smith, Rangaraj et al., 2004), was cited extensively in 
the review by Chang et al. (2009) when clarifying diverse and apparently contradictory reports on 
the relative expression of ACAT-1 and ACAT-2 in liver and intestine. Other examples of trends 
when comparing individuals are elaborated above. The work presented herein demonstrates the 
potential value of this (and future?) screening programs to examine individual variation when 
investigating the role of ACAT in human health and disease. 
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